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SUMMARY
T cells comprise a key component of the immune response and aberrant T cell 
function underlies a number of high profile medical conditions including acquired 
immune deficiency syndrome and autoimmune diseases. Consequently, a better 
understanding of the interactions which control T cell responses has significant 
clinical implications. Recent interest has focused on the role of apoptosis in the 
control of T cell responses and in particular the involvement of the Fas receptor 
(CD95) in this process. This study investigated the role of CD95-mediated 
apoptosis in human T cell responses, with a view to determining how the 
expression of CD95 and its ligand (CD95L) was regulated during the T cell 
response to antigen engagement and the consequences of this for apoptosis 
induction. In particular, the role of the CD95 pathway in activation-induced cell 
death following antigen restimulation was addressed since this is believed to 
represent an important physiological trigger for CD95-mediated killing. Finally, 
the modulation of CD95-induced apoptosis by additional receptor:ligand 
interactions was examined in order to assess how the context o f CD95 
engagement affected the outcome. In contrast to previous studies, the data 
presented here demonstrate that, unlike transformed or cloned T cell lines, normal 
activated human T cells were largely resistant to CD95-mediated apoptosis when 
stimulated with anti-CD95 antibodies or when subjected to TCR restimulation. 
This was found to be the case despite expression of both CD95 and CD95L. Since 
provision of signalling via both the TCR CD3 component and the costimulatory 
receptor CD28 further inhibited the apoptotic response to CD95 ligation, it is 
postulated that "correct" activation of T cells via these receptors may confer 
resistance to CD95-mediated apoptosis. Conversely, T cells which were 
activated non-specifically by supernatant transfer exhibited greater sensitivity to 
CD95-induced death. Thus, a major role for CD95-mediated apoptosis may be the 
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1.1 IMMUNITY VERSUS TOLERANCE
An essential feature of the immune system is the ability to distinguish between 
self and non-self in order to successfully eliminate invading pathogens. To this 
end, a wide variety of cell types cooperate to mount a co-ordinated defence 
response which must be in place as rapidly as possible since pathogens frequently 
replicate rapidly. T cells play a key role in the induction of such a response: 
having recognised foreign material by the use of a specialised T cell receptor 
(TCR) they go on to fulfil diverse functions including cytotoxicity, the facilitation 
o f B cell antibody production and the recruitment of accessory cells which 
together act to eliminate the pathogen. However, the effector mechanisms of the 
immune system may also pose a considerable threat to the host and therefore 
controlled initiation and appropriate termination of immune responses are of 
paramount importance to avoid destruction of self tissue. In order to achieve this 
regulation, cells of the immune system have evolved stringent activation 
requirements such that a co-ordinated set of signals must be provided in order for 
productive activation to occur. Furthermore, the existence of an intrinsic death 
programme which can be receptor-driven potentially allows the controlled 
elimination of cells which have fulfilled their immune function or which may be 
dangerous to the host. The mechanisms of selective activation or apoptosis of T 
cells can thus be used to control the response to antigen engagement in order to 
ensure reactivity against invading pathogens (immunity) and yet to maintain non­
responsiveness (tolerance) against self tissue. The importance of controlled cell 
deletion within the immune system has become increasingly apparent, and this 
study therefore sought to examine the process of CD95-mediated apoptosis as one 
mechanism of peripheral T cell tolerance. Since the signals which mediate T cell 
activation also contribute to subsequent T cell survival, this process therefore has 
a direct bearing on the control of apoptosis induction. Thus a review of current
6
understanding of the interactions controlling the generation of both T cell 
immunity and T cell tolerance follows.
1.2 T CELL IMMUNITY
1.2.1 T Cell Repertoire
In order to create the scope for recognising a wide range of foreign antigens, T 
cells generate the potential for global reactivity yet maintain selective non­
responsiveness against self by the use of tolerance mechanisms. This generation 
of diversity is achieved at the molecular level by gene rearrangement processes 
(Chien et al., 1984) such that large numbers of receptors are produced which can 
recognise numerous different antigens (Marrack and Kappler, 1987; Maryanski et 
al., 1997). The antigen receptor on T cells is the TCR, however similar 
mechanisms operate to generate diversity for B cell antigen receptors (which 
comprise surface immunoglobulin) and together these two cell types mediate 
specific antigen recognition and represent the "eyes" of the immune system. 
Having generated a vast repertoire of antigen recognition receptors, any that might 
be self-reactive, and might therefore trigger autoimmunity, must subsequently be 
screened out. This process is achieved by tolerance mechanisms which allow the 
immune system to selectively ignore the host's own tissue and which are reviewed 
in section 1.3.
1.2.2 Antigen Recognition
The recognition of antigen by T cells is restricted by the requirement for 
appropriate antigen presentation by cells expressing 'self markers (Zinkernagel et
7
al., 1974). The cells which fulfil this function are termed antigen presenting cells 
(APCs) and include dendritic cells, macrophages and B cells (Ellis et al., 1991). 
APCs determine which antigenic epitopes are available for T cell recognition by 
displaying discrete peptide fragments bound to Major Histocompatibility Complex 
(MHC) class I and class II molecules termed Human Leukocyte Antigen (HLA) 
molecules in human and H-2 molecules in mouse. These molecules represent a 
group of highly polymorphic cell surface glycoproteins of which two classes exist 
and which are designed to bind peptide antigens and present them to the TCR 
(Babbitt et al, 1985). The peptides bound by class I molecules are generally 
derived from an intracellular location and are usually approximately 8 -1 0  amino 
acids in length (Townsend and Bodmer, 1989; Yewdell and Bennick, 1992). In 
order to become associated with class I molecules, such peptides are delivered to 
the secretory pathway in conjunction with the transporter associated with antigen 
processing (TAP) complex which is itself encoded by MHC genes (Trowsdale et 
al., 1991; Kleijmeer et al., 1992). In addition, similar mechanisms appear to exist 
for peptide loading of class II molecules using HLA-DM (Morris et al., 1994).
Contrasting with class I molecules, class II molecules bind slightly larger peptides 
of 15-20 amino acids in length (Germain and Hendrix, 1991). An invariant chain, 
a non-polymorphic gene product, is also associated with the class II a  and P 
chains and is essential for their proper assembly (Peterson and Miller, 1990; Lamb 
et al., 1991; Anderson and Miller, 1992). Crystalographic studies established that 
the structure of the HLA class I molecule HLA-A2 comprised a peptide binding 
groove formed by two a  helices lying on a P pleated sheet (Bjorkman et al., 1987) 
and subsequent analysis has revealed a similar structure for class II molecules 
(Brown et al., 1993). Thus the T cell perceives non-self (antigen) only in the 
context of self (HLA).
The class of MHC molecule on which the peptide antigen is presented is 
important in the control of the T cell response since class I molecules interact with
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a T cell co-receptor termed CD8 , whilst class II molecules preferentially bind to 
the T cell CD4 co-receptor (Doyle and Strominger, 1987). The CD8+ subset 
comprise cytotoxic T cells whilst the CD4+ subset are broadly categorised as 
helper T cells since they play a key role in the facilitation of B cell antibody 
production via the secretion of cytokines such as the interleukins (IL) IL-4 and IL- 
5. Since HLA class I is ubiquitously expressed throughout the body, virtually all 
cells can present antigen to the CD8+ cytotoxic subset whereas HLA class II 
expression is mainly restricted to specialised cells of the immune system.
1.2.3 TCR Signalling
T cell antigen recognition is mediated by the TCR which comprises an a  and P 
chain (or less frequently a y and 5 chain) linked by a single disulphide bridge 
(Marrack and Kappler, 1987) and is a member of the immunoglobulin (Ig) 
superfamily of receptors. Each T cell has a unique TCRaP specificity to facilitate 
antigen recognition. However, the apTC R  itself is not believed to mediate signal 
transduction by virtue of its short cytoplasmic domain: rather, a separate 
transmembrane signalling component, CD3, comprising y8e chains in addition to 
the £ family of hetero- and homo-dimers (Marrack and Kappler, 1987; Brocker 
and Karjalainen, 1995), exists in close proximity to the TCR and is thought to 
transduce the signals initiated by the process of T cell antigen engagement (see 
figure 1.1) (Howard et al., 1992; Rudd et al., 1994).
Triggering of the TCR/CD3 complex initiates multiple signalling pathways 
including the requisite activation of intracellular protein tyrosine kinases 
(Klausner and Samelson, 1991). However, the TCR itself does not possess 
intrinsic kinase activity and instead this pathway relies on the recruitment and 
activation of src family protein tyrosine kinases such as p 5 6 ^ , p60>^s, p59^n 
(Klausner and Samelson, 1991). The members of this family are characterised by 
a common structure which includes a unique N-terminal region, src homology
9
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Figure 1.1: Schematic representation of antigen presentation to T cells. Signal 1 
is provided by TCR engagement of the antigen in the context of HLA-DR expressed 
on the APC. Signal 2 (costimulation) is provided by CD28 engagement via APC 
CD80/86. APC = antigen presenting cell, HLA = Human Leukocyte Antigen, TCR = 
T cell receptor
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regions 2 and 3 (SH2 and SH3 domains), a catalytic tyrosine kinase domain (SHI 
domain) and a regulatory C-terminal motif (Rudd et al., 1994). Whilst p56/c* 
associates with the CD4/8 co-receptors (Rudd et al., 1994; Thome et al., 1995), 
p5 9 /yn interacts with the TCR£ chain and the CD3y5e chains via its N-terminal 
region (Rudd et al., 1994). In addition, the syk family tyrosine kinase ZAP-70 is 
recruited to the TCR£ chain and can contribute to T cell signal transduction during 
the antigen presentation event (Samelson and Klausner, 1992; Chan et al., 1994; 
Timson-Gauen et al., 1994; Chan et al., 1995; Thome et al., 1995).
The targets of the kinases associated with TCR-induced signal transduction are 
believed to include phospholipase Cy (Park et al., 1991) which in turn mediates 
the hydrolysis of phosphatidlyinositol 4,5 bisphosphate (PIP2) yielding inositol
1,4,5 triphosphate (IP3) and 1,2-diacylglyerol (DAG) (Berridge and Irvine, 1984; 
Perlm utter et al., 1993). W hilst IP3 triggers calcium (Ca2+) release from 
intracellular stores (Weiss et al., 1984), DAG activates certain isoforms of protein 
kinase C (PKC) (Genot et al., 1995) which can stimulate the activation of cellular 
proto-oncogenes such as p74ra/  and p21ms (Rudd et al., 1994). leading to mitogen 
activated protein kinase (MAPK) cascades (Li et al., 1996). The phorbol ester 
phorbol myristate acetate (PMA) can be used as a pharmacological tool to activate 
PKC by binding to DAG-binding sites (Kraft and Anderson, 1983).
Thus the recognition of foreign material by T cells involves the processing and 
displaying of peptide antigen in the context of self HLA molecules on APCs. 
Binding of this peptide/HLA complex to the TCR triggers T cell activation signals 
via the CD3 complex and £ chains (signal 1). However, TCR ligation per se is not 
sufficient to fully activate T cells and the requirement for an additional 
costimulatory signal (signal 2) is reviewed in section 1.2.5. Figure 1.1 therefore 
illustrates the key receptors involved in T cell recognition of antigen, with the 
addition of CD28, a costimulatory receptor which provides a "go" signal, and its 
homologue CTLA4 which delivers a "stop" signal to T cells. The control of T cell
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fate by receptors such as CD28 and CTLA4 are reviewed in more detail in 
sections 1.2 .6 - 1.2 .11 .
1.2.4 Superantigens
One experimental model of T cell activation which has been exploited in this 
study involves the use of superantigens which differ from conventional peptide 
antigens by interacting with both the TCR and HLA molecules outside their 
specific antigen-binding areas (Herman et al., 1991) as indicated in figure 1.1. 
Superantigens such as Staphylococcal enterotoxins bind directly to HLA class II 
proteins (Buxser et al., 1981) without the need for processing, and interact with 
the V|3 chain of the TCR. In bypassing the specificity-determining regions, 
superantigens thus provide a more global stimulus than conventional peptide and 
activate T cells on the basis of their particular TCR-V6  chain expression (Kappler 
et al., 1989; Dohlsten et al., 1993) triggering the proliferation of approximately 5- 
40 percent of the T cell population (Janeway et al., 1989). In vivo, injection of 
superantigens induces both T cell proliferation and apoptosis highlighting the fine 
balance between life and death in response to activation stimuli (MacDonald et al., 
1991). Superantigen stimulation has therefore been utlised in vitro in this study to 
investigate the processes of T cell activation and apoptosis.
1.2.5 T helper 1 and T helper 2 Cells
W ithin the CD4+ compartment, T cells can be further subdivided according to 
their preferential cytokine output, such that cells which predominantly produce 
interferon y (IFNy) and/or IL-2 are classed as Thl (T helper 1) cells whilst those 
which secrete cytokines such as IL-4, IL-5, and IL-10 are defined as exhibiting a 
Th2 (T helper 2) profile (Fiorentino et al., 1989; Mosmann and Coffman, 1989; 
Lederer et al., 1993). The Thl/2 skewing of T cell responses influences the nature 
of the subsequent immune response (for example T hl responses may favour
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inflammation whilst Th2 responses may favour antibody production) and appears 
to have important consequences for whether a pathogen is successfully eliminated 
(Bass et al., 1989; Else et al., 1993; Reiner and Locksley, 1993). The 
differentiation of T cells towards a particular Th phenotype is largely influenced 
by the cytokine environment (Noble et al., 1993; Seder et al., 1993) and a large 
body of literature exists regarding the categorisation of cells as T hl or Th2, and 
the dangers therein (Allen and Maizels, 1997; Karulin and Lehmann, 1997; 
Romagnani, 1997).
1,2.6 Costimulation via CD28
At the level of a single T cell, the difference between the induction of immunity or 
tolerance ultimately depends on whether the recognition of antigen triggers T cell 
activation, anergy (antigen-specific non-responsiveness) or apoptosis. This 
fundamental choice appears to be largely controlled by the availability of 
alternative receptor:ligand interactions in addition to the triggering of the antigen 
receptor (TCR). It is now well established that effective T cell activation requires 
costimulatory signals, in addition to antigen derived signals via the TCR/CD3 
complex, in order for proliferation to be triggered. In the absence o f such 
costimulation, antigen engagement may instead lead to anergy or even apoptosis 
(Ramensee et al., 1989; Schwartz, 1990; Jenkins et al., 1991) emphasising the 
importance of this interaction in the control of T cell survival. The provision of 
additional signals is thus a key factor in dictating the outcome of a TCR signalling 
event, and one molecule which is important in this regard is the CD28 receptor. 
CD28 has a glycosylated molecular weight of 44 kDa, and is expressed as a 
homodimer on the majority of CD4+ T cells and approximately 50% of CD8+ T 
cells (Linsley and Ledbetter, 1993; June et al., 1994). The gene for CD28 maps to 
chromosome 2q33-34 and encodes a 202 amino acid protein of which 41 amino 
acids comprise an intracellular portion responsible for signal transduction 
(Dariavach et al., 1988). Whilst TCR/CD3 signals alone are insufficient for T cell
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activation, the simultaneous provision of CD28 receptor engagement allows T cell 
proliferation and IL-2 production to ensue (Gimmi et al., 1991; Jenkins et al., 
1991; Linsley et al., 1991a; Razi-Wolf et al., 1992; Sansom et al., 1993). The 
effect on IL-2 production was found to operate via both transcriptional and post­
transcription mechanisms and in addition similar effects were observed for other 
cytokines including IL-4, IL-8 , IL-13 and TN Fa (Lindsten et al., 1989; Thompson 
et al., 1993; June et al., 1994).
In addition to CD28 engagement, a number of other receptor:ligand interactions 
between the T cell and APC may be important in optimising activation, both by 
enhancing adhesion and possibly by playing signalling roles. The interaction of 
CD58 on the APC with CD2 on the T cell is believed to be important in this 
regard (Howard et al., 1992; Kanner et al., 1992;) and similarly adhesion 
molecules such as CD54, CD lla/CD 18 (Damle et al., 1992; van Seventer et al., 
1990) and the integrin associated protein (IAP/CD47) (Reinhold et al., 1997) 
promote the celkcell contact between T cell and APC. In particular, a role for the 
CD95 family member 4 - IBB in costimulating T cell proliferation is gaining 
credence and may preferentially operate in the CD8+ T cell subset (DeBenedette 
et al., 1997; Shuford et al., 1997) whilst the signaling lymphocytic activation 
molecule (SLAM) appears to offer an additional route for the promotion of T cell 
activation (Aversa et al., 1997).
1.2.7 Ligands for CD28
The ligands for the CD28 receptor belong to the CD80 family of proteins and are 
expressed on “professional” APCs of the immune system. The first to be 
identified was termed B7-1 (CD80) and shown to be a 262 amino acid polypeptide 
with a glycosylated molecular weight of approximately 60 kDa (Freeman et al., 
1989). Subsequently B7-2 (B70/CD86) was cloned and characterised as a 323 
amino acid protein glycosylated to approximately 70kDa (Azuma et al., 1993;
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Freeman et al., 1993). CD86  has a slightly larger cytoplasmic domain compared 
to CD80, and exhibits a wider tissue distribution, being present on resting 
monocytes and dendritic cells, whilst CD80 expression is inducible following 
activation of monocytes and B cells (Azuma et al., 1993; Stack et al., 1994; 
Fleischer et al., 1996). Both ligands are members of the Ig superfamily and map 
to the same chromosomal region (3q 13-23) (Femandez-Ruiz et al., 1995) and both 
are capable of efficiently costimulating T cells through CD28 (Lanier et al., 1995). 
Recent studies have reported differences in the binding affinities of CD80 and 
CD86  although the functional significance of this is currently unknown (Greene et 
al., 1996; van der Merwe et al., 1997). The CD28 ligands have also been found 
on activated T cells and have been shown to be reciprocally regulated in murine T 
cells following activation such that CD86  expression decreases whilst CD80 is 
upregulated (Prabhu Das et al., 1995). Expression has also been documented on 
human T cell clones (Sansom and Hall, 1993; Pichler and Wyss-Coray, 1994) 
although little work exists on normal human T cells in this regard. The expression 
of costimulatory ligands on T cells themselves is intriguing, suggesting a role for 
T cells in the control of CD28 signalling and conferring the potential for T cell 
contribution to antigen presentation events.
1.2.8 CD28 and Survival
In addition to costimulating antigen-induced proliferation, CD28 signals have also 
been increasingly associated with promoting T cell survival and are thus of direct 
relevance to studies on apoptosis. Accordingly, whilst T cells from CD28 
knockout mice can initiate antigen-driven proliferation, the response cannot be 
sustained (Lucas et al., 1995) which may be associated with decreased cell 
viability at late time points. Similarly, signalling through the TCR CD3 
component alone can trigger apoptosis induction in in vitro studies, an outcome 
which is prevented by costimulation with anti-CD28 mAb (Boise et al., 1995; 
Radvanyi et al., 1996; Sperling et al., 1996) in some experimental systems. The
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mechanisms which underlie CD28-mediated survival effects are not yet clear, but 
two potential candidates are the production of anti-apoptotic cytokines such as IL- 
2 , and the induction of the anti-apoptotic protein B C L X l (Boise et al., 1995). 
Whilst the role of CD28 in the enhancement of IL-2 production is well established 
(Lindsten et al., 1989; Fraser et al., 1991; Fraser and Weiss, 1992; Thompson et 
al., 1993) the role of this cytokine in apoptosis prevention is less clear. The 
surprising demonstration that IL-2R knockout mice exhibit lymphoproliferation 
and autoimmunity as well as defects in CD95-mediated apoptosis indicates that 
IL-2R signalling may in fact be involved in the maintenance of self-tolerance by 
facilitating programmed cell death (Suzuki et al., 1995). An alternative candidate 
for the mediation of survival signals is the anti-apoptotic protein B C L X l which is 
reviewed in section 1.3.8.5. Further evidence for a role of CD28 in the promotion 
of cell survival is drawn from the inhibitory effect of CD28 stimulation on 
activation induced cell death (Groux et al., 1992; Radvanyi et al., 1996) a process 
of T cell elimination by apoptosis which is reviewed in section 1.3.7. However, 
this CD28-mediated protection remains controversial and was not observed in a 
number of other studies (Tan et al., 1992; Couez et al., 1994; Boehme et al., 
1995).
1.2.9 CD28 Signalling
The signals responsible for mediating CD28-induced effects are not yet fully 
understood and are the focus of much scientific interest. W hilst the CD28 
cytoplasmic tail does not posses intrinsic enzymatic activity, it contains a YMNM 
m otif which can mediate interactions with SH2-domain containing proteins 
following its tyrosine phosphorylation on Y 173 (Prasad et al., 1994; Cai et al., 
1995). One such protein is the lipid/serine kinase phosphatidylinositol 3-kinase 
(PI3K) which has been shown to be recruited to this motif via its p85 regulatory 
domain following CD28 ligation (Ward et al., 1993; Pages et al., 1994). The 
ligand-dependent recruitment and activation of this kinase is believed to play a
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key role in CD28 signal transduction as determined by mutational analysis and 
inhibition studies using the fungal product wortmannin to covalently bind the 
p i 10 catalytic domain of PI3K (Pages et al., 1994; Cai et al., 1995; Ward et al., 
1995). Potential targets for PI3K include protein kinase B (PKB), and p70^6 
kinase (Burgering and Coffer, 1995; Downward, 1995; Franke et al., 1995). In 
addition, CD28 has been reported to signal via acidic sphingomyelinase 
generating ceramide which may mediate CD28-induced activation of c-Jun N 
terminal kinase (JNK) (Boucher et al., 1995). The integration and relative 
contribution of these pathways remains to be determined. The kinase responsible 
for phosphorylating the CD28 Y 173 motif has also not yet been confirmed but one 
candidate is the src tyrosine kinase p 5 6 ^  (Raab et al., 1995). CD28 ligation also 
triggers the phosphorylation of the tyrosine kinase Itk (August et al., 1994) 
however this is believed to play a negative regulatory role during T cell activation 
(Liao et al., 1997).
1,2.10 A CD28 homologue: CTLA4
The CD28 homologue, CTLA4 which was identified 10 years ago (Brunet et al., 
1987) binds the same ligands as CD28 (CD86  and CD80) but rather than 
providing positive costimulatory signals, is believed to negatively regulate T cell 
responses (Walunas et al., 1994; Krummel and Allison, 1995; Krummel and 
Allison, 1996; Walunas et al., 1996). Thus the same ligands (CD80/86) can 
paradoxically both enhance and inhibit T cell responses depending on whether 
they engage CD28 or CTLA4. Whilst CD28 is constitutively expressed on the 
majority of human T cells (-95%  of CD4+ T cells, -50%  of CD8+ T cells) 
(Linsley and Ledbetter, 1993; June et al., 1994), CTLA4 appears to exist primarily 
as an intracellular molecule and exhibits low level surface expression inducible by 
T cell activation (Walunas et al., 1994; Alegre et al., 1996; Wang et al., 1996a). 
However, in terms of ligand binding affinity, CTLA4 is markedly superior and 
binds with approximately 20 fold greater affinity than its homologue CD28
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(Linsley et al., 1991b). Whether CD28 or CTLA4 signalling predominates in the 
context of ligand provision is therefore likely to depend on the balance between 
relative surface expression levels and relative binding affinities of these two 
receptors. Since CD28 and CTLA4 compete for ligand binding, interactions 
which downregulate CD28 expression will therefore potentially favour CTLA4 
signalling. One such interaction is the binding of CD28 by its own ligands 
(CD80/86) which triggers rapid downregulation of CD28 messenger ribonucleic 
acid (mRNA) (Linsley et al., 1993). The significance of this response in terms of 
the effect of subsequent CD80 provision is not known.
The signals which control extemalisation of CTLA4 remain to be fully elucidated 
although a role for Ca2+ signalling has been inferred (Linsley et al., 1996). 
Current evidence indicates that CTLA4 is retained intracellularly via an 
association with the AP50 component of the clathrin associated adapter AP-2 
(Chuang et al., 1997; Shiratori et al., 1997). One motif implicated in this process 
is the CTLA4 cytoplasmic YXMN sequence which binds AP50 only when the 
tyrosine residue is dephosphorylated. The kinase which phosphorylates this motif, 
thus allowing surface expression of CTLA4, remains to be identified, as do the 
conditions which favour its activation. Following induction, CTLA4 appears to 
exhibit focal localisation towards the contact site between the T cell and APC 
(Linsley et al., 1996) possibly explaining why such low surface levels of this 
protein can be functionally significant.
A role for CTLA4 in the downregulation of T cell responses has been identified 
by a number of groups, however the data are presently confined to antibody- 
driven studies predominantly in murine systems (Walunas et al., 1994; Krummel 
and Allison, 1995; Krummel and Allison, 1996; Walunas et al., 1996) and an 
appreciation of how CLTA4 may be triggered under physiological conditions by 
ligand (CD80/86) engagement remains elusive. Accordingly, agonistic anti- 
CTLA4 antibodies have been shown to regulate T cell responses at the level of
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inhibition of IL-2 production and delayed cell cycle entry (Krummel and Allison, 
1996; Walunas et al., 1996). An isolated report documented the induction of 
apoptosis following antibody engagement of CTLA4 (Gribben et al., 1995), but 
this is not supported by other studies (Walunas et al., 1994; Krummel and Allison, 
1996; Walunas et al., 1996). The most striking demonstration of a regulatory role 
for CTLA4 is the dramatic phenotype of mice deficient for this receptor which 
exhibit profound lymphoproliferative disease (Tivol et al., 1995; Waterhouse et 
al., 1995). These animals are characterised by an unchecked expansion of T cells 
indicative of a lack of negative regulation and this phenotype is ameliorated in the 
presence o f CTLA4-Ig (a soluble CTLA4 construct) suggesting that the 
lymphoproliferation is costimulation (CD80/86) dependent (Tivol et al., 1997).
1.2.11 Relevance of CD28 and CTLA4 to T Cell Apoptosis
Since this study is an investigation of T cell apoptosis mediated by the CD95 
receptor, it is o f particular relevance to consider the potential effect of CD28- or 
CTLA4-derived signals on this pathway. In this regard, T cells which have been 
activated in the presence of CD28 ligation have been shown to exhibit enhanced 
survival (Sperling et al., 1996; Vella et al., 1997), but this has not been 
demonstrated to be mediated by CD95 resistance, and CD28 blockade during T 
cell activation triggers equivalent apoptosis in CD95-defective M RL-/pr mice 
(Noel et al., 1996b) implicating CD28 in the regulation of alternative death 
pathways. There is a dearth of literature which directly addresses the effect of 
either CD28 or CTLA4 signalling on CD95-mediated apoptosis induction and this 
therefore remains an important unanswered question.
1.2.12 Therapeutic Manipulation ofT  cell Immunity
Since effective T cell activation can orchestrate the induction of a co-ordinated 
immune response, the therapeutic potential for intervention at this point is
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substantial. In this regard, a number of trials have demonstrated a potent 
immunosuppressive effect associated with blocking T cell costimulation using 
CTLA4-Ig to bind CD80/86. This approach has been successfully applied to 
transplant biology, leading to the prevention of graft rejection and the subsequent 
generation of tolerance (Lenschow et al., 1992; Linsley et al., 1992; Blazar et al., 
1994; Pearson et al., 1994; Ibrahim et al., 1997), as well as to animal models of 
autoimmune disease such as murine lupus (Finck et al., 1994), murine collagen- 
induced arthritis (Webb et al., 1996), the multiple sclerosis model EAE 
(Experimental Autoimmune Encephalomyelitis) (Miller et al., 1995; Perrin et al., 
1995; Racke et al., 1995; Perrin et al., 1996) and diabetes in the NOD (Non Obese 
Diabetic) mouse (Lenschow et al., 1995). Conversely, manipulation o f the 
CD28/CTLA4 system can also be used to enhance immune responses, for example 
in the context of cancer treatment. Accordingly, antibody blocking of the CTLA4 
receptor can be used to inhibit this negative regulatory pathway resulting in 
enhanced immunity against tumour cells (Leach et al., 1996). Despite these 
notable successes, unpredicted outcomes can occasionally arise during such trials 
including the triggering of both disease suppression and exacerbation following 
the administration of anti-CD80/86 antibodies to NOD mice (Lenschow et al., 
1995; Lenschow et al., 1996). Such findings serve as a timely reminder of the 
need for further fundamental research in this area since the current working 
hypotheses do not adequately explain all the data. A better understanding of the 
events which lead to T cell activation is therefore essential both for the 
identification of defects underlying various diseases, and for the successful design 
of therapies to ameliorate these conditions.
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1.3 T CELL TOLERANCE
As previously indicated, the nature of the immune system is such that a diverse 
array of antigen receptors is generated by gene rearrangement processes and 
subsequently those which may recognise self antigens and prove dangerous to the 
host are screened out by tolerance mechanisms. To achieve tolerance, T cells may 
be immunologically silenced by anergy or may be eliminated from the system by 
apoptosis.
1.3.1 Central Tolerance
A critical time for the generation of self-tolerance is during T cell development in 
the thymus which is where T cells migrate to be "educated" following their 
origination in the bone marrow (Kappler et al., 1987; Kappler and Marrack, 1987; 
Pullen et al., 1989; Jones et al., 1990). The education process involves both 
positive and negative selection and is based on the strength of the interaction 
between the TCR and the self HLA molecules which bind peptide antigens and 
present them to T cells. A detailed knowledge of central tolerance mechanisms is 
largely beyond the scope of this review but in essence T cells are required to 
interact sufficiently strongly with HLA molecules in order to be positively 
selected, but those which interact too strongly are deleted by apoptosis (negative 
selection) (Benoist and Mathis, 1989; Finkel et al., 1989; Ashton-Rickardt et al.,
1994). The stringency of thymic selection is such that the majority of T cells 
generated are actually deleted at this stage of development and never enter the 
peripheral pool of circulating lymphocytes. Thus the generation of the T cell 
repertoire is a surprisingly wasteful process but this is necessary in order to 
achieve the fine balance between the recognition of a diverse array foreign 
antigens yet the avoidance of autoimmunity.
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1.3.2 Peripheral Tolerance
In addition to central tolerance, peripheral tolerance mechanisms also exist to 
silence autoreactive cells which have eluded thymic negative selection and have 
escaped to the periphery (Singer and Abbas, 1994; van Parijs et al., 1996; 
Bluestone, 1997). The failure of thymic selection to remove all potentially 
autoreactive T cells is inevitable given that tissue-specific antigens are not 
represented in the thymus and thus may be encountered for the first time in the 
periphery. Similarly to central tolerance, a major mechanism of peripheral 
tolerance is the deletion of T cells by apoptosis, and in addition specific subsets of 
cells can be immunologically silenced in a process termed anergy. Interestingly, 
defects in central tolerance are not widely associated with the induction of 
autoimmunity whilst in contrast, defects in the receptors involved in peripheral 
tolerance mechanisms (including the death receptor CD95 and the negative 
regulatory receptor CTLA4) trigger the onset of a severe autoimmune phenotype 
(Bluestone, 1997). The appropriate induction of peripheral tolerance mechanisms 
is thus a key requirement for the prevention of autoimmunity under normal 
circumstances. However, a detailed understanding of how and when such 
peripheral tolerance mechanisms operate during T cell responses remains elusive.
1.3.3 CD95
Controlled cell deletion is an important mechanism of peripheral tolerance and a 
key receptor for this process is CD95 which triggers an apoptotic pathway when 
ligated. Apoptosis is a morphologically defined process of cell suicide in which a 
characteristic sequence of events occur including nuclear condensation, membrane 
blebbing and DNA fragmentation (Kerr et al., 1972). The key difference between 
this process and that of necrosis or "accidental" cell death is its active gene- 
directed nature and in fact apoptosis plays an integral role in morphogenesis 
during embryonic developmental as well as in tissue homeostasis (Vaux et al.,
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1994). Its importance in the latter process is reflected in the derivation of its name 
from the Greek words "apo" meaning "from/away" and "ptosis" meaning "fall" 
reminiscent of the falling of the leaves in the autumn (Kerr et al., 1972).
Interest in the CD95 receptor as a transducer of an apoptotic signal began in 1989 
with the development of two anti-CD95 monoclonal antibodies, APO-1 by 
Krammer and colleagues (Trauth et al., 1989), and anti-Fas by Yonehara and 
colleagues (Yonehara et al., 1989). The cDNAs for the APO-1 antigen and the 
Fas antigen were subsequently shown to be identical (Oehm et al., 1992). The 
human CD95 protein comprises 325 amino acids (306 amino acids in mouse) with 
a signal sequence at the N terminus and a central transmembrane domain (Nagata,
1994) indicative of a type I membrane protein. It has a molecular weight of 
45kDa and is encoded by a sequence which maps to chromosome 10q24.1 in 
humans (chromosome 19 in mouse) (Nagata, 1994). CD95 is a member o f the 
TNFR/NGFR family which includes the two TNFRs (type I and type II) in 
addition to receptors such as CD40, CD27 and CD30 (Smith et al., 1994). 
Northern blot analysis revealed that CD95 mRNA was expressed in a variety of 
tissues, and was particularly abundant in the thymus, liver, lung and kidney. 
Stimulation with IFNy or T N Fa triggered induction of CD95 expression in 
macrophages and T cells (Nagata, 1994). The CD95 receptor was shown to be a 
potent mediator of apoptosis by the tissue damage and lethality associated with the 
intraperitoneal adm inistration of agonistic anti-CD95 antibody in m ice 
(Ogasawara et al., 1993) and histological examination indicated severe liver 
damage by apoptosis in these animals. A number of further reports confirmed the 
role of CD95 in the transduction of an apoptotic signal, but these studies largely 
examined CD95 ligation in cell lines (Yonehara et al., 1989; Ogasawara et al., 
1993; Suda et al., 1994; Suda and Nagata, 1994), and the role of the CD95 
receptor in normal T cells was not addressed. Significantly, one early report 
which did encompass human peripheral blood T cells documented resistance to 
CD95-mediated apoptosis in activated T blasts and noted the contrast with Jurkat
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T cells which exhibited sensitivity to apoptosis via this route (Miyawaki et al.,
1992). Subsequently, however, two reports claimed that sensitivity of T cells to 
CD95-mediated apoptosis was acquired after several days of activation (Owen- 
Schaub et al., 1992; Klas et al., 1993).
1.3,4 CD95-Ligand
Given that CD95 had been identified as a receptor which could trigger apoptosis 
in susceptible cells, intense scientific interest was subsequently focused on the 
search for a natural ligand for this receptor. The key questions which stimulated 
this research were which cell type(s) express CD95L, how is this expression 
controlled and what is the significance of this for the induction of peripheral T cell 
tolerance? The ligand for CD95 (CD95L) was cloned and characterised by Suda 
and colleagues (Suda et al., 1994; Suda and Nagata, 1994; Takahashi et al., 
1994b) by the use of a chimeric CD95-Fc protein (CD95 linked to Fc region of an 
immunoglobulin molecule) to enrich for CD95L-expressing cells in the cytotoxic 
T cell line dlOS. The cloned CD95L gene was found to encode a type II 
membrane protein comprising 270 amino acids (Suda et al., 1994) with a 
molecular weight of 40kDa. A member of the TNF family, CD95L shares 
significant homology with other family members including TN Fa, Lymphotoxin 
(LT) a  and 6, CD40L, CD27L and CD30L (Alderson et al., 1993; Suda et al.,
1994). The expression of CD95L is relatively restricted and it is predominately 
found on activated T (Suda et al., 1995) and Natural Killer (NK) (Arase et al.,
1995) cells, although expression has also been documented on neutrophils (Liles 
et al., 1996), dendritic cells (Lu et al., 1997a) and macrophages (Badley et al., 
1997). As for TN Fa, a soluble form of CD95L can be produced following 
metalloproteinase cleavage (Kayagaki et al., 1995; Mariani et al., 1995) and has 
been detected in human serum under certain conditions (Tanaka et al., 1995). 
Chemical crosslinking and gel filtration analysis have indicated that human 
soluble CD95L exists as a trimer (Tanaka et al., 1995) consistent with the
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observation that dimerisation of CD95 is insufficient to activate apoptotic 
signalling (Dhein et al., 1992; Kischkel et al., 1995). Interestingly, whilst murine 
CD95L is also proteolytically processed to a soluble form, in contrast to the 
situation in humans, it is unstable and non functional (Tanaka et al., 1995).
T cell CD95L expression provides one mechanism for the induction of cell death 
by cytotoxic T lymphocytes (CTL) (Ju et al., 1994). CTL are traditionally 
associated with a CD8+ phenotype, and a major mechanism underlying the 
induction of cytotoxicity in these cells is the production of perforin and granzymes 
(Jans et al., 1996; Vergelli et al., 1997). However, more recently it has been 
shown that CD4+ T cells can also act as CTL and that the CD95 system is 
particular important for cytotoxicity in this T cell subset (Rouvier et al., 1993; 
Hanabuchi et al., 1994; Ju et al., 1994). In this regard, it has been shown that 
CD4+ T cell killing of CD8+ T cells (Piazza et al., 1997), B cells (Rathmell et al.,
1995) and activated macrophages (Ashany et al., 1995) can be mediated by 
CD95L expression.
1.3.5 Defects in CD95 or CD95L
An indication of the importance of a functional CD95 system for the maintenance 
of normal immune homeostasis can be drawn from the phenotype of mice which 
are defective in this pathway. In MKL-lpr mice, the CD95 gene is interrupted by 
an early transposable element which is inserted into intron 2 (Chu et al., 1993; Wu 
et al., 1993). Similarly, MRL-Zp^g mice are characterised by a point mutation of 
this same allele (isoleucine replaced with asparagine in CD95 cytoplasmic region) 
such that whilst normal size CD95 mRNA is expressed, the receptor encoded fails 
to transmit an apoptotic signal (Watanabe-Fukunaga et al., 1992). These two 
CD95-deficient mice display analogous phenotypes to mice deficient for CD95L 
(MRL-g/d mice) (Ramsdell et al., 1994b; Takahashi et al., 1994a) exhibiting 
lymphadenopathy from approximately 8-12 weeks of age (Sidman et al., 1992;
25
Gillette-Ferguson and Sidman, 1994). It is thought that the massive accumulation 
of T cells in the periphery of these mice is a result of defective cell removal by 
CD 95-induced apoptosis, and importantly the onset of autoimmunity is 
ameliorated by T-cell specific expression of wild-type CD95 in transgenics (Wu et 
al., 1994), demonstrating that this phenotype is indeed attributable to the defective 
CD95 receptor. Thymic events do not appear to be substantially altered in these 
mice (Davignon et al., 1985; Herron et al., 1993; Singer and Abbas, 1994) 
implicating the CD95 pathway in peripheral rather than central T cell tolerance. 
Clearly therefore the expression of functional CD95 and CD95L is a requirement 
for effective immune homeostasis, however a detailed understanding of the 
kinetics and control of peripheral T cell elimination by CD95-mediated apoptosis 
is presently lacking. In particular an appreciation of which cells are eliminated 
and what factors control this process is lacking.
Since data from knockout mice (MRL-/pr, MRL-g/J) indicate the importance of a 
functional CD95 pathway in the prevention of autoimmunity, the identification of 
similar defects in humans was of immediate interest. Children with mutations in 
the CD95 receptor exhibit a broadly similar phenotype to that of Ipr mice, 
characterised by lymph node enlargement and autoantibody production (Rathmell 
and Goodnow, 1995). This syndrome has been term ed Autoim m une 
Lym phoproliferative Syndrome (ALPS) and appears to be conferred by a 
dominant interfering CD95 gene mutation, possibly coding for a truncated version 
of CD95 (for example, lacking the death domain) which associates with normal 
CD95 receptors and inhibits signal transduction (Fisher et al., 1995; Cascino et al.,
1996). A further two patients have been identified in whom CD95 mutations are 
related to an autoimmune phenotype. In these cases a 4bp insertion between exon 
7 and 8 in the CD95 mRNA lead to the deletion of the cytoplasmic death domain 
and a consequent defect in apoptotic signal transduction (Kasahara et al., 1996).
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1.3.6 CD95 and Costimulation
Interestingly, there is a small body of evidence to support a positive, possibly even 
costimulatory role for CD95-derived signals, in stark contrast with its more widely 
accepted function in apoptosis induction. Accordingly, anti-CD95 antibodies 
have been reported to co-operate with suboptimal TCR stimulation in the 
induction of T cell proliferation (Alderson et al., 1993), although these data await 
corroboration. In addition, T cells from CD95-defective Ipr mice are less 
responsive to antigenic stimuli than are normal T cells (Davignon et al., 1985), 
which could be interpreted as implicating CD95 in a stimulatory role. Two 
potentially divergent pathways must therefore be invoked at the level of signal 
transduction in order for CD95 to be responsible for two such polarised outcomes, 
proliferation or apoptosis, and how this might be achieved under physiological 
circumstances is currently unknown.
1.3.7 Activation Induced Cell Death (AICD)
In addition to mediating apoptosis of target cells (Ashany et al., 1995; Rathmell et 
al., 1995; Piazza et al., 1997; Vergelli et al., 1997), T cell CD95L expression has 
also been implicated in the induction of cell suicide since T cells themselves 
express the CD95 receptor. A role for CD95L in cell suicide, as opposed to 
simply fratricide, has been confirmed by studies at the single cell level (Brunner et 
al., 1995) and one physiological trigger for such suicide is believed to be TCR re­
engagement (Wesselborg et al., 1993). The first evidence that T cell antigen- 
receptor engagement might be linked to apoptosis induction came from studies on 
both immature (Smith et al., 1989) and mature (Groux et al., 1993) thymocytes in 
which anti-CD3 treatment was associated with the rapid induction of cell death. 
The mechanism of antigen-induced cell death was not addressed in these studies. 
Since double positive immature murine thymocytes express CD95 (Debatin et al.,
1994) and are susceptible to apoptosis following CD95 ligation (Ogasawara et al.,
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1995) a role for the CD95 pathway in antigen-induced deletion of thymocytes 
cannot be ruled out, and intriguingly is gaining support (Castro et al., 1996; 
French et al., 1997) although alternative mechanisms must compensate for this 
process in Ipr mice.
The findings in thymocytes lead to similar studies using mature T cells to 
establish whether there was a link between antigen-receptor engagement and 
apoptosis induction. This work demonstrated that whilst resting T cells were 
relatively resistant to TCR-induced apoptosis, previously activated T cells could 
be triggered to undergo cell death when stimulated in this manner (Ucker et al., 
1992; Wesselborg et al., 1993). In fact, sensitivity to this form of apoptosis was 
enhanced by cytokines such as IL-2 and IL-4 which promoted S-phase entry 
(Lenardo, 1991; Boehme and Lenardo, 1993). This phenomenon was termed 
activation induced cell death (AICD) but the mechanisms underlying this process 
were not known at this time.
A role for the c-myc proto-oncogene in AICD was inferred from the inhibition of 
TCR-induced apoptosis by antisense c-myc oligonucleotides (Shi et al., 1992) and 
the demonstration that the c-myc protein could directly trigger cell death under 
certain conditions (Evan et al., 1992). Similarly, the Nur77 family of steroid 
receptors have been implicated in TCR-driven apoptosis of T cell hybridomas 
(Liu et al., 1994; Woronicz et al., 1994) and a nuclear protein (the TINUR gene 
product) which binds the same DNA sequence as the above receptors has been 
shown to be induced within one hour of TCR crosslinking in a human T cell line 
(Okabe et al., 1995). However, the demonstration that thymic and peripheral T 
cell apoptosis is intact in Nur77 knockout mice suggests a lack of involvement, or 
at least redundancy, in these processes under physiological conditions (Lee et al., 
1995). The potential involvement of transcription factors normally associated 
with cellular proliferation, such as c-myc and Nur77, in cell death highlights the 
similarity in the signalling pathways which lead to either activation or apoptosis
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and one possibility is that the coupling of these two processes may represent a 
safety mechanism to curb uncontrolled cell proliferation.
1.3.7.1 Role of CD95/CD95L Interactions
An exciting development in the understanding of AICD was the relatively recent 
demonstration that one mechanism underlying this process is the activation-driven 
upregulation of CD95L expression leading to cell suicide via CD95 engagement 
(Alderson et al., 1995; Brunner et al., 1995; Ju et al., 1995; Yang et al., 1995; 
Latinis et al., 1997). Thus the acquisition of cytotoxic potential via the CD95 
pathway is believed to be linked to antigen-specific activation events as illustrated 
in figure 1.2. Further studies have defined that signalling through the IT AM 
(immunoreceptor tyrosine-based activation motif) of the TCR/CD3 £ chain is 
sufficient for the induction of surface CD95L expression and that this event is 
Ca2+ dependent (Anel et al., 1994; Vignaux et al., 1995). In addition, protein 
tyrosine kinase activity (Anel et al., 1994) and macromolecular synthesis (Luciani 
and Golstein, 1994; Vignaux et al., 1995) are required for the induction but not the 
execution of CD95-based cytotoxicity following TCR ligation, in line with the 
need for de novo synthesis of CD95L. Recent work has also identified a key role 
for ZAP-70 (Eischen et al., 1997) and p56/c* (Gonzalez-Garcia et al., 1997) in the 
TCR-driven upregulation of CD95L expression during AICD.
AICD has been particularly well documented in murine T cell hybridomas, and 
transformed T cell lines (Brunner et al., 1995; Ju et al., 1995; Yang et al., 1995) 
and it has been convincingly demonstrated that treatment of these cells with anti- 
CD3 antibody induces the upregulation of both CD95 and CD95L and the 
consequent induction of apoptosis in a proportion of the population. In addition, 
murine CD4+ activated T cells have been shown to exhibit high susceptibility to 
apoptosis following restimulation with the use of anti-CD3 (74% apoptosis) or the 
superantigen, Staphylococcal enterotoxin B (SEB) (68% apoptosis) (Ettinger et
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Figure 1.2: Schematic representation of activation induced cell death.
Signalling through the T cell receptor results in the synthesis of CD95L which 
is expressed at the cell surface. The interaction of CD95L with CD95 can 
trigger cell suicide.
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al., 1995), and furthermore this response was absent in Ipr (CD95 defective) and 
gld  (CD95L defective) mice (Zhou et al., 1992; Russell et al., 1993; Ettinger et al., 
1995) indicative of a CD95-dependent mechanism. However, normal human T 
cells have been less extensively studied in this regard, and whilst work on human 
T cell clones provides clear evidence for substantial AICD (Damle et al., 1993; 
Alderson et al., 1995; Hargreaves et al., 1997) the existing literature on normal 
activated peripheral blood CD4+ T cells indicates considerable variation in the 
percentage of cells undergoing apoptosis in response to anti-CD3 treatment 
ranging from approximately thirty to fifty percent (Groux et al., 1993; Wesselborg 
et al., 1993; Dhein et al., 1995). The restriction of TCR-induced apoptosis to 
approximately thirty percent of the T cell population is in line with our own 
studies (Boshell et al., 1996) using superantigen-activated human peripheral blood 
T cells. Together, these data suggested that apoptosis was not the sole outcome of 
anti-CD3 treatment, at least in normal activated human T cells, and raised the 
question of how the choice between life and death is made within each cell under 
such circumstances.
1.3.7.2 Studies in vivo
In addition to the in vitro approaches outlined above, AICD has also been studied 
in vivo with the use of superantigen-mediated TCR binding. Since superantigens 
bypass T cell specificity by interacting with the TCR outside the antigen-binding 
groove, the T cells which expand under these conditions are determined by the 
TCR-V6 expression (Herman et al., 1991; Dohlsten et al., 1993). Accordingly, 
antibodies towards specific TCR-VJ3 chains can be used to distinguish those T 
cells responding to superantigen treatment providing a powerful tool for the study 
of immune responses. Elegant work of this nature by MacDonald and colleagues 
demonstrated that SEB treatment of mice triggered VJ38+ T cell expansion 
followed by the induction of non-responsiveness in these cells which could be 
attributed to a combination of anergy induction and deletion by apoptotic cell 
death (MacDonald et al., 1991). Similarly, injection of lymphoid cells expressing
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the self superantigen M is-la (Minor lymphocyte-stimulating antigen-1) into mice 
has been shown to stimulate transient proliferation followed by anergy and partial 
deletion of M is-la-reactive T cells (Huang and Crispe, 1993). In the latter study, 
whilst both CD4+ and CD8+ T cells exhibited TCR downregulation, which 
represents one mechanism of anergy induction, apoptosis was preferentially 
observed in the CD4+ compartment. Negative responses such as anergy and 
apoptosis thus appeared to be intimately associated with antigen recognition and 
proliferation in these studies, implicating a role for these processes in the 
termination of normal immune responses. It should be noted however that certain 
reports have suggested that whilst T cell responses to superantigens culminate in 
specific T cell elimination, in contrast the stimulation of T cells with peptide leads 
to clonal expansion (Weber et al., 1995).
1.3.7.3 Contribution of Thl versus Th2 Cells
The relative sensitivity of T h l cells versus  Th2 cells to AICD remains 
controversial. Certain reports, mainly using cloned T cell lines, maintain that 
CD95L is preferentially upregulated in Thl cells leading to greater apoptosis in 
this subset (Ramsdell et al., 1994a; Zhang et al., 1997). One contributory factor to 
the increased CD95 sensitivity in T hl cells is postulated to be the lack of FAP1 
expression (Zhang et al., 1997), a phosphatase believed to negatively regulate the 
CD95 death pathway (Sato et al., 1995). Th2 cells, in contrast, are attributed with 
substantial FAP1 expression consistent with the reduced apoptotic response 
reported for this subset (Zhang et al., 1997). Other reports indicate no major 
differences between T hl and Th2 subsets with respect to apoptosis sensitivity 
(Janssen et al., 1991; Russell et al., 1991; Russell et al., 1992; Watanabe et al., 
1997).
1.3.7.4 Alternative Mechanisms
Importantly, despite strong evidence for a role for CD95/CD95L in AICD, it is 
becoming apparent that this may not be the only pathway involved in TCR-
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mediated apoptosis. Accordingly, it was recently reported that although M RL-/pr 
(CD95-defective) mice were refractory to low dose anti-CD3, they exhibited 
massive activation induced apoptosis in response to intermediate and high doses 
of this antibody, indicating that a functional CD95 receptor was not absolutely 
required for AICD (Tucek-Szabo et al., 1996). In line with this finding, it has also 
been demonstrated that the TNFR offers an alternative mechanism for the 
mediation of AICD (Zheng et al., 1995) but that this proceeds with relatively 
delayed kinetics.
1.3.8 CD95 Mediated Signal Transduction
Much of the recent literature regarding CD95-mediated apoptosis pertains to the 
signalling mechanisms employed by this molecule and considerable progress has 
been made in this area. Various putative mediators have been suggested to 
contribute to or influence CD95-derived signalling including the phosphatase 
HCP (Su et al., 1995) RNA binding proteins such as TIAR (Taupin et al., 1995; 
Tian et al., 1995) and the tyrosine kinase abl (Mcgahon et al., 1995). Current 
ideas on the transduction of the apoptotic signal are reviewed below and a 
schematic diagram illustrating the main points is presented in figure 1.3.
1.3.8.1 Recruitments to CD95 Cytoplasmic Domain
CD95-mediated apoptosis can proceed in enucleated cells (Nakajima et al., 1995) 
and is independent of both RNA and protein synthesis (Itoh et al., 1991) 
suggesting that the chief components of this pathway exist in a preformed state. 
The CD95 cytoplasmic domain comprises 145 amino acids and lacks recognised 
motifs for enzymatic activity such as kinase or phosphatase activities (Itoh et al., 
1991). However, a 68 amino acid shared motif between TNFR and CD95, which 
is necessary for transduction of death signalling, has been identified (termed the 
death domain) and has been shown to interact with death-domain containing 




Figure 1.3: Schematic representation of the CD95 death pathway. The DISC (death inducing signalling complex) is formed by 
the recruitment of death domain containing proteins (such as FADD, RIP and CAPS) to the CD95 death domain. FAP1 is recruited 
to the CD95 salvation domain and may inhibit DISC fomation. The DISC can recruit and activate caspase 8 (FLICE). DAXX 
associates with CD95 cytoplasmic region and may be involved in JNK activation. The release of mitochondrial factors is thought to 
precede caspase 3 activation. Mito = mitochondrion, cyt c = cytochrome c, AIF = Apoptosis Inducing Factor. Arrows do not 
necessarily indicate a direct link.
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in the yeast two hybrid system (Chinnaiyan et al., 1995; Stanger et al., 1995). 
Both of these proteins can induce apoptosis when overexpressed indicating a 
potential role in CD95 signal transduction. Moreover, the binding of FADD to the 
death domain appears to be dependent on the trimerisation of CD95 molecules, 
consistent with a triggering of this association by ligand binding (Kischkel et al.,
1995) and in line with the finding that self association of the CD95 death domains 
is sufficient to induce a death signal (Boldin et al., 1995). Interestingly, a death 
domain containing protein termed reaper is present in the fruit fly Drosophila, 
indicating evolutionary conservation in the mechanism of apoptosis signal 
transduction (White et al., 1996). The fact that RIP contains a consensus kinase 
m otif suggested a possible role of kinase activity in CD95-induced apoptosis, 
although there is little evidence to support this (Eischen et al., 1994) and the 
majority of studies refute this hypothesis (Schraven and Peter, 1995; Janssen et 
al., 1996). Further work on CD95-mediated signalling has identified the CAPS 
(cytotoxicity-dependent APO-1-associated proteins) which associate with 
oligomerised (but not monomeric) CD95: whilst CAP1 and CAP2 have been 
identified as serine-phosphorylated forms of FADD, CAPS 3 and 4 may represent 
novel apoptosis-transducing molecules (Kischkel et al., 1995).
The carboxy terminus of the CD95 receptor cytoplasmic region comprises a 15 
amino acid “salvation domain” which negatively regulates CD95 signalling 
(Cleveland and Ihle, 1995). This region is believed to mediate the interaction with 
the phosphatase FAP1 (Cleveland and Ihle, 1995) and deletion of the “salvation 
domain” has been shown to enhance the interaction with FADD (Chinnaiyan et 
al., 1995). The interaction of an additional protein DAXX with the CD95 
cytoplasmic domain has recently been demonstrated, and is thought to be involved 
in CD95-mediated JNK activation (Yang et al., 1997). The relative contribution 
of the signals emanating from FADD versus those derived from DAXX is 
incompletely understood and how these pathways may integrate to influence the 
final outcome of CD95 ligation remains to be elucidated.
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1.3.8.2 Caspase Cascades
Over the last two years, it has emerged that a key event in the execution of the 
apoptotic pathway triggered by wide-ranging stimuli including CD95 is the 
activation of a cascade of aspartate-specific cysteine proteases (caspases). This 
work has been driven by studies on the nematode Caenorhabditis elegans which 
have identified a large number of genes relevant to the cell death pathway termed 
ced genes (C. elegans death genes) (Yuan and Horvitz, 1990; Hengartner, 1994; 
Hengartner, 1996; Henkart, 1996). Amongst the most well known are ced-3 (for 
which the mammalian homologue is caspase 1) (Schwartz and Osborne, 1994; 
Duan et al., 1996; Kumar and Lavin, 1996; Orth et al., 1996) ced-9 (homologous 
with mammalian BCL-2) (Hengartner et al., 1992; Hengartner and Horvitz, 1994) 
and ced-4 (Yuan and Horvitz, 1992), for which a mammalian homologue remains 
to be identified (Vaux et al., 1994). Which caspases participate in the execution of 
apoptosis is highly cell type and stimulus dependent (Sarin et al., 1996) but CD95 
killing of T cells is believed to involve sequential activation of caspase 8 (FLICE) 
caspase 1 (ICE) and caspase 3 (PRICE) (Los et al., 1995; Armstrong et al., 1996; 
Duan et al., 1996; Enari et al., 1996; Muzio et al., 1996; Anel et al., 1997). In 
support, caspase 1-deficient mice exhibit a defect in CD95-mediated apoptosis, 
yet still undergo cell death in response to dexamethasone or y  irradiation 
(C leveland and Ihle, 1995). Furthermore, treatm ent with cell soluble 
fluoromethylketone caspase inhibitors such as Z-VAD-FMK (Cbz-Val-Ala- 
Asp(OMe)-fluoromethylketone) inhibits CD95-mediated apoptosis in numerous 
cell types (Sarin et al., 1996), implicating caspase activity as an essential step in 
the apoptotic pathway, and this inhibitor has been utilised for part of the study. 
Caspase 8 has been shown to interact directly with the CD95 receptor via the 
DISC (death inducing signalling complex), a complex formed by the recruitment 
of molecules such as FADD to the CD95 death domain (Muzio et al., 1996) (see 
figure 1.3). Caspase 8 interacts with the death effector domains (DEDs) of FADD 
becoming proteolytically activated as a consequence (Medema et al., 1997), and
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the resistance to apoptosis in early activated T cells is reported to reflect a lack of 
recruitment of this caspase to the CD95 cytoplasmic domain (Peter et al., 1997).
W hilst a number of putative substrates for the caspases have been identified 
including p-actin, a-fodrin and lamin B1 (Lazebnik et al., 1994; Martin et al., 
1995a; Martin and Green, 1995; Neamati et al., 1995) the substrate responsible for 
committing cells to apoptosis remains unknown. The early demonstration that one 
substrate for caspase 3 was the enzyme poly(ADP-ribose) polymerase (PARP) 
(Kaufmann et al., 1993; Lazebnik et al., 1994) suggested a possible role in the 
shut-down of DNA repair processes, however whilst providing a useful marker of 
apoptosis induction, PARP cleavage is not a requirement for apoptosis induction 
(Wang et al., 1997). It is of note that PKC6 represents an alternative target for 
caspase 3, and that overexpression of the cleavage product of this kinase is 
associated with the onset of characteristics of apoptosis including chromatin 
condensation, nuclear fragmentation and lethality both in HeLa cells and NIH3T3 
cells (Emoto et al., 1995).
1.3.8.3 Role of Ceramide
The familial relationship of CD95 with the TNFR prompted signalling 
comparisons between these two receptors and indicated some homology, 
particularly in terms of the death domain and protein recruitments (Cleveland and 
Ihle, 1995; Boldin et al., 1996), however elements distinct to each pathway have 
also been identified (Schultz-Osthoff et al., 1994; Wong and Goeddel, 1994). One 
event which has been reported to follow ligation of CD95, TNFR and indeed 
CD28 is the activation of certain forms of the lipid enzyme sphingomyelinase 
which is responsible for mediating the cleavage of sphingomyelin to yield the 
signalling molecule ceramide (Boucher et al., 1995; Gulbins et al., 1995; Tepper 
et al., 1995; Edmead et al., 1996). Ceramide has been implicated in mediating a 
wide range of functions in T cells resulting in both positive and negative 
outcomes. Its production following CD28 ligation suggests potential involvement
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in costim ulatory functions (Boucher et al., 1995), whilst treatm ent with 
exogenously provided cell soluble ceramide analogues can mediate both growth 
arrest and apoptosis in various cell types including T cells (Jayadev et al., 1995; 
Tepper et al., 1995). The nature of the sphingomyelinase enzyme involved in 
such signalling is still subject to debate: whilst the TNF pathway utilises both 
acidic and neutral forms (Kolesnick and Golde, 1994; Higuchi et al., 1996), CD28 
signalling involves only the acidic enzyme (Boucher et al., 1995) and there is 
evidence to support a role for either acidic (Cifone et al., 1993; Gulbins et al.,
1995) or neutral (Tepper et al., 1995) forms in CD95-mediated signalling.
A number of putative targets for ceramide have been identified including ceramide 
activated protein phosphatase (CAPP) (Dobrowsky and Hannun, 1992), ceramide 
activated protein kinase (CAPK) (Mathias et al., 1991), JNK (Westwick et al.,
1995), PKC£ (Hannun and Obeid, 1995), the proto-oncogenes vav  and ra s  
(Gulbins et al., 1995) and caspase 3 (Smyth et al., 1996) which allow ceramide to 
influence wide-ranging biological processes including apoptosis, inhibition of 
proliferation, differentiation, and inhibition of protein secretion (Hannun, 1994). 
Whether ceramide signals trigger positive or negative outcomes is likely to be 
influenced by the location and context of ceramide generation: for example 
ceramide-induced apoptosis in Jurkat cells is converted to a proliferative response 
in the presence of DAG (Hannun, 1994).
1.3.8.4 Mitochondrial Changes
Another event which has recently been implicated in apoptotic signalling is that of 
mitochondrial permeability transition (PT) involving a disruption in the 
mitochondrial inner transmembrane potential (A¥m). In viable cells, the unequal 
distribution of ions either side of the inner mitochondrial membrane generates 
both a chemical and an electrical gradient which are required for effective 
mitochondrial function (Attardi and Schatz, 1988). The disruption of this 
transmembrane potential has recently been identified as an early marker of cells
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com m itted to apoptosis following diverse stimuli including CD95 ligation 
(Castedo et al., 1996) and is believed to involve a process termed permeability 
transition during which mitochondrial proteins can leak out into the cytosol. Such 
proteins include pro-apoptotic factors of which the 15kDa cytochrome c protein 
and AIF (apoptosis inducing factor) have been identified thus far (Liu et al., 1996; 
Zamzami et al., 1996). The biological properties of such factors are only just 
beginning to be defined, but AIF is known to proteolytically activate caspase 3 
and can induce characteristic apoptotic changes when applied to isolated nuclei 
(Susin et al., 1997). Intriguingly, inhibition of capsase 1 prevented CD95-induced 
A¥m disruption (Castedo et al., 1996) demonstrating that part of the caspase 
cascade occurs upstream of such mitochondrial changes, whilst the activation of 
other proteases (including caspase 3) may lie downstream of this process (Susin et 
al., 1997).
1.3.8.5 BCL-2 family and BCL-2-like Proteins
The cellular apoptotic response is subject to modulation by a number of 
intracellular proteins which either inhibit or promote cell death. The list of 
proteins of this nature is steadily growing and recent work has focused on the 
generation of hypotheses to explain their mechanisms of action, although this is 
still a highly controversial area. One of the first to be identified was the 26kDa 
BCL-2 protein which is associated with mitochondrial and perinuclear membranes 
(Hockenbery et al., 1990; Zehava and Cleary, 1990; Nunez et al., 1994). This 
protein has been shown to inhibit apoptosis induced by diverse stimuli including 
irradiation and glucocorticoids as well as perforin and granzymes (Chiu et al.,
1995) and a reduction in BCL-2 expression correlates well with decreased T cell 
survival (Akbar et al., 1993a). In addition, the pathway of apoptosis induced by 
the transcription factor p53 is also subject to regulation by BCL-2 (Vaux et al., 
1994), as is apoptosis resulting from the activation of the proto-oncogene c-myc 
(Bissonnette et al., 1992; Fanidi et al., 1992). Whilst BCL-2 was initially thought 
to function via an anti-oxidant mechanism (Hockenbery et al., 1993), there is now
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evidence that this protein may operate by altering mitochondrial release of 
apoptosis-inducing factors (Shimizu et al., 1996; Kluck et al., 1997; Yang et al.,
1997) and consistent with this theory, hyper-expression of BCL-2 prevents the 
A¥m disruption induced by apoptotic stimuli including glucocorticoids, DNA 
damage, oxidants or ceramide (Zamzami et al., 1995a; Zamzami et al., 1995b). 
Interestingly, transfection of human or murine T cells with BCL-2 fails to block 
CD95-induced apoptosis, although etoposide and dexamethasone induced death 
are potently inhibited under these conditions (Moreno et al., 1996) suggesting that 
CD95 signalling is not regulated by this protein, a view supported by a number of 
other studies (Chiu et al., 1995; Strasser et al., 1995).
Subsequent to BCL-2 a whole family of related pro- and anti-apoptotic proteins 
have been identified. Pro-apoptotic intracellular proteins include BAX (21kDa) 
(Oltvai et al., 1993), BAK (23kDa) (Simonian et al., 1997; Ulrich et al., 1997), 
BCLXs (21kDa) (Boise et al., 1993) and BAD (Gajewski and Thompson, 1996; 
Zha et al., 1997), whilst proteins implicated in protection from apoptosis include 
BAG1 (Takayama et al., 1995) and B C L X l (29kDa) (Boise et al., 1993). BCL-2 
and an additional anti-apoptotic protein B C L X l have been suggested to function 
by heterodimerisation with BAX thus preventing the formation of toxic BAX 
homodimers (Gajewski and Thompson, 1996). Conversely the dimerisation of a 
further protein BAD with BCL-2 or B C L X l serves to liberate BAX and promote 
apoptosis induction (Gajewski and Thompson, 1996). Recent evidence from the 
C.elegans system supports a model in which apoptosis is triggered by the release 
of pro-apoptotic ced-4 from its association with ced-9 (BCL-2 homologue) (Wu et 
al., 1997b) such that it is free to activate ced-3 (caspase 1 homologue) (Wu et al., 
1997a). The relative role of the BCL-2 family members in the modulation of 
mitochondrial events compared to the sequestering of pro-apoptotic proteins 
remains to be resolved.
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Intriguingly, despite their opposing functions BCLXs and BCLXl  are splice 
variants of the same gene first identified by Boise and colleagues (Boise et al.,
1993). BCLXl  (the most common splice variant in both mice and humans) was 
found to prevent apoptosis induced by a diverse array of stimuli including 
glucocorticoids, y-irradiation, Ca2+ ionophore and anti-CD3 antibody (Grillot et 
al., 1995) and has been associated with the promotion T cell survival in a number 
of studies (Boise et al., 1995; Gombert et al., 1996). Transfection studies in Jurkat 
have indicated that BCLXl  expression can also prevent CD95-mediated apoptosis 
(Boise et al., 1995), although a similar approach in primary human and murine T 
cells failed to confirm this (Moreno et al., 1996). Whilst anti-CD3 treatment alone 
is sufficient for BCLXl  induction, simultaneous CD28 ligation significantly 
enhances the levels of expression in a manner which inversely correlates with 
sensitivity to CD95-mediated apoptosis (Boise et al., 1995) indicative of a role for 
B C L X l  in the prevention of CD95-mediated apoptosis. It is likely that the 
phosphorylation status and cellular localisation of such apoptosis regulatory 
proteins is critical in determining their function.
1.3.8.6 Negative Regulation of CD95 Signalling
Interestingly, the most recent revelations pertaining to CD95-mediated signalling 
have related to molecules which serve to inhibit apoptosis induction through this 
pathway, emphasising the stringent control mechanisms which exist to limit 
signalling via this receptor. Accordingly, FLICE inhibitory proteins (FLIPS) bind 
to the DEDs of FADD and inhibit the FADD-caspase 8 interaction (Irmler et al., 
1997; Thome et al., 1997). Thus these molecules effectively act as dummy 
caspase 8 proteins. Two forms of the FLIP molecule appear to be produced in 
human leukocytes as a result of alternative splicing with the shorter form (FLIP§, 
28kDa) comprising two DEDs linked to a 50 amino acid carboxyterminal region 
and the longer form (FLIPl , 55kDa) in which the two DEDs are followed by a C- 
terminal caspase-like domain yielding a structure reminiscent of that of caspase 8. 
Contrasting with caspase 8, however, FLIPl  does not appear to posses protease
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activity, at least not against the caspase substrates tested to date. In being 
recruited to the DISC in the place of caspase 8, these molecules prevent apoptotic 
signalling and interestingly have been found in human melanoma lesions 
suggesting that upregulation of FLIP may occur during tumourigenesis (Irmler et 
al., 1997).
Further negative regulation is made possible by the existence of mutant non­
functional caspase 8 proteins FLICE-1 (Boldin et al., 1996) and FLICE-2 
(Vincenz and Dixit, 1997) in which the catalytic cysteine residue has been 
substituted. In addition, the death effector domain-containing protein CLARP 
(caspase-like apoptosis regulatory protein) interacts with and regulates caspase 8 
(Inohara et al., 1997) whilst the death domain binding protein sentrin can inhibit 
both CD95- and TNFR-induced apoptosis (Okura et al., 1996).
1.3.9 Additional Death Receptors
It has long been known that the TNF type I receptor can transmit an apoptotic 
signal (Wright et al., 1992; Smith et al., 1994), and in fact there is some overlap 
with CD95 in terms of the signalling intermediates utilised for this process 
(Cleveland and Ihle, 1995; Boldin et al., 1996) A recent plethora of reports have 
documented the existence of additional death receptors/ligands which, like 
CD95/CD95L, belong to the TNFR/TNF family. These include the death receptor 
DR-3/ws/ which is characterised by a more restricted tissue distribution than 
TNFR and CD95 being predominantly expressed in spleen, thymus and peripheral 
blood lymphocytes (Chinnaiyan et al., 1996; Kitson et al., 1996). In addition, a 
cytotoxic ligand termed TRAIL (TNF-related-apoptosis-inducing-ligand) has been 
identified (Wiley et al., 1995) and comprises a type II membrane protein of 281 
amino acids (murine version 291 amino acids) which maps to the chromosomal 
location 3q26. Message coding for the TRAIL molecule is found in a variety of 
human tissues including the spleen, lung and prostate, and in addition to the full
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length membrane associated version, a soluble form of the TRAIL molecule has 
been detected (Wiley et al., 1995). The first receptor identified for TRAIL was 
designated DR4 (Pan et al., 1997) and recently two further receptors have been 
discovered namely DR5 and DcRl (Sheridan et al., 1997). Intriguingly, the latter 
encodes a decoy receptor which inhibits TRAIL signalling and provides further 
evidence that apoptosis-inducing receptors are subject to tight regulation. In terms 
of similarity to other death-inducing ligands of this family, TRAIL exhibits closest 
homology to CD95L (28% identity at the C-terminal domain) closely followed by 
TNFoc which shares 23% identity in this extracellular region (Wiley et al., 1995).
One interesting question relates to the ability of the death inducing ligands to 
themselves transduce signals into the cell. In this regard it is of interest that 
members of the TNFR family exhibit cytoplasmic domain conservation between 
species (although not between family members) indicating that this scenario 
remains a possibility. The exception to this observation is provided by TRAIL, 
which lacks inter-species homology in this region and is therefore unlikely itself 
to mediate biological functions via signal transduction (Wiley et al., 1995).
1.3,10 Medical Relevance of the CD95 Pathway
Mice injected with anti-CD95 antibody have been documented to die through liver 
failure with symptoms reminiscent of fulminant hepatitis in humans (Ogasawara 
et al., 1993). The latter is known to involve abnormally activated T cells, and in 
addition the transformation of hepatocytes with Hepatitis viruses B or C induces 
CD95 upregulation (Hiramatsu et al., 1994), indicating the potential involvement 
of the CD95 system in this disease. Aberrant triggering of the CD95 pathway has 
also been implicated in graft-versus host disease (Chu et al., 1995; Via et al., 
1995; Via et al., 1996) and insulitis in IDDM (Insulin Dependent Diabetes 
Melitus) (Dong et al., 1995). In fact, it has recently been demonstrated that NOD 
mice (which represent a diabetes model) are free of insulitis when crossed with the
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M RL-/pr (CD95-defective) mouse, illustrating a requirement for CD95-mediated 
cytotoxicity for the initiation of autoimmune pancreatic P cell destruction (Itoh et 
al., 1997).
One mechanism by which the CD95 pathway may be inappropriately triggered is 
if the controls on CD95L expression are compromised. It is therefore of interest 
that patients suffering from NK lymphoma or large granular lymphocyte 
leukaemia of NK or T cell type are characterised by significant serum levels of 
soluble CD95L, and associated systemic tissue damage, particularly in those cell 
types known to be most susceptible to CD95-mediated apoptosis such as 
hepatocytes and neutrophils (Tanaka et al., 1996). Conversely, the presence of 
soluble CD95 receptor may inhibit CD95-mediated apoptosis and a number of 
reports have suggested that this occurs in patients suffering from SLE (Systemic 
Lupus Erythematosus) (Poulton et al., 1995; Okubo et al., 1996; Jodo et al., 1997; 
Kovacs et al., 1997).
It has been proposed that apoptosis induction plays a role in the immunodepletion 
which characterises acquired immune deficiency syndrome (AIDS) (Groux et al., 
1992; Estaquier et al., 1994; Kanagawa et al., 1995), and it has been demonstrated 
that T cells from Human Immunodeficiency Virus (HIV) -infected individuals are 
unusually susceptible to CD95-mediated apoptosis (Estaquier et al., 1995) 
implicating this pathway in the observed T cell depletion. Furthermore, CD95L 
expression has also been documented to be upregulated on HIV-infected 
macrophages (Badley et al., 1997) indicating a possible role in the T cell deletion 
which is a feature o f the AIDS syndrome.
Certain tissues in the body exhibit constitutive CD95L expression, which is 
believed to bestow on these regions a form of immune privilege (Griffith et al., 
1995; Green and Ware, 1997). These sites (including the anterior chamber of the 
eye comprising CD95L expressing parenchymal cells) show extended/indefinite
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graft survival due to the apoptosis of infiltrating CD95 positive lymphocytes. 
Similar studies in gld  mice demonstrate a lack of immune privilege implicating 
functional CD95L expression as a requirement for this phenomenon. Likewise, 
CD95L-expressing tissues are not subjected to rejection when transferred to 
conventional non-privileged sites: for example testis tissue survives when 
transplanted into renal capsule (Griffith et al., 1995). A better knowledge of how 
and when such death pathways operate would therefore be relevant to 
transplantation biology as well as to the understanding and treatment of disease 
states in which these controls may be lost.
1.4 AIMS OF THE STUDY
This study aimed to investigate the role of apoptosis via the death receptor CD95 
in the context of human T cell activation. At the outset of this study, CD95 had 
been identified as a receptor that could transduce a death signal and its ligand had 
just been cloned. Understanding how and when CD95-mediated apoptosis 
operated during the course of an immune response was therefore the focus of 
enormous scientific interest and formed the basis of this project. In order to 
perform immune functions T cells require activation, thus the first aim of this 
study was to establish effective in vitro T cell activation protocols and verify that 
such treatments resulted in the expected proliferative and phenotypic changes. 
Subsequently this study aimed to establish the expression patterns of the apoptosis 
receptor CD95 and its ligand during the course of T cell activation, with a view to 
discerning the physiological circumstances under which this death pathway might 
be triggered. Crucially, it was hoped to gain an understanding of the factors 
controlling which T cells were eliminated by CD95-mediated apoptosis, and when 
this occurred during the course of an immune response.
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Thus the aims of this project were to:-
• Establish in vitro T cell activation conditions which triggered effective T cell 
proliferation and resulted in the expected phenotypic changes.
• Determine the expression of the death receptor CD95 during the course of T 
cell activation.
• Investigate the sensitivity of T cells to CD95-mediated apoptosis and correlate 
this with the expression levels of this receptor.
• Investigate when and where CD95L was expressed and elucidate the 







Sources of materials are indicated in appendix 1. All chemicals and reagents were 
supplied by Sigma Chemical Company Ltd. unless otherwise stated. Details of 
buffers and solutions can be found in appendix 3.
2.1.1 Tissue Culture Materials
Tissue culture plastics (Becton Dickinson, Falcon) were purchased from 
Fahrenheit Laboratory Supplies Ltd. All medium was purchased from Life 
Technologies and the protocols followed for medium supplementation are 
indicated in appendix 2. Foetal calf serum (Sigma Chemical Company Ltd) was 
heat inactivated. Chimeric proteins comprising the extracellular portions of CD95 
or CD23 fused to the Fc region of an Ig molecule (CD95-Fc, CD23-Fc) were 
kindly provided by Y. Patel (Bath Institute for Rheumatic Diseases, UK) and J.-Y. 
Bonnefoy (Glaxo Ltd, Geneva).
2.1.2 Antibodies
Hybridomas were purchased from the American Type Culture Collection (ATCC) 
(Rockville, Maryland, USA) where indicated and monoclonal antibodies (mAbs) 
were purified in our laboratory. The control IgM antibody (Ab) OBI was a kind 
gift from S. Walsh (Bath Institute for Rheumatic Diseases, UK). This Ab was 
used as a control for the anti-Fas Ab, CHI 1, and is thought to bind selectively to 
an intracellular protein expressed by osteoblasts. FITC/PE-conjugated secondary 
Abs (anti-mouse polyvalent-FITC, anti-mouse IgG-FITC, anti-mouse IgG-PE) 
were purchased from Sigma Chem ical Company Ltd. Abs utilised for 
intracellular cytokine detection were purchased from R&D Systems Ltd. The 





CD4 84H10 kind gift from P. Beverley, 
Jenner Institute, Compton, 
UK
CD8 UCHT4 ATCC
CD 14 UCHM1 kind gift from P. Beverley
CD19 BU12 k in d  g if t  fro m  I. 
MacLennan, University of 
Birmingham, UK
CD25 HB8784 ATCC
CD28 9.3 kind gift from P. Linsley, 
B risto l-M yers Squibb, 
Seattle, USA
CD28:FITC Serotec Ltd
CD80 BB1 kind gift from P. Linsley
CD86 IT2.2 Serotec Ltd
CD58/LFA3 TS2/9 ATCC
CD95/Fas CH11 (IgM), ZB4 (IgG) TCS Biologicals Ltd
M3 (IgG) kind gift from D. Lynch, 
Immunex, Seattle, USA
HLA-DR L243 ATCC
TCRcxP B M A  0 3 1 , F IT C - 
conjugated
Serotec Ltd





Cells were cultured at 37°C and 5% C 02 (95% air) in a humidified incubator with 
experimental manipulations being performed using sterile technique in a laminar 
flow hood (Class II). Cell lines were maintained free of mycoplasma as 
determined by routine testing (Mycoplasma ELISA, Boehringer Mannheim). 
Adherent cells were passaged by trypsinisation. Briefly, medium was removed 
from flasks by aspiration and cells were washed once with 10ml phosphate 
buffered saline (PBS, pH 7.3). Cells were incubated at 37°C for 5min in the 
presence of trypsin-EDTA (2ml for a 75cm2 flask, 3 ml for a 125cm2 flask). 
Trypsinisation was terminated by the addition of fresh culture medium to a final 
volume of 10ml and cells were passaged appropriately (routinely 1:10).
To maintain stocks, cell lines were regularly frozen for long term storage under 
liquid nitrogen. Cells (5 X 106 - 1 X 107) were pelleted (350g, lOmin), 
resuspended in 20% FCS/10% DMSO and aliquoted into freezing vials. Vials 
were placed at -80°C for 15-18h prior to liquid nitrogen storage. Cells were 
thawed rapidly in a water bath (37°C), washed twice with fresh medium and 
returned to culture. Cell counts were performed using a haemocytometer. Unless 
otherwise stated, washes for all protocols were performed by the addition of PBS 
and cells were pelleted by centrifugation (350g) for lOmin.
2.2.1.2 Transfected Cells
CHO (Chinese Hamster Ovary) cell and COS-7 cell transfectants were cultured in 
D ulbecco's M inim al Essential M edium (DMEM) containing 10% FCS 
supplemented as described (appendix 2). CHO cells stably transfected with
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human cDNAs encoding the Human Leukocyte Antigen HLA-DR4, CD80 (the 
costimulatory ligand) or both were available in the laboratory (Sansom et al., 
1993). Expression of transfected molecules was routinely checked by FACS 
staining. For experim ental use, transfectants were routinely fixed with 
glutaraldehyde (0.025%, 2min) and washed twice with PBS.
2.2.1.3 Transformed T Cell Lines and T Cell Clones
Jurkat T cells (J16, ATCC) were maintained in RPMI-1640 containing 10% FCS 
supplemented as described (appendix 2 ) (complete medium).
Alloreactive human T cell clones (7418, kind gift from Eric Culbert, Zeneca 
pharmaceuticals, Cheshire) were maintained in RPMI-1640 supplemented with 
5% human AB serum and restimulated every 14 days with glutaraldehyde-fixed B 
cells (ROF, ATCC ) and irradiated PBMC. Briefly, ROF cells were washed once 
with PBS and resuspended (5 X 105 cells/ml) in 500pl glutaraldehyde (0.025%) 
for 2min then washed 3 times with medium and used at a ratio of 1:5 (ROF:7418). 
PBMC (1 X 107 cells/ml) were irradiated (3000rad) for lOmin and used at a ratio 
of 1:1 (PBMC:7418). IL-2 (10 IU/ml) was added every 3-4 days. ROF cells were 
cultured in RPMI-1640 supplemented as above.
2.2.1.4 Generation of CD95-resistant Jurkat T Cells
JLW cells were generated from J16 cells by repeated challenge with the apoptotic 
anti-CD95 Ab CH11 (0.1(ig/ml) and surviving cells were expanded in culture. 
Five rounds of selection were performed and the resulting population was cloned 
by serial dilution. The generated cell line (JLW) exhibited a significantly reduced 
apoptotic response to CD95 engagement compared to the parent line (J16) (figure 
4.6) despite expressing equivalent levels of surface CD95. JLW cells were 
cultured using the same conditions as for J16 cells.
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2.2.1.5 Purification of Peripheral Blood T Cells
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation (density, 1.077 g/ml) (Boyum, 1964) of heparinsed (6  IU/ml) 
peripheral blood from healthy donors. PBMC were washed twice with complete 
medium and stimulated as indicated, or purified to T cells by immunomagnetic 
depletion (Sansom et al., 1993). Briefly, PMBC were incubated in complete 
medium ( 10ml) in a petri dish for lh  (37°C, 5% CO2 ) to remove the adherent 
fraction. Non-adherent cells were recovered, washed in complete medium and 
incubated for lh  at 4°C with mAbs (l|ig /m l) against HLA-DR, CD 19 (B cell 
marker) and CD 14 (monocyte marker) in a final volume of 500pl. W here 
indicated anti-CD8 mAb (lpg/m l) was also included to allow depletion of CD8+ 
T cells. Following washing with complete medium, cells were incubated for a 
further hour at 4°C with 50 j l l 1 sheep anti-mouse IgG conjugated to magnetic beads 
(Dynabeads). Cells which had been bound by Ab could thus be removed using a 
magnet (negative selection by immunomagnetic depletion). FACS analysis 
confirmed that the resultant cell population were routinely >95% T cells as judged 
by positive staining with OKT3 (which recognises the CD3 component of the 
TCR).
2.2.1.6 Activation of Peripheral Blood T Cells
To generate activated T cell lines, PBMC were treated with the superantigen SEB 
(lpg/m l), or the lectins phytohaemagglutinin (PHA) (2pg/ml), or concanavalin A 
(ConA) (lpg/m l). Cells ( I X  107/ml) were cultured in complete medium or serum 
free medium (AIM-V) as indicated and restimulated every 10-15 days using fixed 
SEB-pulsed HLA-DR/CD80 transfectants (1:5 ratio transfectant: T cell).
For supernatant transfer experiments, purified T cells ( I X  107/m l) were 
stimulated using immobilised anti-CD3 and CD80 transfectants (ratio 1:5, 
transfectant:T cell). Anti-CD3 was plate-coated at lpg/m l (in PBS) for 15-18h at 
40jil per well in 96 well plates and wells were washed twice with PBS to remove
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unbound Ab prior to the addition of cells. Following 3 days of activation in this 
manner, T cells were pelleted and the supernatant was applied to purified resting T 
cells. T cell blasts were subjected to density gradient centrifugation (as above) 
prior to use in apoptosis assays.
2.2.1.7 Generation of soluble CD95L
For the generation of soluble CD95L, a CD95L cDNA clone was manipulated to 
include a marker epitope (FLAG, Kodak) and the transmembrane and intracellular 
portions removed to preclude membrane binding and allow release in a soluble 
form. To target the resultant protein for secretion, a signal sequence (from CD80) 
was also added to the cDNA construct which was subsequently cloned into the 
eukaryotic expression vector pCDNA3 which contained a neomycin resistance 
gene. The vector containing this construct was then used for the transfection of 
COS-7 cells by electroporation. The production of the CD95L-flag construct was 
carried out by Dr Yusuf Patel and the transfection of COS-7 cells with this 
construct was performed by Dr Julie McLeod working in our laboratory. A stable 
line was generated by culture in the presence of neomycin (lOOpg/ml) to select for 
cells expressing the vector. Cells were then cloned into 96 well plates and 
supernatants were subsequently screened for apoptotic activity in the JAM assay 
(Matzinger, 1991) using J16 cells. Selected clones were expanded and cell 
supernatants were harvested, filtered and tested for specific CD95L-dependent 
apoptotic activity in the JAM assay.
2.2.2 Proliferation Assays
To measure the initiation of cell division in T cells subjected to various 
treatments, proliferation assays were employed (Waldmann et al., 1987). T cells 
were added to a 96 well plate (2 X 104 cells/well) with the treatments described in 
the figure legends in a final volume of 150pl of medium. Where anti-CD3 Ab
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(0KT3) treatment is included, this Ab was diluted to the indicated concentration 
in PBS and plate-coated as described in section 2.2.1.6. Transfected cells were 
pulsed with superantigen (SEB, lpg/ml) for 4h in medium (37°C, 5% CO2 ) where 
indicated then washed three times and fixed (0.025% glutaraldehyde, 2min) prior 
to use in proliferation assays.
Cells were incubated at 37°C in 5% CO2 for 3 days and pulsed with tritiated 
thymidine (3H-thymidine) to a final concentration of ljiC i/well for the last 
overnight incubation. Plates were then harvested onto glass fibre filter mats 
(using a semi-automatic cell harvester, Skatron Ltd) and assayed by liquid 
scintillation counting (1290 Rackbeta, Wallac Ltd).
2.2.3 FACS staining
2.2.3.1 Surface Staining
All FACS analysis was performed on a Becton Dickinson FACStar Plus using a 
lOOmW 488nm argon laser with light being channelled by an FL-1 filter (520nm 
±20) and an FL-2 filter (580nm ±20) (Ormerod, 1990). Lysis II software (Becton 
Dickinson) was utilised.
To prepare T cells for FACS analysis, 1 X 105 cells were washed with PBS and 
incubated with primary staining Ab at lpg/m l (unless otherwise stated) in a 
volume of 50jli1 for 30min at 4°C. The details of the Abs utilised for staining can 
be found in table 2.1 (section 2.1.2.) and for analysis of CD95 expression, ZB4 
(rather than CH11) was used as the primary staining Ab. Following incubation 
with primary Ab, cells were washed once with PBS to remove excess Ab and then 
incubated for 30min at 4°C with FITC- or PE- conjugated secondary Ab. Anti­
mouse polyvalent (anti-IgM, IgG, IgA)-FITC was used as the secondary Ab
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unless otherwise stated and was added at a concentration o f 50|ig/ml in a volume 
o f 50jll1.
In certain experiments, the aim was to treat T cells with the anti-CD95 Ab (CHI 1) 
and subsequently stain for expression of surface receptors. Since CHI 1 is an IgM 
Ab, anti-mouse IgG-PE/FITC was used as a secondary Ab to allow visualisation 
o f the staining Ab without detecting CH11. Where indicated, CHO cells were 
gated out during FACS analysis due to their autofluorescence in both the FL-1 and 
FL-2 channels following glutaraldehyde fixation.
2.2.3.2 Intracellular Staining
For intracellular cytokine staining, 5 X 105 T cells were stimulated for 6h with 
PMA (0.04|ig/ml) and ionomycin (ljiM ) in the presence of the golgi transport 
inhibitor monensin (2mM) in a final volume of 500|il of complete medium. Cells 
were fixed and permeabilised in accordance with the “Fix and Perm” kit (TCS 
Biologicals) protocol and stained using FITC- or PE-conjugated antibodies (anti- 
IL-2-FITC, anti-IFNy-PE, anti-IL-4-FITC) or isotype-matched controls. 10}ig Ab 
was used in a final volume of 20 0 jil.
2.2.4 Apoptosis Detection
2.2.4.1 Agarose Gel Analysis of Fragmented DNA
DNA fragmentation has been identified as a characteristic process during 
apoptosis induction (McConkey et al., 1994). To detect the presence of 
fragmented DNA in the cytoplasm of cells undergoing apoptosis, the following 
protocol was employed (Trauth et al., 1989). 1 X 107 Jurkat T cells were lysed on 
ice in 300|il of buffer comprising lOmM NaCl, lOmM Tris-HCL (pH 7.5), ImM  
EDTA and 0.2% (v/v) Triton-X-100. Nuclei were pelleted by centrifugation at 
15,000g for 15min at 4°C and the supernatant (containing low molecular weight
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DNA) was incubated with RNAse A (final concentration 50|ig/ml) for lh  at 37°C. 
Following addition of proteinase K (final concentration 100jig/ml) a further 4h 
incubation was performed at 50°C. DNA was then isolated by extracting with 
phenol/chloroform (5:1 v/v) twice and the aqueous phase was precipitated by 
addition of 0.1 X volume 3M sodium acetate and 2.5 X volume absolute ethanol 
for 15-18h. DNA was pelleted by centrifugation at 15,000g for 20min (4°C), 
washed with 70% ethanol and resuspended in 20|Lil Tris-EDTA. ljxl of each 
sample was subjected to horizontal submarine agarose gel electrophoresis using 
IX TAE as a buffer. Briefly, a 2% agarose (w/v in IX TAE) gel was made by 
adding lg  agarose to 50ml IX TAE and heating in a microwave until dissolved. 
The liquid was allowed to cool to approximately 60°C, when ethidium bromide 
was added to give a final concentration of 0.5|ig/ml and the gel was poured 
immediately. Ethidium bromide intercalates between bases within DNA or RNA 
and allows visualisation under ultra violet light using a transilluminator. The 
molecular weights of 0X174 markers (0X174 DNA digested with H ae  III) in 
base pairs are as follows: 1353, 1078, 872, 603, 310, 271, 194, 118, 72.
2.2.4.2 JAM Assay
In the JAM assay (Matzinger, 1991), cells (at a density of 1 X 106/ml) were pre­
labelled with 3H-thymidine (1.5jiCi/ml) diluted in medium for 7-10h at 37°C, 
washed twice and subsequently cultured in fresh complete medium for a further 
15-18h. Prior to experimental treatment, cells were washed once, then incubated 
in a 96-well plate (1 X 105 cells/well) in the presence of the treatments described 
in the figure legends at 37°C in 5% CO2 for the indicated time periods. 
Treatments were performed in triplicate. Plates were harvested as described for 
proliferation assays (section 2 .2 .2 .) and assayed by liquid scintillation counting. 
Fragmented low molecular weight DNA from apoptotic cells was not retained on 
the filter mat during harvesting thus apoptotic samples were distinguished by a 
decrease in radioactive counts. This assay was adapted for the detection of T cell 
cytotoxicity by co-incubation of effector T cells with 3H-thymidine-labelled target
56
J16 cells (JAM bioassay). Target cells were labelled as described above and 
plated at 1 X 105 cells per well in a 96 well round-bottomed plate. The plate was 
subjected to centrifugation (60g) for 3min to pellet the cells, and the medium was 
removed by aspiration. Target cells were then resuspended under test conditions 
(i.e. in the presence of effector cells) in triplicate.
2.2.4.3 TUNEL assay
To detect fragmented DNA an in situ cell death detection kit (TUNEL, Boehringer 
Mannheim) was utilised (Negoescu et al., 1996). 5 X 105 cells were fixed with 
100(11 4% paraformaldehyde in PBS (pH 7.4) for 30min, washed once, 
permeabilised with 0.1% (v/v) Triton-X-100 in 0.1% (w/v) sodium citrate (2 min, 
on ice) and incubated for lh  at 37°C with the reaction buffers provided in 
accordance with the manufacturers' instructions. Apoptosis was measured by 
FACS analysis as an increase in fluorescence in the FL-1 channel. For 
simultaneous analysis of apoptosis and surface phenotype, cells were first 
incubated with mAb against the surface marker of interest, stained to completion 
with primary and secondary Ab as described in section 2.2.3.1, following which 
the TUNEL assay was performed. Thus apoptosis was detected by FL-1 
fluorescence and surface markers were visualised by FL-2 fluorescence.
2.2.4.4 Annexin-FITC Assay
The annexin-FITC binding assay (A poptest™ , Boehringer Mannheim) uses 
FITC-conjugated annexin-V to detect phosphatidylserine (PS) which is rapidly 
externalised during apoptosis (Martin et al., 1995b). Briefly, 3 X 105 cells were 
exposed to experimental treatment then washed once in ice cold PBS and 
resuspended in lOOjil HEPES buffer containing annexin-FITC (2|il neat per 
sample) and propidium iodide (PI) (final concentration 2jig/ml). Following a 10- 
15min incubation at room temperature, samples were diluted 1:5 with HEPES 
buffer and analysed by FACS. Annexin-FITC binding was visualised as an 
increase in fluorescence in the FL-1 channel. This technique was adapted to allow
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two colour analysis by staining for the T cell surface marker (CD58 or CD28) 
detected using PE-conjugated secondary Ab (as described in section 2.2.3.1) prior 
to resuspension in the annexin-FITC buffer, excluding the PI addition step. 
Accordingly, apoptosis was detected by FITC fluorescence with surface marker 
expression being visualised by PE fluorescence.
In certain experiments PI incorporation (5jig/ml) alone was used as a measure of 
cell death by allowing discrimination of cells which had lost membrane integrity 
and which incorporated this nuclear dye as a consequence.
2.2.5 Cell Cycle Analysis
2.2.5.1 Propidium Iodide Cell Cycle Staining
Prior to commencing the cell division process cells are referred to as existing in 
the GO state and they possess one copy of DNA. When division is triggered, cells 
enter the G1 phase of the cell cycle and then commence the process of 
synthesising a second copy of their DNA during a phase termed S (synthesis) 
phase. When the DNA content has doubled, the cell is designated as being in the 
G2 phase of cell cycle which is following by the mitosis (M) phase during which 
the cell physically splits into two and partitions one copy of DNA into each newly 
formed cell. Thus cells in the G2 phase possess double the DNA content of those 
in the GO/1 phase whilst S phase cells possess intermediate quantities of DNA 
(Ormerod, 1990). Cell cycle status can be visualised by using the DNA binding 
dye PI to measure cell DNA content (Vindelov et al., 1983; Darzynkiewicz et al.,
1992). To perform this analysis, 3 X 105 T cells were permeabilised in 1ml 70% 
ethanol (in ddH20) for 15-18h at -20°C. Cells were washed twice and 
resuspended in 200jil PBS containing 20jig/ml RNAse A and incubated for 30min 
in a cell culture incubator (37°C, 5% CO2 ). PI was added to a final concentration 
of lOOpg/ml and samples were incubated for a further 15min at room temperature.
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Cells were washed once following which FACS analysis was performed. PI was 
visualised in the FL-2 channel using a linear scale.
2.2.5.2 Dual Staining for Cell Cycle and Apoptosis
For the simultaneous analysis of cell cycle status and apoptosis by TUNEL, the 
method was adapted as follows:- the ethanol incubation step was preceded by 
paraformaldehyde fixation (2% paraformaldehye in PBS, 15min, 4°C) and 
washing with 10% FCS/PBS. Following ethanol fixation (as described in section 
2.3.5.1), samples were washed twice in PBS and the TUNEL reaction was 
performed (lh , 37°C). Samples were then washed twice in 10% FCS/0.1% (v/v) 
Triton-X-100 in PBS and resuspended in PI (5(Xg/ml) and RNAse A (200|ig/ml) in 
a final volume of 200jil for 30min at room temperature. Samples were analysed 
by FACS with cell cycle being visualised in the FL-2 channel (linear 
fluorescence) and apoptosis being visualised in the FL-1 channel (log 
fluorescence).
2.2.6 Measurement o f Calcium Mobilisation
Ca2+ mobilisation was measured using the fluo-3/acetoxymethyl ester (fluo- 
3/AM) -loading technique (Vandenberghe and Ceuppens, 1990). T cells were 
washed in Hank's balanced salt solution (HBSS) and resuspended ( I X  107 
cells/ml) in 4jxM fluo-3/AM in HBSS. Cells were incubated in the dark for 20min 
(37°C) then diluted 1:5 in 1% FCS/HBSS and incubated under the same 
conditions for a further 40min. Following washing (1% FCS/HBSS) cells were 
resuspended (1 X 106 cells/ml) in HEPES buffered saline and stored at room 
temperature in the dark until use. Immediately prior to analysis, cells were 
incubated at 37°C for lOmin. Fluorescence (FL-1 channel) was measured by 
FACS using a linear scale. 2000 events per time point were acquired and the
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presented data represent the mean fluorescence intensity (MFI) value for each 
time point.
2.2.7 Northern Blot Analysis
All solutions for northern blot analysis were made up in DEPC-treated water.
2.2.7.1 RNA Extraction
1 X 107 cells per treatment were used for RNA extraction (Chomczynski and 
Sacchi, 1987). Briefly, cells were dissolved in 500(4,1 denaturing solution 
comprising 4M guanidinium thiocyanate, 25mM sodium citrate (pH 7.0), 0.5% 
sarcosyl and 0.1M 2-mercaptoethanol. The following reagents were added 
sequentially with mixing by inversion between addition: 50(4,1 2M sodium acetate 
(pH 4.0), 500(4,1 w ater saturated  phenol (aquaphenol) and 100(4,1 
chloroform:isoamyl alcohol (49:1 v/v). Samples were vortexed for 10 seconds 
and cooled on ice for 15min followed by centrifugation at 15,000g for lOmin at 
room temperature. The chloroform/isoamyl alcohol extraction process was 
repeated once more following which the aqueous (upper) layer containing RNA 
was precipitated with an equal volume of isopropanol at -20°C for 15- 18h. The 
precipitate was pelleted by centrifugation (15,000g) for lOmin at room 
temperature and redissolved in 150(4,1 denaturing solution. Isopropanol (150(4,1) 
was used to precipitate the RNA once more in a 15- 18h incubation at -20°C. 
Samples were centrifuged at 15,000g for lOmin and pellets were washed twice 
with 70% ethanol and once with absolute ethanol prior to drying under vacuum 
for approximately 15min. The RNA pellet was resuspended in 50(4,1 DEPC-treated 
water and allowed to dissolve for 15-18h at 4°C. Quantification of RNA was 
determined by spectrophotometry at 260nm using the equation:-
A260 x 40 x dilution = (Xg/ml RNA, where A = Absorbence
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2.2.7.2 RNA Electrophoresis
For northern blot analysis, lOjig RNA was reprecipitated overnight by the addition 
of 1/10 volume ammonium acetate (3M) and 2 X volume absolute ethanol, and the 
RNA pellet was resuspended in DEPC-treated water. A 1% agarose gel was 
prepared by heating 4g agarose in 8ml 50X 3-[N-Morpholino]propanesulfonic 
acid (MOPS) and 325ml ddH 20 with 67ml formaldehyde being added once the 
solution had cooled to approximately 60°C. The gel was poured in a fume hood 
and left to set for at least 30min at room temperature. RNA was mixed with 
loading buffer to a volume of 50pl per sample as follows: 20|il RNA in DEPC- 
treated water, 20pl formamide, 7pl formaldehyde, l |i l  50X M OPS, 2jil 
bromophenol blue (0.025% final). Samples were heated to 70°C for 5min and 
chilled on ice prior to loading. The gel was run in IX MOPS (in DEPC-treated 
water) at 60-80 V for approximately 6 h with the buffer being continually 
recirculated by pumping (negative to positive).
2.2.7.3 Transfer of RNA from Gel to Membrane
After rinsing the gel with DEPC-treated water to remove formaldehyde, the 
blotting apparatus was set up as indicated in figure 2 .2  to facilitate transfer of 
RNA by capillary action. The gel was placed onto a filter paper wick on a glass 
support in a reservoir of 20X SSC. Hybond-N membrane was cut to the same size 
as the gel, pre-soaked for 30min in 20X SSC at room temperature and placed 
directly above the gel. Several layers of absorbent filter paper were stacked above 
the membrane to facilitate movement of the buffer by capillary action. The 













Figure 2.2: Blotting apparatus for the transfer of RNA from a formaldehyde 
agarose gel to a hybond membrane. The wick and stacked filter/blotting papers 
served to draw buffer upwards by capillary action thus facilitating transfer of
Following transfer, the gel was discarded and the membrane soaked in 50mM 
sodium phosphate for lOmin. Subsequently, RNA was fixed by ultra violet 
crosslinking (2min, 1200pW/cm2), then baking (80°C, 1H) of the membrane. 
Ribosomal bands were visualised by staining for 2min in methylene blue and 
destaining by sequential washes with DEPC-treated water. The membrane was 
then stored at -70°C prior to hybridisation.
2.2.1.5 Hybridisation
Full length cDNAs encoding CD58 (Seed, 1987) or CD28 (Aruffo and Seed, 
1987) were used as probes for the detection of specific mRNA. Probes were 
labelled using a Prime-a-gene kit (Promega). Briefly, 25ng template DNA was 
heated to 95°C for 2min, chilled on ice and incubated for 3h at room temperature 
with mixed dNTP (A,T,G), nuclease-free BSA, nuclease free H2O, Klenow, oc32P- 
dCTP and the provided buffer in a final volume of 40jil in accordance with the 
manufacturers' instructions. The reaction was terminated with 1.5pl of EDTA 
(20mM) and the percentage incorporation of the probe calculated. Accordingly, 
lp l of reaction mix was applied to 2 DE81 discs: one was washed 3 times with
RNA
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0.5M Na2 HPC>4 followed by ddH 20 and absolute alcohol then air dried. Both 
discs were counted by liquid scintillation and the percentage incorporation of 
radioactive counts was calculated (CPM washed disc / CPM unwashed disc X 
100).
If the membrane had been previously probed, it was soaked in stripping buffer 
(2mM EDTA, 1% SDS) at 80°C for 30min, then rinsed with DEPC-treated water 
prior to re-probing. Membranes were incubated in pre-hybridisation buffer at 
50°C for 2h under rotation prior to addition of the probe which was heated to 95 °C 
immediately prior to use. Hybridisation was allowed to proceed for 15-18h at 
50°C. The membrane was then washed in a prewarmed buffer (65°C) comprising 
0.5% SDS in 2X SSC. A further wash with 0.5% SDS in 0.2X SSC was 
performed for lOmin or until no background was detectable by monitoring. The 
membrane was then rinsed with 2X SSC and radioactivity was detected by 
autoradiography.
2.2.8 Data Analysis
All experiments presented were performed 3 times unless otherwise indicated in 
the figure legend. Data from proliferation assays and JAM assays is displayed as 
the mean of triplicate wells and the standard error of the mean (SEM) is shown. 
Statistical analysis was performed using the Mann Whitney U test where indicated 
and significance is taken as p < 0.05.
63
CHAPTER 3 
Control of T Cell Activation
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3.1 INTRODUCTION
In order to address the role of CD95-mediated apoptosis during T cell immune 
responses, it was first necessary to define the interactions which lead to productive 
T cell activation in response to antigen. An appreciation of the requirements for 
effective T cell stimulation, and an understanding of some of the surface receptor 
changes which characterise this process was considered a prerequisite for studies 
on the relevance of CD95 in the context of these events. In particular, it has been 
established that T cells are not necessarily triggered to proliferate in response to 
antigen engagement, but instead may become immunologically silenced (anergy) 
or may undergo apoptosis (Lo et al., 1988; Markmann et al., 1988; Lo et al., 1989; 
Ramensee et al., 1989; Schwartz, 1990). The context of antigen engagement, in 
terms of the additional ligands provided by the antigen-presenting cell, is a key 
factor in determining the nature of the response to TCR engagement, and must 
therefore be carefully defined prior to the study of apoptosis in activated T cell 
cultures. A key receptor for T cell activation is CD28 and a large body of work 
has established the importance of CD28 signals in costimulating antigen-mediated 
activation (Gimmi et al., 1991; Jenkins et al., 1991; Linsley et al., 1991a; Razi- 
W olf et al., 1992; Sansom et al., 1993). Therefore initial work was carried out to 
establish that costimulation-dependent human T cell activation could be initiated 
in vitro and that such protocols triggered the predicted changes in T cell surface 
receptor expression. In addition, since a primary aim of these studies was to 
investigate T cell apoptosis induction, the CD28 receptor warranted particular 
attention as this molecule has recently been implicated in the promotion of T cell 
survival (Boise et al., 1995; Noel et al., 1996a; Radvanyi et al., 1996; Sperling et 
al., 1996). Therefore a number of experiments were carried out to investigate the 
expression patterns of this receptor during the T cell activation process.
T cells can be activated in vitro in a number of ways which fulfil the two signal 
requirem ent described earlier, including use of anti-CD3 and anti-CD28
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antibodies, T cell mitogens such as PHA and ConA or superantigen. The use of 
superantigen is particularly suited to studies of this nature since, like peptide, it 
provides a TCR-derived signal and yet because it binds a site on the TCR which is 
distinct from the peptide-binding groove it stimulates a larger proportion of the T 
cell population than would specific peptide. A large proportion of this study 
therefore utilised T cells which were activated using the bacterial superantigen 
SEB and thus are referred to as SEB blasts or T blasts. These lines were generated 
by the addition of SEB to resting PBMC, such that T cell activation was facilitated 
by endogenous APCs such as monocytes. Alternatively, for experiments in which 
T cells were purified from the PBMC population, superantigen was pulsed onto 
HLA-DR expressing CHO cell transfectants which coexpressed CD80 and served 
as APCs to allow T cell activation. The use of CHO transfectants expressing 
defined combinations of T cell ligands thus provided a powerful tool for 
m anipulating which receptors were engaged during T cell activation. 
Superantigen-driven T blast lines had the additional advantage that they could be 
readily restimulated in culture by the further addition of superantigen-pulsed 
HLA-DR transfectants coexpressing CD80. For the long term culture of T cells, 
therefore, superantigen-stimulation offered the activation model of choice, whilst 
for shorter term cultures a whole spectrum of activation stimuli were applicable.
3.2 RESULTS
3.2.1 An Investigation of the Requirements for T cell Activation
To control which signals were initiated during T cell activation, CHO cells 
expressing defined T cell ligands were utilised. These cells essentially provided a 
blank background for the genetic introduction of the molecule o f interest and 
figure 3.1 illustrates the surface expression levels of these transfected ligands
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(CD80, HLA-DR). The data also demonstrate that double transfectants expressed 
an equivalent levels of transfected molecules as single transfectants.
To test the two-signal dependence of T cell activation, proliferation assays were 
perform ed whereby resting purified T cells were treated with various 
combinations of stimuli and cell cycle entry was monitored by incorporation of 
3H-thymidine. In figure 3.2, TCR signalling was provided by immobilised anti- 
CD3 antibody, whilst costimulation was provided by CD80-transfected CHO cells 
which were fixed to preclude 3H-thymidine incorporation. Clearly the presence of 
anti-CD3 or CD80 transfectants alone was insufficient to support productive T 
cell activation, whereas the provision of both signals triggered marked thymidine 
incorporation. This therefore established that T cells generated as the result of 
"two signal" protocols were activated and were proliferating.
In order to investigate variation in the temporal provision of the costimulatory 
signal relative to the antigen-derived signal, the addition of the CD80 transfectants 
was delayed following the initiation of TCR signalling using immobilised anti- 
CD3 antibodies. This analysis revealed (figure 3.3.A) that the addition of CD80 
transfectants could be delayed for up to two hours following anti-CD3 stimulation 
without a detectable reduction in the proliferative response. Subsequent to this 
time point however, further delays in the timing of CD80 provision negatively 
affected T cell responses and resulted in decreased proliferation. The data also 
indicated that T cells which were simply retained in medium for the 12 hour delay 
period (i.e. in the absence of anti-CD3) did not exhibit a defect in their subsequent 
response to activating stimuli (column labelled CD80 + T 12h), indicating that the 
negative regulation was attributable to anti-CD3 signalling.
These data therefore indicated that following TCR signalling there existed a finite 
window of time in which a costimulatory signal could successfully be delivered 











Figure 3.1: Expression of T cell ligands on transfected CHO cells. CHO cells 
transfected with cDNAs encoding CD80 and/or HLA-DR4 were stained for 
expression of CD80 and HLA-DR (filled histograms). Open histograms indicate 
control staining with secondary antibody alone. Surface expression of transfected 
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Figure 3.2: Anti-CD3 induced T cell proliferation. Purified human T cells (2 x 
104 cells per well) were incubated with immobilised anti-CD3 (OKT3, plate- 
coated for 15-18h) in the presence of CD80 transfectants (ratio 5:1 T 
cellitransfectant) where indicated. Proliferation was assessed after 72h by 
incorporation of 3H-thymidine and liquid scintillation counting. The mean (+/- 
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Figure 3.3: Effect of delayed addition of CD80 transfectants on anti-CD3 
induced T cell proliferation. (A) Purified human T cells (2 x 104 cells per well) 
were incubated with immobilised anti-CD3 (OKT3, plate-coated for 15-18h) and 
CD80 transfectants (ratio 5:1 T cell:transfectant) were added after the indicated 
delay. Controls included the use of untransfected CHO cells and the delayed 
addition of both T cells and transfectants (column marked T + CD80 12h). 
Proliferation was assessed after 72h by 3H-thymidine incorporation and the mean 
(+/-SEM) of triplicate wells is shown. (B) TCRap expression was assessed by 
surface staining of untreated (filled histogram) versus anti-CD3 (lpg/m l, 8h) 
treated (open histogram) T cells. Staining was carried out using a TCRap-FITC 
conjugate and the dotted line indicates staining with a control FITC conjugate. 
Data are representative of 3 experiments.
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to proliferate due to the delay in CD80 addition nevertheless exhibited 
downregulation of the T C R ap (fig 3.3.B), a phenomenon which has been 
identified as a characteristic mechanism of anergy induction (Huang and Crispe,
1993) and which may therefore preclude the induction of a proliferative response 
following subsequent antigen-presentation events.
Similarly to anti-CD3-driven proliferation, superantigen-driven T cell responses 
were also found to be dependent on the provision of costimulation. In figure 3.4 
(panel A), resting purified T cells were stimulated with fixed transfectants 
(expressing HLA-DR and/or CD80) which had been previously pulsed with SEB 
where indicated. The resultant proliferative response was shown to be antigen- 
specific (SEB-dependent) and chiefly restricted to those T cells which were 
stimulated by transfectants expressing both HLA-DR and CD80 (figure 3.4). 
Interestingly, the presence of agonists for the death receptor CD95 at the time of 
antigen engagement always resulted in a decreased CPM relative to the maximal 
response although there was variability in the extent of this reduction (up to 
approximately 45% inhibition observed) (figure 3.4). Inhibition by anti-CD95 
antibody, CH11, and soluble CD95L was comparable within each individual 
experiment and the inclusion of control supernatant instead of CD95L had no 
detectable affect. These data implied that the ligation of death receptors could 
potentially negatively influence the antigen presentation event, such that a 
diminished proliferative response ensued, and suggested that the relative provision 
of signalling through costimulatory receptors (such as CD28) versus death 
receptors (such as CD95) on T cells may be crucial in determining cell fate.
Having established successful protocols for the productive stimulation of T cells 
in vitro , the effect of this process on T cell surface receptor changes was 
examined. T cell activation is a complex series of events involving a number of 
phenotypic changes including an increase in cell size to achieve characteristic 
blastic morphology and alterations in the expression of various membrane
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Figure 3.4 (A): SEB-induced proliferation in resting T cells. Resting human T 
cells (2 x 104 cells per well) were stimulated with fixed CHO transfectants as 
indicated (at a ratio of 5:1, T celhtransfectant). Transfectants were pulsed with 
SEB (lpg/m l, 4h) prior to fixation where indicated. CD95 engagement was 
provided by antibody (CH11, 0.3|ig/ml) or CD95L (COS-7 cell supernatant). 
Column height represents the mean (+/-SEM) of triplicate wells and this 
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Figure 3.4 (B): SEB-induced surface m arker changes in resting T cells. Resting or day 4 
activated (SEB, 1 lag/ml) human PBMC were stained for surface expression of CD25, CD28, CD69, 
HLA-DR or CD95. Control staining indicates use of secondary antibody alone. Data are respresentative 
of 4 experiments.
receptors. Figure 3.4 (panel B) illustrates the changing expression patterns of a 
selection of key T cell surface markers during the process of cellular activation, in 
this example mediated by superantigen stimulation. The left panel shows the 
constitutive expression levels of the indicated surface receptors on freshly isolated 
(Day 0) PBMC whilst the right panel illustrates the changes in receptor expression 
by day 4 following SEB stimulation. Induction of the IL-2 receptor a  chain 
(CD25) allows the generation of a high affinity receptor for IL-2 to allow 
autocrine proliferation, and other markers of activation include CD69, which is 
thought to be involved in T cell:macrophage interactions, and HLA class II which 
may allow T cells themselves to take on an antigen presentation role. It was 
therefore possible to confirm that the activation protocols employed in these 
studies were competent to trigger the expected changes in T cell surface receptor 
expression.
In addition to altered surface receptor expression, activated T cells are also 
characterised by changes in functional responses to certain stimuli. Previous work 
in the laboratory has established a differential response to CD28 ligation in 
activated versus resting T cells, such that activated T cells can proliferate 
following ligation of this receptor alone whilst resting T cells require the co­
ordinated provision of a TCR-derived signal (Edmead et al., 1996). To further 
elucidate the functional distinctions between resting and activated T cells, the 
response to CD3-derived signals in these cells was investigated by proliferation 
assay. Figure 3.5 illustrates a titration of immobilised anti-CD3 in the presence of 
differing ratios of CD80 transfectants:T cells. These data demonstrated that 
resting T cells required higher concentrations of anti-CD3 to initiate proliferation 
than T cell blasts, however at the highest doses of anti-CD3 (10|ig/ml, lOOfig/ml) 
there was a reduction in the proliferative response. Activated T blasts, in contrast, 
proliferated vigorously even at the highest concentrations of anti-CD3 indicating 
that activated T cells were less susceptible to negative regulation via TCR- 
mediated signalling than resting cells.
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Figure 3.5. Effect of anti-CD3 titra tion  on proliferation  of resting and 
activated T cells. Resting T cells (A) or activated T blasts (day 12 SEB blasts) 
(B) were incubated with immobilised anti-CD3 in the presence of CD80 
transfectants at the indicated ratios (transfectant: T cell). Proliferation was 
measured by 3H-thymidine incorporation and the mean (+/-SEM) of triplicate 
wells is shown. Data are representative of 4 similar experiments.
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Figure 3.6: Role of apoptosis following high dose anti-CD3 treatm ent. (A)
Purified human T cells (2 x 104 cells per well) were incubated for 3 days with 
immobilised anti-CD3 (OKT3, plate-coated at the indicated concentrations for 15- 
18h) in the presence of CD80 transfectants (at a ratio of 5:1, T celhtransfectant). 
The blocking anti-CD95 antibody ZB4 (0.5jig/ml) was included where indicated. 
Proliferation was assessed by incorporation of 3H-thymidine and the mean (+/- 
SEM) of triplicate wells is shown. Data are representative of 3 experiments. (B) 
Samples treated with anti-CD3 (lOpg/ml, lOOpg/ml) in the presence of CD80 
transfectants (as above) were incubated for 3 days then removed for apoptosis 
analysis by TUNEL. Apoptosis is visualised by increased fluorescence on the x- 
axis. This experiment was repeated twice with similar results.
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In an attempt to elucidate the nature of the negative regulation observed in resting 
T cells, experiments were carried out to establish whether the reduced 
proliferation was a result of apoptosis induction. A major pathway for the 
induction of cell death in T cells is via the surface receptor CD95, therefore to 
preclude the triggering of this pathway, the blocking anti-CD95 antibody ZB4 was 
utilised. As indicated in figure 3.6 (A), the defect in proliferation at high dose 
anti-CD3 was not restored in the presence of ZB4 and furthermore, assessment of 
DNA fragmentation by TUNEL assay indicated no corresponding increase in 
apoptosis in these cells (figure 3.6, B), indicating that the decrease in proliferation 
was not attributable to the induction of apoptosis via alternative death receptors. 
These data indicated that the proliferative response of resting T cells was 
positively regulated by low concentrations of anti-CD3, but negatively regulated 
at high doses by a mechanism which did not involve detectable apoptosis 
induction, and which did not appear to be triggered in activated T cells. Further 
experimentation is required to establish whether this decrease in proliferation is a 
result of anergy induction and whether, as such, it is reversible under appropriate 
conditions.
3.2.2 Regulation ofCD28 expression during T cell Activation
Since CD28 signals have been implicated in the promotion of cell survival, and 
the aims of this work were to examine the regulation of cell death, the expression 
patterns of this receptor during T cell activation represented an important target 
for investigation. It has previously been reported that engagement of CD28 by 
ligand (CD80/86) triggered rapid downregulation of CD28 expression both in 
terms of mRNA and or protein levels (Linsley et al., 1993) however the 
significance of this response is not known. Given that levels of CD28 expression 
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Figure 3.7: Effect of CD80 transfectants on T cell CD28 expression. Resting 
purified human T cells were incubated for 7h with CD80-transfected CHO cells at 
the indicated ratios (CHO cell:T cell) then stained for CD28 expression (filled 
histograms). CHO cells were gated out on autofluorescent properties during FACS 
analysis. Control treatment indicates the absence of transfectants and CHO 
treatment indicates the addition of untransfected CHO cells. Open histograms 
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Figure 3.8: Effect of anti-CD3 treatm ent on CD28 re-expression following 
CD80-mediated CD28 downregulation. Resting T cells were treated with CD80 
transfectants (at a ratio of 1:3, transfectant:T cell) in the presence of immobilised 
anti-CD3 (plate-coated at lpg/ml) as indicated. After 24h cells were stained for 
surface expression of CD28 (filled histograms). Transfectants were gated out on 
autofluorescence during FACS analysis. Open histograms indicate control staining 
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Figure 3.9: Effect of PMA on CD28 re-expression following CD80-mediated 
CD28 dow nregulation. T cells were stimulated with CD80 transfectants (at a 
ratio of 1:3, transfectant:T cell) in the presence or absence of PMA (0.04|ig/ml) 
and CD28 expression measured at the indicated time points (filled histograms). 
The percentage of CD28 high cells is plotted according to the gate indicated in the 
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Figure  3.10: Re-expression of CD28 following trea tm en t w ith CD80 
transfectants in the presence of PMA and ionomycin. Resting human T cells 
were incubated with CD80 transfectants or untransfected CHO cells (at a ratio of 
1:3, transfectant:T cell) for 48h in the presence or absence of PMA (0.04|ig/ml) 
and ionomycin (lpM ) as indicated. Cells were then stained for expression of 
CD28 with the CHO cells being gated out on autofluorescence during FACS 
analysis. The filled histogram shows CD28 staining following treatment with 
untransfected CHO cells alone and the same trace is plotted in each panel for 
comparative purposes. Solid lines represent CD28 staining following CD80 
treatment. Dotted lines indicate staining with secondary antibody alone. Data are 
representative of 3 similar experiments.
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As shown in figure 3.7, CD80-mediated CD28 downregulation was a dose- 
dependent phenomenon in terms of the number of CD80-transfected CHO cells 
present during the 7 hour incubation period, and the extent of the reduction in 
CD28 expression did not plateau even at high ratios of CHO-CD80 to T cells 
(highest ratio 1:3). In contrast, addition of untransfected CHO cells did not trigger 
CD28 downregulation, demonstrating that the observed decrease in CD28 
expression following CHO-CD80 treatment was not due to CHO cells interfering 
with the staining procedure.
Data presented in figures 3.8 and 3.9 demonstrated that in order for CD28 to be 
re-expressed following CD80-mediated downregulation, there was a requirement 
for TCR engagement, or TCR-like signals i.e. PMA. In the absence of such 
signalling, CD28 levels remained downregulated, whereas the provision of PMA 
or anti-CD3 triggered rapid CD28 re-expression, ultimately reaching surface 
levels which exceeded those found on resting T cells (figure 3.9). Interestingly, 
whilst incubation with PMA was an effective trigger for CD28 re-expression, this 
response was weakened if ionomycin was also present (fig 3.10). Data from 
colleagues in the laboratory have indicated that treatment of PMA/Ionomycin (P/I) 
stimulated T cells with CD80 is a favourable system for the induction of CTLA4- 
mediated signalling (detected by a decrease in the proliferative response in the 
presence of CD80) and the illustration that P/I treated T cells were less effective at 
upregulating CD28 may be important in this regard.
3.3 DISCUSSION
The data presented in this chapter illustrate "baseline" experiments to establish 
that the activation conditions utilised in this study resulted in effective activation
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of T cells according to a number of criteria. However they also revealed a number 
of interesting points. Productive initiation of T cell activation has been 
demonstrated to be dependent on the provision of costimulatory signals within a 
defined time period and in addition it has been shown that the expression of 
CD28, a receptor increasingly associated with cell survival, is controlled both by 
costimulatory and antigen-derived signals. It therefore follows that the conditions 
under which T cells are activated may have important consequences for their 
subsequent responses, including their sensitivity to apoptosis pathways such as 
that triggered by CD95. This observation may be of relevance in the 
interpretation of apoptosis studies carried out on T cells which have been 
"activated" in the absence of costimulatory signals (Owen-Schaub et al., 1992; 
Klas et al., 1993) and this will be critically analysed in more detail in chapter 6 .
One consequence of antigen receptor signalling is the downregulation of the TCR 
(Kishimoto et al., 1995) and the data presented in figure 3.3 (B) illustrate that this 
response is intact even in the absence of costimulatory signals. These data 
indicated that a failure to receive a "second signal" within the requisite time period 
may potentially render T cells refractory to subsequent stimulation as a result of 
antigen receptor (TCR) downregulation. Such a mechanism might be important 
for tolerance since self antigens may be presented in the absence of costimulatory 
ligands whereas foreign antigens are more likely to be presented by APCs 
expressing upregulated CD80 levels as a consequence of pathogen-associated 
molecules such as lipopolysaccharide (LPS) (Razi-W olf et al., 1992). Also 
apparent from these experiments is that activated T cells require a less intense 
TCR-derived signal to initiate proliferation compared to resting cells, in line with 
the findings of others (Dubey et al., 1996), and suggesting that pre-formed 
signalling intermediates may exist in these cells to facilitate rapid responses. A 
further regulatory mechanism in the control of T cell responses pertains to the 
nature of the antigen-derived signal, such that TCR ligation which induces high 
magnitude signal transduction may ultimately be a less effective trigger for T cell
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activation than TCR ligation which leads to signals of an intermediate magnitude 
(figure 3.5). The nature of this negative regulation does not appear to involve 
apoptosis induction (figure 3.6), and one possibility is that high affinity TCR 
interactions favour CTLA4 upregulation and signalling leading to T cell silencing 
via this route in line with recently published findings (Alegre et al., 1996; Linsley 
et al., 1996). The concept that high affinity TCR ligation might trigger negative 
regulation in T cells is intriguing and the implications of this for self tolerance are 
not clear. It is possible that the nature of the interaction between antigen and TCR 
might represent one mechanism for the distinction between self and non-self, 
although other mechanisms clearly operate to influence this choice. In this regard, 
the rate of change of antigen dose offers one potential defining feature in the 
discrimination between pathogenic antigen, which is likely to rapidly increase 
during post-invasive replication, and host antigen which is unlikely to be subject 
to such rapid quantitative change.
The nature of the antigen-derived signal, as well as additional costimulatory 
signals, is therefore influential in determining the consequent T cell response. 
Likewise, the provision of ligand for death receptors may also be of relevance 
during the course of antigen presentation, as illustrated by the inclusion of the 
anti-CD95 antibody CH11 or soluble CD95L in proliferative assays. These data 
implied that APCs which expressed CD95L might be less effective at triggering T 
cell proliferation and consistent with this, it has been demonstrated that the 
balance between the provision of costimulatory ligand (CD80) and the provision 
of death-inducing ligand (CD95L) on APCs is a key determinant in the subsequent 
T cell response (Lu et al., 1997a; Lu et al., 1997b). It is also of note that 
proliferation was not entirely abrogated by the ligation of CD95 during activation 
(figure 3.3), indicating that whilst this pathway appeared to be activated in a 
subset of T cells, the universal induction of apoptosis was not triggered under 
these conditions. Which features distinguished the subset of T cells which were
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CD95-sensitive, from those which exhibited CD95 resistance, under these 
circumstances thus emerged as an important question for this study.
The examination of CD28 expression revealed that this receptor was particularly 
tightly modulated during the T cell activation being both downregulated by CD80 
binding then subsequently upregulated in a manner which was dependent on TCR 
or TCR-like signalling (figure 3.10). Ligand-induced downregulation of CD28 
may represent a form of negative feedback to limit the extent of signalling through 
this receptor. In addition, and perhaps of greater significance, the downregulation 
of CD28 may allow the homologous molecule CTLA4 access to their shared 
ligands (CD80/CD86), implying that these conditions may be permissive of 
CTLA4-mediated signalling. In support of this hypothesis, staining data from our 
laboratory have indicated that CD28 and CTLA4 are reciprocally regulated during 
early T cell activation with surface CTLA4 expression being detectable within 4 
hours of P/I stimulation. The balance between CD28-derived stimulatory signals 
and CTLA4-mediated negative regulation may thus depend upon the extent of 
CD80-mediated CD28 downregulation and the kinetics of its subsequent TCR- 
dependent upregulation, relative to the activation-associated induction of CTLA4 
surface expression. The rapidity of CD28 re-expression would therefore be vital 
in determining the time window during which CTLA4 signalling could 
predominate, and thus could potentially dictate whether a given T cell underwent 
productive activation or experienced CTLA4-induced shut-down. In addition, the 
association of CD28 signalling with cell survival renders changes in expression 
levels potentially relevant to T cell sensitivity to apoptosis, for example following 
the ligation of receptors such as CD95, and this point is addressed in more detail 
in chapter 6 .
A key point from these experiments is the importance of the APC in directing the 
T cell immune response. It has previously been established that in addition to 
determining which antigens are made available for T cell recognition, APCs can
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also dictate whether antigen presentation results in tolerance or immunity 
depending on the provision of costimulation. Moreover, APCs can activate 
specific T cell subsets as a result of HLA class usage, manipulation of the local 
cytokine environment and possibly by the differential use of costimulatory ligands 
(Freeman et al., 1995; Kuchroo et al., 1995). Given the delicate balance between 
the induction of signalling through CD28 and CTLA4, it seems likely that APCs 
may also influence the state of T cell activation by controlling the level of ligand 
(CD80/86) expression, since low levels could potentially favour CTLA4 
engagement. Thus APCs play a key role in determining the immunogenicity of 
antigens by controlling ligation of T cell "on switches", such as CD28, and T cell 
"off switches" such as CTLA4 and CD95.
In summary, the presented data indicated that effective costimulation-dependent T 
cell activation could be established in vitro and that the activation status of T cells 
could be monitored in terms of the expected changes in surface receptor 
expression. Productive T cell activation was shown to be dependent on the co­
ordinated provision of both antigen and costimulatory signals, and in addition the 
timing and magnitude of signalling via these routes was shown to influence the 
subsequent T cell response. Staining data illustrated the dynamic regulation of T 
cell surface receptor expression, with particular regard to the costimulatory 
receptor CD28, raising the possibility that such modulation may have important 




CD95-mediated Apoptosis in T Cells
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4.1 INTRODUCTION
Apoptotic cell death has emerged as a mechanism of immunoregulation and a 
greater understanding of how this response is initiated under physiological 
circumstances represents an important challenge. Unlike necrosis, apoptosis 
induction is an active gene-directed process such that cell surface receptors are 
induced for the purpose of transducing the "death signal" following ligation. Thus 
the coupling of a cell suicide pathway to surface receptor ligation offers a potent 
mechanism for the selective removal of lymphocytes during the course of an 
immune response or to limit T cell clonal expansion. Equally, however, the 
possession of such a pathway represents a potential danger to the host and the 
aberrant triggering of signals via this route must clearly be avoided. Receptor 
triggered death pathways would therefore be expected to be subject to tight 
controls.
One important receptor for the induction of apoptosis is CD95 which is a 45KDa 
transmembrane protein found on numerous cell types including T cells, B cells 
and monocytes (Nagata, 1994). In order to study the role of the CD95 system in T 
cells, experiments were performed to measure the surface expression of the CD95 
receptor on T cells during the process of cellular activation, and to elucidate the 
ability of this receptor to transmit an apoptotic signal following ligation. As a pre­
requisite to this investigation, a number of assays to measure apoptosis were 




4.2.1 Establishment of Apoptosis Assays
Apoptotic cell death is distinguished from necrosis on the basis of morphological 
criteria which include chromatin condensation, membrane blebbing and the 
partitioning of fragmented DNA into membrane-bound apoptotic bodies (Kerr et 
al., 1972; McConkey et al., 1994). A characteristic feature of apoptosis is the 
systematic cleavage of nucleosomal DNA into first high molecular weight 
(300kbp and 50kbp) then low molecular weight (oligomers of 180bp) fragments 
(McConkey et al., 1994). One of the earliest methods of detecting whether cells 
were undergoing apoptosis was therefore to extract the cellular DNA and run it on 
an agarose gel such that fragmented DNA could be visualised as laddering. In 
order to establish assays to measure apoptosis induction, DNA laddering was 
directly compared with a PI exclusion assay in which cell death was measured by 
nuclear staining following the loss of plasma membrane integrity. Thus, cells in 
the late phases of apoptosis fail to exclude the DNA-binding dye PI and the 
resultant red fluorescence can be monitored by FACS at the single cell level.
To induce apoptosis, the anti-CD95 antibody CHI 1 was utilised in the presence or 
absence of a blocking anti-CD95 antibody (ZB4) or an inhibitor of CD95 signal 
transduction (Z-VAD-FMK) (Sarin et al., 1996). Jurkat T cells (J16) were treated 
for 15 hours with the indicated reagents following which samples from the same 
incubation were assayed using the two detection methods indicated (figure 4.1). 
The data generated from the PI exclusion assay (figure 4.1, A) indicated that, in 
this experiment, CH11 treatment induced a 62% increase in the PI bright (non 
viable) population and additionally the cell shrinkage associated with apoptosis 
could be visualised as a decrease in forward light scatter (FSC). Consistent with 
this picture, a smear which is characteristic of degraded DNA was clearly visible 










W r r  •»; • / b
;• •
■"-% V 11 -' •
1 A
k*?#:. .
■ 1^.1 EUh SrjjR5 +
P B P ^ :r '88.7
2 0 0  - 1 0 0  6 0 0  8 0 0  1 0 0 0  
FSC-Height
CHI 1
; i i i  » - [  l  l l I |  I l I l |  l l l l i 1 
2 0 0  - 1 0 0  6 0 0  8 0 0  1 0 0 0
FSC-Height





•3&C r-: V •. •
21.8
\y'l8.2









1 3 . 7




W r ' : 8 6 . 3
0  2 0 0  - 1 0 0  6 0 0  8 0 0  1 0 0 0  
FSC-Height
Figure 4.1 (A): Apoptosis m easurem ent by propidium  iodide (PI) staining.
Jurkat T cells (5 x 105 cells per treatment) were incubated for 15h with medium 
(control), the apoptotic anti-CD95 antibody CH11 (0.05pg/ml), the blocking anti- 
CD95 antibody ZB4 (0.5|ig/ml) or the caspase inhibitor Z-VAD-FMK (lOpM) as 
indicated. 105 cells were removed for PI (5pg/ml) staining whilst the remainder 
were reserved for DNA laddering analysis (figure 4.1, B) These data are 





F igure  4.1 (B): A poptosis m easurem ent by DNA laddering  analysis.
Jurkat T cells (5 x 105 cells per treatment) were incubated for 15h with medium, the 
apoptotic anti-CD95 antibody CH11 (0.05jig/ml), the blocking anti-CD95 antibody 
ZB4 (0.5]LLg/ml) or the caspase inhibitor Z-VAD-FMK (10pM) as indicated. Cells were 
lysed and analysed for DNA laddering by agarose gel eletrophoresis as described in the 
methods section. Lane 1= medium, Lane 2 = CHI 1, Lane 3 = CHI 1 + ZB4, Lane 4 = 
CHI 1 + Z-VAD-FMK. Data are representative of 2 experiments.
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Since this protocol involved the initial removal of whole nuclei, only low 
molecular weight fragmented DNA remained for analysis, explaining the lack of 
material in non-apoptotic lanes. Since apoptotic cells have undergone DNA 
fragmentation, even after the nuclei have been pelleted, low molecular weight 
DNA still remains in the cytoplasmic fraction, and can be isolated using this 
protocol. The apoptotic response was almost completely inhibited in the presence 
of the caspase inhibitor Z-VAD-FMK as measured by PI exclusion, and in line 
with this result there was no detectable DNA laddering in this sample. However, 
cells which were treated with CH11 in the presence of the blocking anti-CD95 
antibody ZB4 were not entirely spared from apoptosis and exhibited a small 
(10%) increase in the proportion of PI bright (non viable) cells in this experiment. 
Interestingly, the DNA laddering assay failed to distinguish the sample in which 
there was 10% apoptosis from that in which there was 62% apoptosis, since there 
was comparable DNA smearing in both lanes. One possibility is that the 
difference between treatm ents is masked by gel overloading although 
electrophoresis of decreased amounts of sample did not support this hypothesis. 
Repeated experiments revealed a similar trend, indicating a potential limitation 
associated with the use of DNA laddering assays for the quantitative measurement 
of apoptosis in that even low levels of apoptosis resulted in marked DNA ladders 
raising the concern that the degree of apoptosis within a cell sample could be 
overestimated by this method. Equally, the protective effect of certain treatments 
(such as the blocking anti-CD95 antibody, ZB4) could be m issed if the 
visualisation of DNA laddering on agarose gels were to be relied upon as a 
measure of apoptosis.
Since the degree of DNA laddering did not appear to provide an adequate 
reflection of the proportion of apoptotic cells within a sample, alternative assays 
were investigated with a view to providing a more quantitative approach to 
apoptosis detection. The JAM assay (Matzinger, 1991) allowed apoptosis to be 
detected as a measure of DNA fragmentation by pre-labelling cells with 3H-
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thymidine and harvesting through a glass fibre filter mat following experimental 
treatment. Fragmented DNA from apoptotic samples is not retained on the mat 
and apoptosis can therefore be detected by a decrease in radioactive counts. In 
order to set up this assay for routine use in the laboratory, a number of preliminary 
investigations were carried out to establish a suitable cell labelling protocol in 
addition to appropriate cell numbers and cell incubation times. As demonstrated 
in figure 4.2, the resultant assay provided a sensitive and quantitative measure of 
apoptosis induction since the anti-CD95 antibody decreased radioactive counts 
(CPM) in a dose-dependent (A), time-dependent (B) and ZB4 blockable (C) 
manner.
During the course of these studies, two further apoptosis assays became available 
for use, namely the TUNEL assay (Negoescu et al., 1996) and the annexin-FITC 
binding assay (Martin et al., 1995b). The former used DNA end-labelling with 
fluorescence-tagged nucleotides to allow cells with fragmented DNA to be 
distinguished by increased fluorescence. This method required that cells were 
fixed and permeabilised following experimental treatment, and could only detect 
apoptosis once the DNA cleavage stage had been reached. The annexin-FITC 
assay, in contrast, allowed identification of apoptotic cells at very early time 
points since it was based on changes in the phospholipid bilayer which occurred 
shortly after the triggering of an apoptotic stimulus (Martin et al., 1995b). FITC- 
conjugated annexin-V was used to bind PS, a lipid normally restricted to the inner 
leaflet of the plasma membrane, but which is actively externalised as a rapid 
response to apoptotic signalling (Martin et al., 1995b). In certain cell types, 
though not in T cells, PS exposure serves as a recognition marker for the ingestion 
of dying cells by phagocytes (Martin et al., 1995b), a process which needs to 
precede cell lysis in order to avoid an inflammatory response.
In order to establish the annexin-FITC assay for use in our T cell system, dose 
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Figure 4.2: Establishment of the JAM  assay for apoptosis m easurem ent. 3H-
thymidine-labelled Jurkat cells were incubated as indicated, harvested and assayed 
by liquid scintillation counting. Apoptosis is calculated as % decrease CPM 
relative to control-treated Jurkats. (A) J16 cells were incubated for 15h with the 
indicated concentrations of the apoptotic anti-CD95 antibody CH11. (B) Cells 
were treated with CHI 1 (0.1|ig/ml) or a control IgM antibody (OBI, supernatant) 
for the indicated time period. (C) OBI or CH11 (0.05|ig/ml) treated cells were 
incubated for 15h with the blocking anti-CD95 antibody ZB4 at the indicated 
concentrations. Data indicate the mean (+/-SEM) of triplicate wells, and each 
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Figure 4.3: D ose-dependent C H ll-in d u ced  apoptosis m easured by the 
annexin-FIT C  binding assay. J16 cells were exposed to the indicated 
concentrations of the apoptotic anti-CD95 antibody CHI 1 for 4h then assayed for 
annexin-FITC binding and analysed by FACS. The control sample was incubated 
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Figure 4.4: Apoptosis m easurem ent using TUNEL analysis and annexin- 
FITC binding. J16 cells were incubated with the anti-CD95 antibody CH11 
(0.05pg/ml) for the indicated time periods then assayed for apoptosis using 
annexin-FITC binding or TUNEL analysis, with increased fluorescence being 
visualised by FACS. The % of apoptotic cells at each time point is presented 
graphically in the lower panel. Data are representative of 2 similar experiments.
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using FACS based assays was the ability to acquire data separately for individual 
cells which could then be collated into dot-plot form. Figure 4.3 illustrates 
apoptosis induction in J16 cells in response to a 4 hour incubation with the 
indicated concentration of the anti-CD95 antibody CH11 as measured by the 
annexin-FITC assay. The x axis represents annexin-FITC binding whilst on the y 
axis plasma membrane integrity was assessed by PI uptake. During the course of 
an apoptotic response, therefore, cells move from the lower left quadrant to the 
lower right (annexin bright) region and finally undergo secondary necrosis and 
occupy the upper right portion of the dot-plot. Since this was a short term 
experiment (4 hours), the cells largely retained membrane integrity and thus 
accumulated in the lower right (“early apoptosis”) region of the dot plot. These 
data demonstrated the annexin assay to be a powerful and sensitive measurement 
of early apoptotic membrane changes.
The ability of the annexin-FITC assay to distinguish cells at an early time point 
during commitment to apoptosis was highlighted by a direct comparison with the 
TUNEL assay. Accordingly, the data shown in figure 4.4 reflect the temporal 
separation associated with the detection of membrane changes (by annexin-FITC 
binding) as compared to DNA fragmentation events (visualised by TUNEL). 
Therefore apoptotic cells could begin to be distinguished on the basis of their PS 
exposure only 2 hours after treatment with CHI 1, whilst DNA fragmentation was 
not apparent by TUNEL until at least 4 hours post stimulation. Thus a number of 
assays were established to detect different events which occurred during 
apoptosis.
4.2,2 Generation of soluble CD95L and a CD95-insensitive Cell Line
Since the use of monoclonal antibodies may not precisely mimic the effects of 
natural ligand, steps were taken to generate a source of soluble CD95L as an
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additional tool with which to probe T cell responses to CD95 ligation. Details of 
the soluble CD95L production are presented in the methods section. Briefly, a 
CD95L cDNA clone was generated comprising the extracellular portion of 
CD95L fused to a marker epitope (FLAG, Kodak) with the addition of the CD80 
signal sequence to target the resultant protein for secretion. The resulting 
construct was cloned into the eukaryotic expression vector pCDNA3 which 
contained a neomycin resistance gene and this vector was transfected into COS-7 
cells by electroporation. The production of the CD95L-flag construct was carried 
out by Dr Yusuf Patel and the transfection of COS-7 cells with this construct was 
performed by Dr Julie McLeod working in our laboratory. A stable line was 
generated by culture in the presence of neomycin to select for cells expressing the 
vector. Cells were then cloned into 96 well plates and supernatants were 
subsequently screened for cytotoxic activity in the JAM assay using J16 cells. As 
indicated in figure 4.5 (A), a small number of colonies exhibited cytotoxic 
potential, and these clones were therefore selected and expanded in culture. 
Following expansion, the supernatants were harvested, filtered and tested in the 
JAM assay for the ability to induce CD95-dependent apoptosis. As a control, 
supernatant from untransfected COS cells was also tested for cytotoxicity in the 
JAM assay. Figure 4.5 (B) illustrates that the apoptotic effect of the resultant 
CD95L-containing supernatant was dose-dependent and occurred only in 
supernatants from transfected cells. In addition, CD95L-induced apoptosis was 
inhibited in the presence of CD95-specific blocking reagents (CD95-Fc), but not a 
control blocking reagent (CD23-Fc), ruling out the possibility of non-specific 
toxicity (figure 4.6, panel A).
As a further tool for these studies, a 'CD95-resistant' Jurkat cell line was also 
generated. To achieve this, J16 cells were subjected to sequential treatment with 
the apoptotic anti-CD95 antibody CHI 1. After each round of selection, surviving 
cells were expanded in culture prior to further treatment with augmented titres of 




7 0  -  
6 0  -
C / 3
T tm v o r 'o o  onO  — m  — cn m cr, o^ m » o\ 0  — cn —■ <n  m  o o o \ 0  — n
< < < < < < - - " B Q B Q B Q f l Q C Q O Q C Q f l Q O Q - - - U U U U U U U U U - r ( -  
< < <  CQ 0Q DQ UUU
Well Number in 96 well plate
(B)
5 0 - ,
Treatment
Figure 4.5: Production of soluble CD95L. (A) COS-7 cells transfected with 
CD95L were cloned into 96 well plates and screened for apoptotic activity against 
3H-thymidine-labelled Jurkats in a 15h JAM assay. (B) Supernatants from 
selected colonies were titrated in a 6h JAM assay. Supernatant from untransfected 
COS-7 cells was included as a control and apoptosis is presented as % death 
relative to control-treated Jurkats. Data in panel (B) indicate the mean (+/-SEM) 
of triplicate wells and this experiment was repeated twice with similar results.
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Figure 4.6: Analysis of the specificity of soluble CD95L using CD95-Fc and a 
MCD95-insensitive" cell line (JLW). (A) 3H-thymidine-labelled J16 cells were 
incubated with supernatants from transfected (CD95L) or untransfected COS-7 
cells in the presence of CD95-Fc or a control Fc construct (CD23-Fc). (B) JLW 
cells were derived from J16 by selection with apoptotic anti-CD95 antibody 
(CH11). J16 and JLW cells were 3H-thymidine labelled and exposed to the 
indicated dilution of soluble CD95L. Apoptosis was measured by JAM assay and 
is presented as % death relative to control-treated Jurkats (mean +/-SEM of 
triplicate wells).
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to the parental line, but nevertheless exhibited a marked reduction in the apoptotic 
response to CD95 ligation as illustrated by treatment with soluble CD95L (figure 
4.6, panel B). This cell line proved useful in bioassays designed to dissect the 
cytotoxic mechanisms utilised by T blasts as presented in chapter 5.
4.2.3 Study of CD95 in Normal Activated T Cells
Having established that T cells could be effectively activated using the in vitro 
protocols described earlier, and having established assays for apoptosis 
measurement using Jurkat T cells, it was then possible to examine CD95 receptor 
engagement in normal peripheral blood T cells. Since Jurkat T cells readily 
exhibited CD95-induced apoptosis, these cells served as a useful control for the 
studies on normal T lymphocytes. Initial comparisons between J16 cells and 
normal T cell blasts on day 6 after activation (SEB blasts) indicated equivalent 
expression of the CD95 receptor as detected by surface staining and FACS 
analysis (figure 4.7, panel A). However, measurement of apoptosis induction 
using the JAM assay revealed a striking difference in the response to CD95 
ligation between these two cell types (figure 4.7, panel B). Whilst the majority of 
J16 cells were apoptotic following a 15 hour incubation with the stimulating anti- 
CD95 antibody CH11 (0.05pg/ml), SEB blasts in contrast exhibited only a small 
decrease in viability as measured by DNA fragmentation in the JAM assay.
Since the viability of SEB blasts did not appear to be greatly compromised by 
incubation with CH11, the effect of different concentrations of this antibody was 
investigated. Previously presented data from J16 cells (figure 4.2, A) indicated 
maximal killing was achieved at approximately 0.025pg/ml CH11 under these 
conditions, and this dose induced apoptosis with equivalent potency and kinetics 
in a number of other human T cell lines examined (including HUT78). However, 
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Figure 4.7: Resistance to CD95-induced apoptosis in SEB blasts com pared to 
Ju rk a t cells despite equivalent CD95 expression. (A) Cells (J16 or day 6 SEB
blasts) were stained for surface expression of CD95 (filled histograms). Open 
histograms indicate staining with secondary antibody only. (B) ^-thym idine- 
labelled cells from the same cultures as (A) were treated for 15h with OBI 
(supernatant) or the apoptotic anti-CD95 antibody CH11 (0.05pg/ml) in the JAM 
assay. Apoptosis is indicated as % death relative to control-treated cells (mean +/- 















Figure 4.8: Dose response to CH11 in J16 cells and SEB blasts, ^-thym id ine- 
labelled cells (J16 or day 6 SEB blasts) were exposed to the indicated 
concentration of the apoptotic anti-CD95 antibody CH11 for 15h in the JAM 
assay. Apoptosis is indicated as % death relative to control treated cells (mean +/- 
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Figure 4.9: Resistance to CD95-m ediated apoptosis in SEB blasts as 
m easured by TUNEL and annexin-FITC analysis. SEB blasts (day 6) were 
treated for 15h with the apoptotic anti-CD95 antibody CH11 (0.5pg/ml) then 
assayed for apoptosis using the TUNEL assay (A) or annexin-FITC binding (B). 
Apoptosis is measured as an increase in fluorescence in the gated region of the 
histogram. The CHI 1-dependent increase in fluorescence is 17.59% as measured 
by TUNEL and 22.77% as measured by annexin-FITC binding in this experiment. 
























Figure 4.10: Comparison of antibody- and ligand-m ediated CD95-induced 
apoptosis in T blasts. SEB blasts (day 6) were incubated for 15h with the anti- 
CD95 antibody CH11 (0.5|ig/ml) or soluble CD95L (COS-7 cell supernatant). 
Apoptosis was measured by annexin-FITC binding and visualised as an increase 
in fluorescence by FACS (27.44% increase for CHI 1 treatment, 24.65% increase 
for soluble CD95L). Data indicate the maximum apoptotic response from 4 
experiments.
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experiments were performed utilising greater concentrations in order to establish 
whether the resistance to apoptosis was a consequence of limiting antibody. The 
data presented in figure 4.8 illustrate a dose-response to CHI 1 for both J16 cells 
and SEB blasts in the JAM assay. At concentrations as low as 0.005|ig/ml, there 
was a marked apoptotic response in the J16 cells which increased before 
plateauing at approximately 0.05pg/ml in this experiment. In contrast, whilst SEB 
blasts exhibited a small dose-dependent increase in apoptosis as the CH11 
concentration increased, the response was substantially lower than that seen in 
Jurkat cells. The fact that Jurkat cells exhibited maximal sensitivity to apoptosis 
at these doses of CH11, and that SEB blasts expressed equivalent surface CD95 
receptor as detected by FACS analysis, indicated that there was sufficient 
antibody availability in these experiments to trigger apoptosis in susceptible cells.
To confirm that CD95 resistance in SEB blasts was not an artefact associated with 
use of the JAM assay for apoptosis measurement, alternative apoptosis assays 
were also used. Again, the restricted response to CD95 ligation in SEB blasts was 
confirmed regardless of the methodology employed: apoptosis following CH11 
treatment was confined to a minority of the SEB blast population as measured by 
both annexin-FITC binding and TUNEL analysis (figure 4.9), even when using a 
relatively high concentration of CH11 (0.5pg/ml). Furthermore, apoptosis 
induction using soluble CD95L as an alternative to antibody-mediated ligation 
gave a similarly limited apoptotic response (figure 4.10), demonstrating that the 
resistance to apoptosis in SEB blasts was not simply an artefact associated with 
the anti-CD95 antibody CHI 1, but was a reproducible finding.
Since the surface marker expression and functional responses of T cells change 
during the activation process (chapter 3), the relationship between extent of 
cellular activation and resistance to CD95-mediated apoptosis was investigated. 
Accordingly, parallel analysis of CD95 receptor surface expression and sensitivity 
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Figure 4.11: CD95 expression and CD95 sensitivity of hum an peripheral 
blood T cells during superantigen stimulation. Human PBMC were treated with 
SEB (lpg/ml) on day 0 and assayed for CD95 receptor expression (A) and CD95- 
induced apoptosis (B) at the indicated time points. Control staining reflects use of 
the secondary antibody only. (B) Apoptosis was induced by a 15h incubation with 
the anti-CD95 antibody CH11 (0.5|iig/ml) and was measured by TUNEL assay. 
Data are presented as % CD95-induced death relative to control treated cells and 
this experiment was repeated using 6 different donors with similar results.
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superantigen stimulation. As shown in figure 4.11, the CD95 receptor was 
upregulated during the first 4 days of activation (panel A) and the sensitivity to 
apoptosis via this route increased accordingly (from 0 % to approximately 2 0 %) 
(panel B). After this time point, however, despite high CD95 receptor expression, 
which was equivalent to levels found on J16 cells, the apoptotic response was 
nevertheless confined to a minority of cells (less than 35% at all time points) 
whereas J16 cells underwent apoptosis readily following CD95 ligation. These 
data therefore contrasted with previously published findings which demonstrated a 
substantial apoptotic response of human T cells at these time points (Owen- 
Schaub et al., 1992; Klas et al., 1993).
To rule out the possibility that resistance to CD95-mediated apoptosis was merely 
a feature of superantigen stimulation of cells, a number of alternative mitogenic 
treatments were utilised including PHA and ConA. As outlined in the 
introduction, these reagents are routinely used for the in vitro generation of 
activated T cells from resting PBMC and are competent to induce proliferation 
and the predicted surface marker changes. A comparison of day 6  activated T 
cells generated by use of the above stimulations revealed that substantial CD95 
resistance, as measured by TUNEL assay, was common to all of these activated T 
cell cultures rather than being specifically associated with superantigen 
stimulation (figure 4.12).
Another possibility to be addressed was that T cell blasts may be protected from 
apoptosis by the serum used in their culture medium. Therefore to investigate this 
hypothesis, resting T cells from the same donor were cultured by superantigen 
stimulation either in routine medium (RPMI-1640 plus 10% FCS) or in serum free 
medium (AIM-V). As shown in figure 4.13, cells grown in AIM-V underwent the 
characteristic surface marker changes associated with T cell activation including 
upregulation of CD95 (A) and were able to proliferate to a comparable degree as 
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Figure 4.12: CD95-mediated apoptosis of hum an PBMC activated using 
diverse stimuli. Resting human PBMC were stimulated with PHA (2pg/ml), 
ConA (lpg/m l) or SEB (lpg/m l) for 6 days then treated with the anti-CD95 
antibody CH11 (0.5jig/ml) for 15h. Apoptosis was measured by TUNEL analysis. 
CHI 1-specific increases in apoptosis of 2.54% (A), 17.05% (B), 12.99% (C) and 
13.87% (D) were observed in this experiment. Data are representative of 3 
independent experiments.
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F igure  4.13: Effective activation of T cells stim ulated  in serum  free 
m edium . Human PBMC were stimulated with SEB (lpg/m l) in routine medium 
(RPMI +10% FCS) or serum free medium (AIM-V). (A) Surface expression of CD25, 
HLA-DR, and CD95 was assessed for cells cultured in serum free medium. Control 
staining indicates use of secondary antibody alone. (B) Proliferation of T cells (2 x 104 
cells per well) stimulated in routine medium versus serum free medium was measured 
by ^H-thymidine incorporation and are displayed as the mean of triplicate wells (+/- 
SEM). These data are representative of 2 similar experiments.
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Figure 4.14: C D 95-m ediated apoptosis of T cells stim ulated  in serum  
free medium. Human PBMC were activated for 6 days with SEB (lpg/ml) in routine 
medium (RPMI + 10% FCS) or serum free medium (AIM-V) then labelled with 3H- 
thymidine and treated for 15h with the indicated concentrations of the anti-CD95 
antibody CH11. Apoptosis was measured by JAM assay and is calculated as % 
apoptosis relative to control treated cells. The mean (+/-SEM) of triplicate wells is 
shown. Data are representative of 2 experiments.
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activation had occurred in cultures generated in serum free medium. The 
sensitivity to CD95-mediated apoptosis, as measured by JAM assay (figure 4.14), 
was also equivalent between these two cultures, indicating that the resistance to 
apoptosis exhibited by activated T cells was not associated with protective factors 
present in the FCS.
To examine whether the resistance to apoptosis in SEB blasts was mediated by a 
soluble factor, supernatants from activated T cell cultures were tested for their 
ability to inhibit CHI 1-mediated apoptosis of J16 cells in the JAM assay. One 
possibility was that a soluble version of the CD95 receptor might be produced by 
these cells and might act as a competitive inhibitor for CD95L/CH11 binding, and 
indeed it has been demonstrated that soluble CD95 proteins can be generated by 
alternative splicing (Cheng et al., 1994; Cascino et al., 1995). However, as 
indicated in figure 4.15, supernatants from activated T cells were unable to inhibit 
CD95-mediated apoptosis of J16 cells, suggesting that resistance was not 
transferable by a soluble factor.
Since the apoptotic response appeared to be restricted to a subpopulation of cells, 
one possibility was that sensitivity to CD95 may be cell cycle dependent. If, for 
example, S-phase entry was a requirement for the acquisition of sensitivity to 
CD95, then this might explain the limitation on apoptosis induction in these 
cultures. Consistent with this hypothesis, it has been previously suggested that 
cell cycle status may influence apoptosis sensitivity in normal human T cells 
(Lenardo, 1991; Boehme and Lenardo, 1993). To assess this, simultaneous cell 
cycle analysis and apoptosis measurement by TUNEL was performed both for J16 
cells and SEB blasts. To visualise the cell cycle status of cells within a 
population, the DNA dye PI was used following ethanol permeabilisation of T 
cells. In the resulting histogram, the G0/G1 peak (comprising cells containing one 
copy of DNA) can be distinguished from S-phase (DNA synthesis phase) and G2 
(two copies of DNA prior to cell division) phase cells, as indicated in figure 4.16
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Figure 4.15: Effect of T blast supernatants on C H ll-m ediated  apoptosis in 
J16 cells. Cell supernatants from day 6 SEB-activated (lpg/m l) human PBMC 
were tested for their ability to inhibit CD95-mediated apoptosis of J16 cells in the 
JAM assay. 3H-thymidine-labelled J16 cells were incubated with the anti-CD95 
antibody CH 11 in the presence of T blast supernatants as indicated. Apoptosis was 
measured by JAM assay and is calculated as the % decrease in CPM relative to 
control-treated cells. Columns represent the mean (+/-SEM) of triplicate wells. 
Supernatants from SEB blast lines generated from 2 further donors were tested 
with similar results.
114
(A). By incorporation of TUNEL analysis into this protocol, the extent of 
apoptosis within each portion of the cell cycle histogram could be simultaneously 
assessed. Figure 4.16 (B) illustrates a viable J16 population denoted by contour 
plot, with the PI based cell cycle analysis plotted on the y axis in this case.
Application of this methodology to J16 cells (figure 4.17, A) indicated that, as 
expected, there was a strong apoptotic response to CD95 ligation, and 
interestingly this response was not restricted to one particular phase of the cell 
cycle since there was a reduction in both the upper left and lower left quadrants 
following CH11 treatment. In contrast, the SEB blast contour plots (figure 4.17, 
B) showed only a 9% increase in the TUNEL bright (right) quadrants following 
CD95 ligation indicating that, consistent with the previous data, the apoptotic 
response to CD95 engagement appeared to be subject to restrictions in activated 
peripheral blood T cells as compared with Jurkat T cell lines. Importantly, 
analysis of the cell cycle data revealed that rather than S-phase/G2 entry being a 
requirement for CD95 sensitivity, in fact there appeared to be a bias towards cells 
from the G0/G1 region of the histogram (lower left) exhibiting more apoptosis 
following CH11 treatment. Accordingly, the S-phase/G2 portion of the contour 
plot (upper left) was not reduced following exposure to anti-CD95, whilst the 
G0/G1 region (lower left) in contrast exhibited an 11% decrease following 
treatment. Since the majority of T blasts existed in this G0/G1 state (as visualised 
by cell cycle histograms), the restricted response to CD95 engagement did not 
merely reflect the proportion of cells which were transiting S-phase or were 
present in G2 phase at the time of the CD95 challenge.
Since an apoptotic response appeared to be favoured in those cells which were 
present in the G0/G1 peak, T blasts were allowed to quiesce in culture such that 
their viability was not substantially impaired, but they began to exit cell cycle. To 
achieve this, cultures were left without restimulation for 14-20 days in the absence 
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Figure 4.16: Cell cycle analysis by DNA staining with PI. (A) J16 cells were 
permeabilised with ethanol (15-18h, -20°C) and stained with PI (lOOjLtg/ml, 
15min) to allow visualisation of DNA content. The peaks represent cells in 
different phases of cell cycle as indicated. (B) Simultaneous analysis of cell cycle 
and TUNEL positivity was performed as detailed in the methods section. Data 
was displayed as a contour plot allowing cell cycle to be measured on the y axis 
and TUNEL fluorescence on the x axis. This plot features a viable J16 population 
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Figure 4.17. Dual staining for cell cycle status and apoptosis following CH11 
treatm ent of T cells. J16 cells, day 6 SEB blasts or quiescent SEB blasts (day 17) 
were treated for 15h with the anti-CD95 antibody CH11 at 0.01pg/ml (A) or 
0.5pg/ml (B) and (C). Simultaneous analysis of DNA content by PI staining (FL-2 
fluorescence) and apoptosis by TUNEL assay (FL-1 fluorescence) was performed 
as described in the methods section. Data are representative of 3 experiments.
FL1-Height
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with overall viability dropping dramatically. However, on other occasions it 
proved possible to quiesce cultures in this manner with the result that DNA 
content histograms exhibited a near total absence of cells in S/G2-phase. This is 
illustrated by the PI cell cycle histogram shown in figure 4.17 (panel C) where the 
withdrawal from cell cycle can be clearly visualised by FL-2 fluorescence on the y 
axis. The data in this figure indicate that despite this lack of cycling, the 
proportion of cells sensitive to CD95-mediated apoptosis nevertheless remained 
low (9% kill as measured by TUNEL assay).
Since the responses of T cells may differ according to whether they exhibit a Thl 
or Th2 profile of cytokine secretion (Mosmann and Coffman, 1989) it was 
possible that the subpopulation of SEB blasts which underwent apoptosis 
following CD95 ligation represented those displaying a certain Th phenotype. 
Therefore experiments were carried out in an attempt to elucidate whether there 
was a differential response to CD95 engagement depending on Th differentiation. 
In order to address this issue purified CD4+ T cells were activated with HLA- 
DR/CD80-presented superantigen (SEB) in the presence of cytokines which 
reputedly bias the nature of the Th response: either IL-12 to favour T hl 
development, or IL-4 to bias towards a Th2 phenotype (Noble et al., 1993; Seder 
et al., 1993). Surface staining following purification confirmed that all detectable 
CD8+ cells had been successfully removed from these starting cultures (figure 
4.18, A). Intracellular staining was then performed to assess which cytokines 
could be produced by these cultures. As indicated in figure 4.18 (panel B), IL-2 
production was substantially increased in the "Thl"-like population, with IFNy 
also being detected in these T blasts. In contrast, the "Th2"-like cells exhibited a 
reduced IL-2 output and undetectable IFNy. Disappointingly, IL-4 was not 
detectable in either of these populations making it difficult to draw conclusions 
regarding the extent of differentiation achieved in these cultures. Whilst IL-4 is 
not a categorical marker for Th2 cells, some positivity would be expected from a 
population biased in this way. Thus whilst the differential IL-2 production is
118
CD8 Expression






Figure 4.18 (A): Purification of CD4+ T cells. Resting human CD4+ T cells 
were purified from PBMC by immunomagnetic depletion. The resultant 
population was stained for surface expression of CD4 and CD8 (filled 
histograms). Dotted lines indicate control staining with secondary antibody only. 
Data are representative of the staining patterns observed each time CD4+ T cells 
were purified.
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Figure 4.18 (B): Differentiation of CD4+ T cells by addition of exogenous 
cytokines. CD4+ T cells were activated with SEB-pulsed HLA-DR/CD80 
transfectants in the presence of either exogenous IL-12 (0.5ng/ml) to favour Thl 
differentiation or IL-4 (0.5ng/ml) to favour Th2 differentiation. Cells were 
restimulated in this manner every 10-14 days. Six days following the third 
stimulation, cells were stained for intracellular cytokine expression using FITC- or 
PE- conjugated antibodies (open histograms). Filled histograms indicate staining 
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Figure 4.19: Sensitivity to CD95-induced apoptosis in " T h l" a n d  "T h2" T 
cells. Resting CD4+ T cells were activated with SEB-pulsed HLA-DR/CD80 
transfectants in the presence of IL-12 ("Thl" cells) or IL-4 ("Th2" cells). 
"Undifferentiated" indicates cells activated in the absence of exogenous cytokine. 
Cells were treated for 15h with the anti-CD95 antibody CH11 (0.5|ig/ml) and 
apoptosis was measured by annexin-FITC binding and is calculated as % increase 
in fluoresence relative to control-treated cells. Data are representative of 3 
experiments.
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indicative of some measure of successful differentiation, the absence of a marker 
for "Th2"-like cells, renders firm conclusions difficult.
Since it appeared that the populations generated by the cytokine treatm ent 
described above exhibited some distinctions in terms of cytokine output, 
experiments were undertaken to determine whether there was a differential 
response to CD95 ligation in these cultures. Accordingly, samples from each 
population were treated with the anti-CD95 antibody CH11 and apoptosis was 
measured by annexin-FITC binding (figure 4.19). These data illustrated that there 
were no obvious differences in the sensitivity to CD95-mediated apoptosis 
between populations, with the apoptotic response being confined to a minority of 
cells in all cases. If a degree of T cell differentiation had indeed occurred in these 
populations, as indicated by the IL-2 and IFNy staining data, then it had not 
affected the susceptibility to CD95-m ediated apoptosis in these cells. 
Alternatively, polarised Th differentiation simply may not have occurred under 
these conditions and in the absence of a successfully tested marker for Th2 cell 
identification, these studies were not extended further.
As an alternative model for studying T cell responses, T cell clones which are 
long term cultures but which retain the requirement for antigen and costimulation 
in order for proliferation to be maintained were also used. Since normal activated 
T cells appeared to be restricted in their response to CD95 ligation, whilst Jurkat T 
cells were constitutively sensitive to apoptosis via this route, the relative 
sensitivity of T cell clones to this form of cell death was also assessed. The 
alloreactive T cell line 7418 was utilised for these studies and restimulated every 
10-17 days using the B cell line ROF (expressing CD80 and HLA-DR) (figure 
4.20, panel A) and irradiated PBMC. The latter are routinely used in the culture 
of T cell clones for the provision of undefined stimulatory ligands/cytokines, with 
the irradiation process being necessary to prevent their own proliferation. The 
successful stimulation of this T cell clone under the conditions described is
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Figure 4.20: ROF-dependent proliferation of alloreactive T cells. (A) ROF B
cells were stained for surface expression of CD80 or HLA-DR (open histograms). 
Filled histograms indicate control staining with secondary antibody alone. (B) 
7418 alloreactive T cells were treated with fixed ROF cells (ratio 5:1 T celFROF 
cell), and irradiated PBMC (ratio 1:1T celhPBMC) as indicated. Proliferation was 
assessed by 3H-thymidine incorporation and the mean (+/-SEM) of triplicate wells 
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Figure 4.21: CD95 expression and CD95 sensitivity in alloreactive T cells. (A)
7418 alloreactive T cells were stained for CD95 expression. (B) T cells were 
incubated for 15h with the anti-CD95 antibody CH11 (0.5pg/ml) and apoptosis 















Figure 4.22: Sensitivity to CD95-mediated apoptosis in T cells. J16 cells, 
7148 T cell clones (day 6 post stimulation) or SEB blasts (day 6) were incubated for 
15h with 0.5|ig/ml of the anti-CD95 antibody CH11 (0.05|ig/ml for J16 cells) and 
apoptosis was measured by TUNEL analysis. The % increase in fluorescence relative 
to control-treated cells is shown. Data are pooled from 4 independent experiments and 
columns indicate the mean (+/-SEM).
illustrated in figure 4.20 (panel B). Surface staining and FACS analysis of these 
cells indicated expression of the CD95 receptor (figure 4.21, panel A) and 
sensitivity to CD95 ligation was therefore tested. Following CH11 treatment, 
approximately 50% of these cells underwent apoptosis as assessed by TUNEL 
analysis (figure 4.21, panel B). This analysis indicated that the CD95 pathway 
was operative in this alloreactive T cell line. In addition, two other T cell clones 
were analysed in the laboratory and exhibited similar sensitivity to CD95- 
mediated apoptosis.
In terms of the percentage apoptosis following CD95 challenge, the T cell models 
investigated could be ranked in order of CD95 sensitivity as indicated in figure 
4.22. This figure illustrates the average CD95-induced kill (as measured by 
TUNEL) from 4 experiments with each of these T cell types and demonstrates 
clearly that Jurkat cells were most sensitive to CD95 ligation followed by T cell 
clones and finally normal activated T cells. Since in terms of closeness to a 
physiological model of an activated T cell, SEB blasts are arguably closest whilst 
Jurkat cells are furthest removed from normality, it would appear that resistance to 
apoptosis is a feature of normal T cells which is diminished in T cell clones, and 
may be absent from transformed T cell lines.
4.3 DISCUSSION
In order to carry out an investigation into the control of programmed cell death, 
the establishment of a series of assays was performed, to allow apoptosis 
assessment according to a number of different criteria. This was important since 
apoptosis is a morphologically defined phenomenon and there is no single 
criterion which serves universally as a marker for this process. The most widely 
accepted marker, which is associated with the induction of apoptosis in nearly all 
systems tested, is the systematic cleavage of nuclear DNA initially yielding
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300Kbp and 50Kbp fragments followed subsequently by the appearance of 
smaller fragments comprising multimers of 180pb (McConkey et al., 1994). Early 
work on apoptosis relied heavily on the visualisation of DNA fragmentation by 
the use of laddering assays (Owen-Schaub et al., 1992; Groux et al., 1993), but 
with the rapid growth of interest in this field came more advanced methodologies 
which facilitated more accurate quantification of DNA fragmentation. For 
example the TUNEL assay uses fluorescence-tagged nucleotides to label the free 
DNA ends created as a result of the fragmentation process and, when monitored 
by FACS analysis, provides a powerful tool for assessing the extent of apoptosis 
within a cell population. Alternatively, the JAM assay (Matzinger, 1991) offers a 
rapid and simple approach to apoptosis detection with the filtration of DNA from 
lysed cells through glass fibre filter mats serving as an indication of DNA 
fragmentation. The laddering data presented in figure 4.1(B) supported the 
general consensus that, whilst a qualitative distinction between viable (control- 
treated) and apoptotic (CHI 1-treated) samples was unequivocal, quantitative 
interpretation of the extent of apoptosis between samples was more difficult. For 
the purpose of this study, therefore, alternative methods for the assessment of 
apoptosis were utilised.
A significant advance in apoptosis detection which occurred during the course of 
this investigation was the development of the annexin-FITC binding assay. By 
focusing on early changes in membrane phospholipid asymmetry associated with 
the induction of apoptotic signalling, this assay provided for the first time an early 
m arker of commitment to cell death. As dem onstrated in figure 4.4, 
externalisation of membrane PS (which is bound by annexin-FITC) preceded 
detectable DNA fragmentation by a substantial time period and thus enabled early 
apoptotic cells to be discerned with greater sensitivity at early time points. 
Combined with the use of PI as a marker of cell membrane integrity, this assay 
provided multiparameter analysis of apoptosis-associated membrane changes,
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thereby allowing viable, early apoptotic and late apoptotic populations to be 
readily distinguished.
The opening experiments (figures 4.1-4.6) therefore represent background work 
perform ed to accumulate the necessary methodology and expertise for an 
investigation into apoptosis of human T cells. In addition, the production of 
further tools to address this aim is described. For example, a soluble source of 
CD95L was generated in order that CD95 ligation could be achieved in a 
physiologically relevant manner as a comparison with antibody (CH11) -driven 
studies. Interestingly, several differences between ligand and antibody-mediated 
effects have recently been demonstrated (Suda et al., 1996; Zipp et al., 1997) 
although no obvious differences were observed during the course of this study. 
Additionally, a CD95-expressing but CD95-resistant cell line was derived from 
Jurkat cells by sequential treatment with CH11. This cell line (JLW) proved 
particularly useful as a control for dissecting the mechanisms of T cell 
cytotoxicity as measured by the JAM bioassay. The defect in CD95-mediated 
apoptosis in JLW cells was not targeted for investigation, but interestingly this 
cell line was found to be sensitive to ceramide-induced apoptosis, exhibiting an 
equivalent apoptotic response to that of the parent line (J16). One downstream 
event which has been implicated in CD95 signal transduction is the activation of 
acidic sphingomyelinase which cleaves sphingomyelin to yield the lipid signalling 
molecule ceramide. Since the addition of cell soluble ceramide to bypass this step 
appeared to overcome the defect in apoptosis in JLW cells, this suggests that the 
coupling of CD95 ligation to acidic sphingomyelinase activation may be defective 
in this cell line, but that the downstream components of the apoptotic pathway are 
intact. Interestingly, recent literature has highlighted the complex series of protein 
recruitments to the CD95 receptor which control the initiation of the death signal 
at a receptor-proximal location (Chinnaiyan et al., 1995; Kischkel et al., 1995; 
Yang et al., 1997) making these proteins potential targets for the signalling defect 
in JLW cells.
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Following the establishment of assays and reagents, it was then possible to apply 
these to the investigation of CD95 expression and function in human T cells. As 
indicated previously, CD95-mediated apoptosis is thought to be a key mechanism 
for the negative regulation of the T cell immune system, however a detailed 
understanding of the physiological circumstances under which this process occurs 
is largely absent from the literature. As the basis for investigations of this nature, 
the first question to be addressed regarded the expression of the CD95 receptor 
and the sensitivity of T cells to apoptosis following its ligation with antibody 
(CHI 1) or soluble CD95L.
The striking observation from this series of experiments was the marked lack of 
apoptosis induction in the majority of activated human T cells following CD95 
ligation. It has been reported that although resting and early activated T cells 
undergo limited CD95-mediated apoptosis, in contrast after several days of in 
vitro cultivation sensitivity to this pathway is acquired (Owen-Schaub et al., 1992; 
Klas et al., 1993). Clearly the presented data refute this hypothesis since even 
after prolonged periods in culture the T cells examined remained largely 
insensitive to apoptosis induction by CD95 ligation. As such, these data are 
somewhat controversial and therefore warranted detailed scrutiny in an attempt to 
identify the underlying source of these conflicting conclusions. Obvious sources 
of experimental variation included firstly differences in the activation stimuli 
utilised for the expansion of T cells in culture, and secondly the choice of assay 
methodology employed to assess the extent of apoptosis induction. Accordingly, 
these issues were addressed by the comparative analysis of T cells activated by a 
range of different stimuli whilst analysis of apoptosis was undertaken by JAM, 
TUNEL and annexin-FITC binding to minimise the possibility of artefact at the 
level of apoptosis measurement. Further controls included the use of soluble 
CD95L to preclude problems arising from the use of antibody (CH11) for the 
purpose of CD95 ligation (fig 4.10), and the parallel treatment of Jurkat T cells
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indicating that T cell CD95-mediated apoptosis could be both successfully 
induced and adequately detected under these experimental conditions (figures 4.7, 
4.8).
Overall these experiments represented a comprehensive effort to test the initial 
hypothesis, namely that activated human T cells were largely resistant to CD95- 
mediated apoptosis even after several days in culture. This premise was tested by 
a wide range of approaches and nevertheless remained robust, representing the 
most logical interpretation of these accumulated data. Whilst this concept appears 
controversial, it is becoming increasingly evident from the literature that a wide 
range of physiological mechanisms exist for the negative regulation of CD95 
signalling, including the recently identified FLIP molecules (Irmler et al., 1997; 
Thome et al., 1997) and mutant caspase 8 proteins (Boldin et al., 1996; Vincenz 
and Dixit, 1997), supporting the concept that CD95-mediated apoptosis can be 
regulated downstream of receptor ligation. In addition, the fact that both double 
positive (expressing both CD4 and CD8 coreceptors) and single positive 
thymocytes express equivalent CD95 yet only the former apoptose following 
CD95 ligation (Ogasawara et al., 1995) provides further evidence that CD95 
expression does not necessarily equate to CD95 sensitivity. Thus my data clearly 
suggest that normal activated human T cells are in fact mainly resistant to CD95- 
mediated apoptosis.
Since the resistance of activated human T cells to CD95-mediated apoptosis 
appeared to be a consistent finding, a number of experiments were carried out in 
an attempt to identify whether such resistance was merely a feature of the T cell 
culture conditions. One possibility was that the serum present in culture medium 
was contributing towards the insensitivity to apoptosis since serum deprivation 
has been reported to promote apoptosis induction (Kulkami and Mcculloch, 1994; 
Allen et al., 1995; Lindenboim et al., 1995) and is permissive of c-myc -induced 
apoptosis (Evan et al., 1992). Therefore to address this issue, serum free medium
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(AIM-V) was utilised. As illustrated in figure 4.13, this medium was competent 
to support productive T cell activation and proliferation, as assessed by 3H- 
thymidine incorporation and surface marker changes. However, cells cultured in 
this manner did not exhibit an increased apoptotic response following CD95 
ligation when compared to cells cultured under routine conditions, rendering it 
unlikely that growth in serum is responsible for the observed resistance to 
apoptosis.
Since it has recently been shown that splice variants of the CD95 receptor in 
lymphocytes can yield truncated CD95 proteins which are soluble (Hughes and 
Crispe, 1995; Papoff et al., 1996) it was possible that local protection from 
apoptosis could be afforded by such a mechanism. Interestingly, it has been 
suggested that levels of soluble CD95 are elevated in SLE patients consistent with 
a possible defect in CD95-mediated apoptosis associated with this condition 
(Cheng et al., 1994). In addition, the same study demonstrated that injection of 
mice with soluble CD95 protein triggered the onset of autoimmune features, 
presum ably reflecting the disruption of CD95-based peripheral tolerance 
mechanisms. W hilst the inhibition of T cell apoptosis by the production of 
soluble CD95 proteins has therefore been documented, the CD95 resistance in 
SEB blasts was not transferable by cell supernatants in this study (figure 4.15) 
rendering involvement of a soluble factor unlikely. Furthermore, if resistance was 
due to competitive inhibition by soluble CD95 molecules, this would be expected 
to be overcome at high concentrations of CH11/CD95L, a prediction which was 
not borne out by the data.
The examination of cell cycle status in conjunction with apoptosis in SEB blasts 
(figures 4.16 and 4.17) revealed that S-phase entry was not a requirement for the 
acquisition of CD95 sensitivity, in fact on the contrary there was preferential 
apoptosis of cells in the G0/G1 region of the cell cycle histogram. This finding is 
consistent with recent work in which T cells arrested in G0/G1 were not less
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sensitive to CD95-mediated apoptosis but rather exhibited a slightly enhanced 
apoptotic response (Foumel et al., 1996). The SEB blast analysis contrasts with 
the situation in J16 cells where approximately equivalent apoptosis was observed 
between G0/G1 cells and S/G2 cells following CD95 ligation, illustrating the lack 
of constraint on apoptosis induction regardless of cell cycle status in this cell line.
The fact that CD95-mediated apoptosis was routinely restricted to a subpopulation 
of T cells in this study and in work by others (Miyawaki et al., 1992; Klas et al., 
1993; Alderson et al., 1995) raised the issue of heterogeneity within T cell 
cultures and therefore a critical question relating to this investigation was how the 
subset of CD95-sensitive cells differed from the remaining population. One 
possibility was that Th phenotype could contribute to relative sensitivity to CD95 
ligation thus prompting the experiments presented in figures 4.18 and 4.19. Since 
the starting T cell populations are CD8 -depleted for this study, it can be concluded 
that CD95 resistance in SEB blast lines (which are predominantly but not 
exclusively CD4+) is not CD8+ T cell dependent as it is also observed in lines 
generated in the absence of CD8+ cells. However, differential CD95 sensitivity 
was not detected between cells activated in a Thl-like way (in the presence of IL- 
12) versus those stimulated such that Th2 differentiation would be favoured (in 
the presence of IL-4) (figure 4.19, B). The lack of a marker to successfully 
identify the IL-4 treated cells as Th2-like precludes formal conclusions regarding 
the influence of Th status on CD95 resistance. However, the evidence that 
cytokine output is differentially regulated between the IL-12- and IL-4-treated 
populations provides an indication that these cultures may indeed represent 2 
pathways of differentiation. The categorisation of CD4+ T cells has historically 
been fraught with controversy (Bass et al., 1989; Fiorentino et al., 1989; Mosmann 
and Coffman, 1989; Karulin and Lehmann, 1997) and a recent cautionary review 
(Allen and Maizels, 1997) has highlighted the danger of accepting these 
subdivisions as dogma. One interesting issue raised in this article is the dearth of 
adequate markers to equivocally distinguish between T helper subsets cells. In the
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light of this limitation, it was therefore decided that further experimentation 
following this approach was not appropriate to this study since it is clear that 
categorisation of Th cells is a more complex issue than initial reports may have 
suggested.
The evidence from work on alloreactive T cell clones provides a useful 
comparison for normal peripheral blood T cells. The rationale underlying this set 
of experiments was drawn from the fact that much of the published data 
addressing sensitivity to CD95-mediated apoptosis was based on studies using 
longer term T cell cultures such as clones or hybridomas (Brunner et al., 1995; Ju 
et al., 1995; Yang et al., 1995). Such cultures provide an alternative model of 
activated T cells which represents a useful intermediate between immortalised cell 
lines and freshly isolated peripheral blood T cells. The fact that apoptosis 
following CD95 ligation was readily induced in about 50% of the population in 
these studies (figure 4.21) was encouraging from the perspective that it provided 
yet another control for the resistance observed in normal activated T cells. Thus 
there was no universal defect in the ability to induce CD95-mediated apoptosis in 
human T cells under these experimental conditions. It is of note that the ranking 
of cell types according to CD95 sensitivity is in accordance with their broad 
closeness to physiological relevance. Jurkat cells, which represented the greatest 
divergence from physiology in terms of loss o f proliferative controls and 
immortalisation, exhibited the greatest sensitivity to CD95 ligation whilst freshly 
isolated activated peripheral blood T cells were the most tightly modulated in this 
regard. Clones ranked as intermediate, and since they by definition had been 
subjected to repeated stimulation, and had therefore undergone many population 
doublings, this raised the intriguing possibility that sensitivity to CD95-mediated 
apoptosis might be a function of approximation to cellular senescence. In support, 
it has been recently observed that ageing of human T cell clones is associated with 
an increase in the sensitivity to apoptosis via this route (Pawelec et al., 1996).
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The differential sensitivity of Jurkats, clones and normal activated T cells to 
apoptosis is enlightening and prompted a closer analysis of the cell types used to 
form the prevailing hypothesis that activated T cells are CD95 sensitive. The 
majority of studies linking CD95 ligation with an apoptotic outcome utilised 
immortalised cell lines such as Jurkats, CEM cells and HELA cells (Yonehara et 
al., 1989; Ogasawara et al., 1993; Suda et al., 1994; Suda and Nagata, 1994) and 
the remaining reports have largely been confined to murine hybridomas (Brunner 
et al., 1995; Ju et al., 1995) or T cell clones (Ramsdell et al., 1994a; Hargreaves et 
al., 1997). Given the differential sensitivity of cloned versus normal activated T 
cells observed in this study, it is clear that the extrapolation of findings between T 
cell models is potentially misleading and equally the possibility of species-specific 
differences between murine and human T cells cannot be ruled out. Thus the only 
reports which can be considered to contradict the data presented in this study are 
those pertaining to CD95 sensitivity in human activated peripheral blood T cells. 
In this regard, activated human T cells were initially reported to be resistant to 
CD95-mediated apoptosis (Miyawaki et al., 1992) but two subsequent reports 
claimed that sensitivity to apoptosis via this route was acquired after four (Owen- 
Schaub et al., 1992) or six (Klas et al., 1993) days of in vitro activation, 
contrasting with the data presented in this thesis. Closer analysis of the study by 
Klas and colleagues reveals that sensitivity to apoptosis was construed from 
CD95-specific increases in TUNEL positivity of 51%, 57.6% and 59.6% 
indicating that a proportion of the population nevertheless exhibited resistance to 
CD95 ligation. Another important difference between these reports and the data 
presented in this study relates to the T cell activation protocols employed and the 
relevance of this will become apparent in the light of experiments detailed in 
chapter 6 .
In summary, these data demonstrated that normal activated peripheral blood T 
cells exhibited a restricted apoptotic response following CD95 engagement, and 
that this could not be attributed to the type of activation stimulus employed, the
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nature of ligand provision (antibody versus natural ligand) nor was it a function of 
the criteria used to assess apoptosis induction. Resistance was observed in SEB 
blasts generated from purified CD4+ T cells, it was not serum dependent and was 
not transferable by a soluble factor. Cells from all phases of the cell cycle 
exhibited CD95 resistance, although this was particularly marked in the S/G2 
portion of the DNA histogram. An investigation of the potential mechanisms 
underlying control of CD95 resistance is presented in chapter 6  of this thesis.
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CHAPTER 5
CD95-Ligand Expression in T Cells: 




Given the inherent danger in the existence of biological pathways which trigger 
cell death, it is likely that such pathways are subject to regulation at a number of 
levels, and controlling sensitivity to apoptosis following CD95 ligation is one 
potential mechanism of achieving this. A further obvious point of control is the 
provision of ligand for these death-inducing receptors, and accordingly, cellular 
distribution of CD95L is tightly restricted, with expression being mainly limited to 
low levels on activated T lymphocytes (Suda et al., 1994; Suda and Nagata, 1994) 
as well as on some APCs (Badley et al., 1997; Lu et al., 1997a).
Since T cells upregulate the CD95 receptor upon activation (as illustrated in the 
previous chapter), it is apparent that the potential for cell suicide exists under 
these circumstances and indeed this forms the basis for the concept of activation 
induced cell death (AICD). Thus, physiological regulation of the CD95 system in 
T cells may occur in part by the upregulation of CD95L following TCR ligation 
during the activation process. Signalling via the TCR£ ITAM has been shown to 
be sufficient to mediate CD95L upregulation (Vignaux et al., 1995), and the 
process is believed to be calcium-dependent (Anel et al., 1994; Vignaux et al., 
1995). Thus whilst antigen engagement can result in positive outcomes such as 
the initiation of proliferation, conversely under certain circumstances antigen- 
mediated signals can negatively regulate T cell responses, and may even trigger 
the induction of apoptotic pathways.
The following experiments examined the ability of activated T blasts as compared 
to resting cells to express CD95L. In addition, the effect of TCR restimulation on 
CD95L expression in previously activated T cells was examined.
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5.2 RESULTS
5.2.1 FACS Staining for CD95L
In order to investigate the possible expression of CD95L on human T cells, 
surface staining and FACS analysis was utilised. Early experiments failed to 
detect CD95L staining, and during the course of these studies it emerged that 
surface CD95L is subject to metalloproteinase cleavage (Kayagaki et al., 1995; 
Mariani et al., 1995) to allow release as a soluble factor. Therefore detection by 
FACS staining required the use of a metalloproteinase inhibitor (BB2116). Fig
5.1 (A) illustrates that under conditions of P/I stimulation, in the presence of such 
an inhibitor, CD95L could be visualised at low levels. The specificity of the anti- 
NOK1 antibody was demonstrated by the inhibition of soluble CD95L-induced 
apoptosis (figure 5.1, panel B) yet the detection of surface CD95L using this 
antibody was nevertheless marginal. Since the expression levels detected under 
optimal staining conditions were considered too marginal to be routinely useful, a 
bioassay based on the ability of T cells to kill CD95-positive 3H -thym idine 
labelled Jurkats in the JAM assay was used for assessment of CD95L expression 
in this study.
5.2.2 Activation-induced Cytotoxicity in T Cells
An early observation emanating from these studies was that activated but not 
resting T cells were able to induce apoptosis in a target population comprising 3H- 
thymidine labelled J16 cells (figure 5.2, panel A). Accordingly, the addition of 
resting PBMC had little effect on the viability of the Jurkat population, whilst 
PBMC which had been cultured in the presence of SEB for 4 days were competent 
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Figure 5.1: Expression of CD95L on activated T cells. (A) Day 6 SEB blasts 
were activated for 6h with PM A (0.04|ig/ml) and ionomycin (l|iM ) in the 
presence (open histograms) or absence (filled histogram) of the metalloproteinase 
inhibitor BB2116 (Grey line = 2jLig/ml, black line = 5|ig/ml). Staining was 
performed using the anti-CD95L antibody NOK1 (lpg/m l) followed by anti­
mouse polyvalent-FITC. Data indicate the maximum staining observed in 5 
experiments. (B) To demonstrate CD95L binding, NOK1 was used to inhibit 
soluble CD95L-induced apoptosis of 3H-thymidine-labelled J16 cells in an 8h 
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Figure 5.2: Activation-induced cytotoxicity in T cells. (A) Day 3 SEB blasts (or 
resting PBMC) were incubated for 15h with 3H-thymidine-labelled J16 cells at the 
indicated ratios (effector:target). (B) SEB blasts (day 3) were incubated with 3H- 
thymidine-labelled J16 cells (1:1 ratio) for the indicated time period. The anti- 
CD95 antibody CH11 was used at 0.05pg/ml. Apoptosis was measured by JAM 
assay and is calculated as the % decrease in CPM relative to control-treated cells. 
Data indicate the mean (+/-SEM) of triplicate wells and are representative of 4 
similar experiments.
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dose dependence and it is notable that even low ratios of effector cells were 
sufficient to induce apoptosis under these conditions, demonstrating the potency 
of this response. These ratios are considerably lower than those used in standard 
perforin/granzyme CTL assays, and furthermore the lack of a T cell receptor target 
on Jurkat T cells indicates that cytotoxicity is not dependent on allorecognition. 
In addition, the potency of the response even at low ratios of effector:target cells 
indicated the possible involvement of a soluble mediator rather than a requirement 
for celkcell contact. Inclusion of CH11 in this assay served as a positive control 
for apoptosis induction and interestingly triggered broadly equivalent cytotoxicity 
to that induced by the higher ratios of SEB blasts.
To further examine the cytotoxicity exhibited by activated T cells, kinetic analysis 
was performed. These data (figure 5.2, panel B) revealed that co-incubation of 
SEB blasts with 3H-thymidine labelled Jurkat cells for as little as 3 hours resulted 
in detectable apoptosis of target cells and that this effect was maximal by 6 hours. 
PBMC from two donors were used in this experiment and were cultured for 4 days 
with SEB prior to use in the JAM bioassay. The kinetics of apoptosis induction 
by these two SEB blast cultures were similar, and interestingly closely mimicked 
that induced by the anti-CD95 antibody CHI 1. In contrast, apoptosis induced by 
perforin and granzymes is known to occur with substantially slower kinetics (D. 
Sansom, personal communication).
To determine the duration of this ability to induce apoptosis, SEB blasts were 
tested on a daily basis following initial activation with SEB, revealing that even 
up to 6  days post stimulation, the cells were competent to kill J16 cells (figure 5.3, 
panel A). In contrast, resting PBMC which remained in medium in the absence of 
SEB for this time period, were unable to induce apoptosis in the labelled J16 cells, 
indicating that the mechanism(s) underlying this process were induced by T cell 
activation. Acquisition of this cytotoxic potential in peripheral blood T cells was 
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Figure 5.3: Duration of activation-induced cytotoxicity in T cells. (A) SEB
blasts on the indicated day post stimulation were incubated for 15h with 3H- 
thymidine-labelled J16 cells (1:1 ratio). Apoptosis was measured by JAM assay 
and is plotted as the % decrease in CPM relative to control-treated cells. Data are 
representative of 2 experiments. (B) Resting PBMC were activated for 3 days with 
PH A (2pg/ml), Con A (lpg/m l), SEB (l|ig /m l) or a combination of PM A 
(0.04|ig/ml) and ionomycin (lpM ). The % apoptosis (by JAM assay) relative to 
control-treated cells is shown. Data indicate the mean (+/-SEM) of triplicate wells 
and are representative of 3 similar experiments.
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alternative stimuli including PHA, ConA, or a combination of PMA and 
ionomycin also triggered this process (figure 5.3, panel B). These data therefore 
indicated that T cell activation, by diverse stimuli, induced a mechanism(s) of 
cytotoxicity which could be visualised by the rapid induction of apoptotic cell 
death in CD95 positive J16 cells, the kinetics and potency of which were 
consistent with a potential role for the CD95 pathway.
In order to examine the contribution of CD95L upregulation to the ability of SEB 
blasts to induce apoptosis, CD95-specific blocking reagents were employed. 
Resting purified T cells were therefore activated with SEB (presented on HLA- 
DR/CD80 transfectants) in the presence of the anti-CD95 blocking antibody M3 
and cytotoxicity was measured by co-incubation with 3H-thymidine labelled J16 
cells. As in previous experiments, addition of CHI 1 to the J16 cells served as a 
positive control for the JAM bioassay. Consistent with the data presented in 
figures 5.2 and 5.3, figure 5.4 illustrates the requirement for cellular activation for 
the induction of cytotoxic potential since resting T cells or those treated with 
HLA-DR/CD80 transfectants in the absence of SEB failed to induce apoptosis in 
the Jurkat population. In addition, this experiment demonstrated that the 
mechanism of cytotoxicity was CD95-dependent, since inclusion of the anti-CD95 
blocking antibody M3 ablated the induction of apoptosis by activated T cells 
(figure 5.4). With the exception of M3, which was pre-incubated with the target 
cells (J16) for one hour, there was simultaneous addition of all cells and reagents 
in this experiment, such that both the induction and execution of cytotoxicity 
occurred during the course of this 15 hour assay. Since the observed apoptosis 
was CD95-mediated, this indicated that CD95L upregulation was an early event 
during human T cell activation and was functional less than 15 hours following 
addition of the activation stimulus.
At this early time point, therefore, activation-induced cytotoxicity appeared to be 













Figure 5.4: Inhibition of activation-induced T cell cytotoxicity by anti-CD95 
b lo ck in g  an tib o d y . Resting purified T cells were treated with SEB- 
pulsed/unpulsed transfectants as indicated in the presence of ^ - th y m id in e -  
labelled J16 cells (1:1 ratio). Anti-CD95 blocking antibody (M3) was used at 
3p.g/ml and was pre-incubated with J16 cells for lh. The apoptotic anti-CD95 
antibody CHI 1 was used at 0.05jig/ml. Apoptosis of J 16 cells (calculated relative 
to control-treated cells) was assessed by JAM assay and data are representative of 
3 independent experiments.
143
by specific inhibitors of the CD95 pathway. However at later time points 
following activation there was more variability in the ability of CD95-specific 
reagents to block the induction of apoptosis by SEB blasts, indicating that 
pathways other than CD95 may be utilised under some circumstances. For 
example, in figure 5.5 (panel A), the SEB blast line derived from donor 1 induced 
apoptosis by a mechanism which was clearly dependent on CD95L expression, 
since it was blocked by CD95-Fc. In contrast, the SEB blast culture derived from 
donor 2  exhibited broadly equivalent apoptosis induction to the donor 1-derived 
line in terms of the percentage cytotoxicity, yet showed no decrease in 
cytotoxicity following the inclusion of the CD95-specific blocking reagent CD95- 
Fc, indicative of a non CD95-dependent mechanism.
To verify that this result was not a feature of the limitations of the blocking 
reagents utilised, these SEB blasts were also tested for cytotoxicity against 3H- 
thymidine labelled JLW cells in parallel with J16 cells. Since JLW cells had been 
selected for resistance to apoptosis via the CD95 pathway (Chapter 4.2.2), they 
provided a useful tool for the detection of apoptosis-inducing interactions which 
did not occur via this route. Interestingly, SEB blasts which killed J16 cells in a 
manner which was not inhibited by CD95-Fc were equally potent in their ability 
to kill JLW cells, whilst SEB blasts which failed to kill in the presence of CD95- 
Fc were unable to induce apoptosis in JLW cells (figure 5.5, panel B). These data 
therefore indicated the existence of alternative inducible cytotoxic ligands on T 
cells in addition to CD95L. At the time of these studies, a major candidate for 
such a pathway was TN Fa which was known to be expressed in T cells under 
various circumstances. However since Jurkat T cells are resistant to TNF induced 
apoptosis (Wong and Goeddel, 1994), the killing detected in the JAM bioassays 
was unlikely to have occurred via this route suggesting the existence of still more 
death pathways. In this regard, the recent discovery of several new members of 
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Figure 5.5: Effect of CD95-Fc on cytotoxicity of T blasts. SEB blasts (day 6) 
were incubated for 6h with 3H-thymidine-labelled J16 cells (A) or ^-thym idine- 
labelled JLW cells (B) (1:1 ratio) in the presence of CD95-Fc or a control Fc 
construct (CD23-Fc). Anti-CD95 antibody (CH11) was used at O.lpg/ml. 
Apoptosis was measured by JAM assay and the % decrease in CPM relative to 
control-treated cells is shown. Columns show the mean (+/-SEM) or triplicate 
wells. Data are representative of 4 similar experiments.
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Pan et al., 1997) makes these pathways potential candidates for the CD95- 
independent mechanism(s) of cytotoxicity utilised by activated SEB blasts.
5.2.3 TCR-induced CD95L Upregulation in Activated T Cells
The initial TCR-mediated activation of resting T cells is considered unlikely to 
mediate AICD, since resting T cells require time for CD95 upregulation and 
acquisition of CD95 sensitivity before undergoing apoptosis (Wesselborg et al., 
1993). However, following activation, CD95 expression remains high in T cells, 
and restimulation via the TCR can therefore potentially trigger apoptosis induction 
(Wesselborg et al., 1993). In order to investigate TCR restimulation in previously 
activated T cells, TCR signalling was provided by the use of superantigen or anti- 
CD3 antibody. Thus in these experiments, previously activated T cell blasts were 
restimulated and apoptosis was measured.
In order to test the ability of SEB-mediated TCR restimulation to induce apoptosis 
in activated T cells, SEB blasts were 3H-thymidine labelled and exposed to a 
range of concentrations of SEB to assess the induction of AICD in the JAM assay. 
Thus in contrast to previous assays, the viability of the SEB blasts themselves 
(rather than a target J16 population) was assessed and the aim was to study the 
effect of TCR restimulation in cells which had already once been activated with 
superantigen. For these experiments, SEB was added directly to culture wells 
rather than being pulsed onto HLA-DR/CD80 transfectants since we have 
previously shown that the provision of APCs upon SEB rechallenge of T blasts 
favours a proliferative rather than an apoptotic response (Boshell et al., 1996). As 
illustrated in figure 5.6, whilst a degree of apoptosis was detectable in response to 
high dose SEB addition (donor 1), the proportion of sensitive cells was low, and in 
all experiments of this nature performed (>6 ) the amount of apoptosis observed 
did not exceed 30%. Indeed, many SEB blast lines appeared to be strikingly
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Figure 5.6: Effect of TCR restimulation using SEB on apoptosis of T blasts.
Day 6 3H-thymidine-labelled SEB blasts were incubated for 15h with the 
indicated concentrations of SEB and apoptosis was measured by JAM and is 
calculated as % decrease in CPM relative to control-treated cells. Columns show 
the mean (+/-SEM) of triplicate wells and the experiment was repeated with 4 
separate donors with similar results.
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resistant to the induction of AICD via SEB treatment as reflected by the response 
of cells from donor 2  in this experiment.
One interpretation of these results was that SEB stimulation of previously 
activated T blasts failed to induce sufficient TCR signalling to allow CD95L 
upregulation, although this was clearly not the case for resting T cells activated 
with HLA-DR/CD80 presented SEB as demonstrated earlier (figure 5.4). To 
address this possibility, the induction of CD95L during restimulation of T blasts 
with SEB was examined using 3H-thymidine labelled J16 cells as targets. Figure 
5.7 illustrates that whilst the basal apoptosis induced by SEB blasts could be 
CD 95-independent (consistent with previous findings), when blasts were 
restimulated with SEB they became more effective at killing J16 cells, and 
furtherm ore this inducible cytotoxicity was largely CD 95-dependent. 
Accordingly, the additional apoptosis which occurred when T blasts were further 
stimulated with SEB was markedly inhibited in the presence of the anti-CD95 
blocking antibody M3. Thus, stimulation with SEB induced upregulation of 
functional CD95L in these T cell blasts rendering them competent to induce 
apoptosis in 3H-thymidine labelled CD95 positive target cells.
Thus it appeared that whilst TCR restimulation with SEB was sufficient to 
upregulate CD95L expression, the majority of T blasts were nevertheless 
protected from apoptosis under these circumstances, despite the consequent 
coexpression of CD95 and CD95L in these cultures. This finding once more 
highlighted that a number of distinct controls appeared to regulate CD95-mediated 
apoptosis in normal activated T cells.
An alternative method for mimicking antigen-derived signals is direct ligation of 
the TCR CD3 component, and therefore investigations were also carried out to 
assess the competence of anti-CD3 antibody to trigger AICD in T blasts. Since 
the use of antibody to ligate the TCR CD3 component bypasses TCR specificity,
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Figure 5.7: Effect of anti-CD95 blocking antibody on cytotoxicity induced by 
TCR restim ulation using SEB. Day 6 SEB blasts were incubated for 15h with 
3H-thymidine-labelled J16 cells (1:1 ratio) in the presence of l|ig/ml SEB and/or 
the anti-CD95 blocking antibody M3 (3|ig/ml) where indicated. The apoptotic 
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Figure 5.8: Effect of anti-CD3 treatm ent on apoptosis induction in J16 cells 
and SEB blasts. J16 cells or day 6 SEB blasts were incubated for 24h on 
immobilised anti-CD3 (plate-coated for 15h at 10pg/ml) and apoptosis was 
measured by TUNEL analysis. Anti-CD3 dependent increases in TUNEL 
fluorescence of 3.21% (J16) and 9.61% (SEB blasts) were observed. Data are 
representative of >5 similar experiments.
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this approach was also applicable to Jurkat T cells. Accordingly, both J16 cells 
and SEB blasts were subjected to a 15 hour incubation with immobilised anti-CD3 
prior to apoptosis measurement using the TUNEL assay. Figure 5.8 illustrates the 
results of this analysis, which revealed only a 3% increase in TUNEL positivity 
for J16 cells, whilst in SEB blasts, the extent of apoptosis in response to anti-CD3 
was also limited (< 10%). Restimulation of activated T cells using anti-CD3 
antibody therefore did not appear to provide an effective trigger for the induction 
of AICD, suggesting either a lack of CD95L induction or that the cells were not 
susceptible to CD95-mediated apoptosis under these conditions.
Given the low apoptotic response observed in these experiments, the effectiveness 
of the anti-CD3 antibody was therefore investigated. A key event in the induction 
of AICD is the mobilisation of intracellular calcium which has been demonstrated 
to be a requirement for TCR-mediated CD95L upregulation in studies using 
cyclosporin A (Vignaux et al., 1995). In order to verify the ability of the anti-CD3 
antibody to effectively elevate intracellular calcium ion concentration in activated 
T cells, assays to detect this process were carried out. Thus the aim of these 
experiments was to validate the anti-CD3 antibody rather than to provide a 
quantitative analysis of intracellular calcium levels. Calcium mobilisation was 
measured by fluo-3 loading of cells and an ionomycin titration was performed to 
establish the effectiveness of the assay. As illustrated in figure 5.9 (panel A), 
increasing concentrations of ionomycin resulted in calcium fluxes of similar 
duration but larger amplitude, as measured by an increase in MFI (mean 
fluorescence intensity). Similarly, treatment of T blasts with anti-CD3 antibody 
(OKT3) in conjunction with crosslinker (anti-mouse Ig) triggered dose-dependent 
calcium fluxes verifying that this antibody was competent to induce calcium 
mobilisation in these cells. This experiment also demonstrated the requirement 
for crosslinking of the anti-CD3 antibody (using anti-mouse Ig) for the initiation 
of calcium signalling as detected in this assay. An alternative method for the 
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Figure 5.9: M easurem ent of intracellular calcium mobilisation in T cells. (A)
Day 6 SEB blasts were loaded with fluo-3 and treated with the indicated 
concentrations of ionomycin (IONO). (B) Fluo-3 loaded SEB blasts (day 6) were 
treated with anti-CD3 antibody (OKT3) at the indicated concentrations and 
crosslinker (anti-mouse Ig) was added at the 5min time point where indicated. 
Calcium mobilisation was measured by an increase in FL-1 fluorescence and the 
mean fluorescence intensity (MFI) is shown. Data are representative of 3 
experiments.
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anti-CD3 treatment in figure 5.8 as well as for the proliferation assays presented in 
chapter 3 of this thesis.
Having established that this anti-CD3 antibody was competent to induce calcium 
mobilisation, the effect of anti-CD3 treatment on CD95L expression was 
examined in both Jurkat cells and T blasts with the use of the JAM assay (figure 
5.10). Panel A of this figure illustrates the viability of 3H-thymidine labelled 
Jurkats following treatm ent with im m obilised anti-CD3 antibody, and 
demonstrated a lack of detectable apoptosis induction. This finding suggested that 
CD95L was not upregulated in J16 cells under these experimental conditions. 
Contrasting with this result, the incubation of normal activated T blasts with 
immobilised anti-CD3 indicated upregulation of CD95L in this cell type, since the 
ability to kill CD95 positive Jurkat cells in the JAM bioassay was induced under 
these conditions. The specificity of the induced cytotoxicity was shown to be 
CD95-dependent since it was inhibited in the presence of CD95-Fc but not the 
control Fc construct (CD23-Fc).
Since there is some evidence that CD28 ligation can promote T cell survival 
during activation (Groux et al., 1992; Radvanyi et al., 1996) experiments were 
carried out to determine whether CD80-mediated signals might confer protection 
from AICD by inhibiting the process of CD95L upregulation. Accordingly, the 
effect of anti-CD3 in the presence of CHO-CD80 cells was also monitored in 
terms of the degree of CD95L induction in the JAM bioassay (figure 5.10, panel 
B). This analysis revealed that costimulatory signals through this route did not 
appear to affect the extent of CD95L upregulated following TCR ligation, 
suggesting that if CD80 does indeed protect from AICD, the mechanism would 
appear to be downstream of CD95L induction.
Overall, these data indicated that both SEB stimulation and anti-CD3 treatment 








Figure 5.10: Effect of anti-CD3 treatm ent on apoptosis induction in T cells.
(A) 3H-thymidine labelled J16 cells were incubated for 15h with immobilised 
anti-CD3 (plate-coated at 10|ig/ml) and apoptosis was measured by JAM assay. 
The anti-CD95 antibody CH11 (0.05pg/ml) served as a positive control for 
apoptosis induction. (B) Day 6 SEB blasts were incubated with anti-CD3 antibody 
(plate coated at lOpg/ml) and the induction of CD95L was measured by apoptosis 
induction in target 3H-thymidine labelled J16 cells. CD95-Fc or a control Fc 
construct (CD23-Fc) were used at a 1 in 5 dilution. CHO transfectants were used 
at a ratio of 1:5 (transfectant:T cell). Apoptosis was calculated as the % decrease 
in CPM relative to control-treated cells and the mean (+/-SEM) of triplicate wells 
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Figure 5.11: Effect of anti-CD3 treatm ent on cell cycle in T cells. J16 cells (A) 
or day 6 SEB blasts (B) were exposed to immobilised anti-CD3 (plate-coated at 
10|ig/ml) for 24h then cell cycle status was analysed by PI staining. Data are 
representative of 3 individual experiments.
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co-expressing both CD95 and its ligand, the T blasts themselves appeared to be 
spared from apoptosis via this route. In contrast, whilst Jurkat T cells were also 
resistant to anti-CD3 induced apoptosis under these conditions, this was likely to 
be due to a failure to effectively upregulate CD95L in this cell type, emphasising 
the potential for variation between cell types in the control of the CD95 system.
In order to further characterise the response to CD3 ligation in both Jurkats and 
normal T cells, experiments were undertaken to establish whether this signal had 
any observable effect on cell cycle, for example by mediated cell cycle arrest 
since this has been reported for some transformed T cell lines (Zhu and Anasetti, 
1995). Consistent with such reports, figure 5.11 demonstrates a decrease in the 
number of cells in S/G2 phase following anti-CD3 treatment of J16 cells (A) 
indicative of growth arrest at the Gl/S-phase checkpoint. In contrast, the cell 
cycle trace for SEB blasts (B), showed a marked increase in the number of cells 
present in the S/G2-phase implying that rather than mediating growth arrest, 
signalling through the CD3 complex appeared to be favouring S-phase entry in 
this cell type. This is significant in that it provided further evidence of 
functionality associated with the use of this anti-CD3 antibody, and yet a clear 
lack of apoptosis in the presented data suggested that outcomes other than cell 
death could be initiated under these circumstances.
5.3 DISCUSSION
The experiments performed in this chapter established that activated but not 
resting human T cells exhibited cytotoxicity against Jurkat cells which proceeded 
with rapid kinetics reminiscent of that observed for CD95-induced apoptosis. The 
acquisition of cytotoxic potential occurred irrespective of the initial activation
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stimulus and was observed for cells stimulated with PHA, ConA, P/I or SEB. The 
data further demonstrated that immediately post T cell stimulation with SEB, the 
induced cytotoxicity was largely attributable to the expression of CD95L since it 
was inhibited in the presence of CD95-specific blocking reagents. Thus CD95L 
upregulation was shown to be an early event occurring during the first 15 hours of 
the T cell activation process (figure 5.4). This is consistent with several reports 
which have documented upregulation of mRNA for CD95L during the first 3-12 
hours following TCR stimulation (Brunner et al., 1995; Ju et al., 1995; Vignaux et 
al., 1995; Yang et al., 1995).
Therefore as immune responses are initiated and T cells acquire stimulatory 
functions, the propensity to undergo apoptosis is simultaneously increased via the 
upregulation of the mediators of cell death (CD95 and CD95L). The coupling of 
the activation process to elements of an apoptotic pathway may represent an 
intrinsic control mechanism designed to preclude unregulated immune stimulation 
which poses a potential threat to the host. W hilst the data presented in the 
previous chapter indicate that the CD95 death pathway is not constitutively 
functional in activated T cells, nevertheless the induction of both CD95 and its 
ligand during the activation process confers the potential to initiate an apoptotic 
signal under circumstances when CD95 sensitivity is acquired.
An interesting point arising from these experiments is that CD95-dependent 
cytotoxicity is detectable in certain T blast lines as long as 6  days following the 
initial activation stimulus (figure 5.5). Published reports on CD95L expression 
have focused on the transient upregulation of mRNA and protein at early time 
points (Brunner et al., 1995; Ju et al., 1995) and the persistence of CD95L 
expression subsequent to this time has not been addressed. In one report, the 
authors state that activated T cells do not express CD95L prior to TCR 
restimulation (Vignaux et al., 1995), however the data on which this premise is 
based are not presented. Since the sensitivity of CD95L surface staining protocols
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is low (figure 5.1), and activated T cell lines appear heterogeneous in their 
capacity to express this protein as judged by functional assays (figure 5.5), it is 
clear that CD95L expression on activated T cells could potentially be overlooked. 
The data presented in this thesis provide evidence for functional CD95L 
expression 6  days following activation in certain T cell lines, and it would be of 
interest to characterise this finding further. For example, future studies could 
investigate the kinetics of CD95L mRNA changes relative to protein changes 
during the 6 days following T cell stimulation to determine whether CD95L 
expression persists or whether the reported transient upregulation of mRNA and 
protein (Brunner et al., 1995; Dhein et al., 1995; Ju et al., 1995) is followed by a 
second wave of CD95L synthesis.
It is also of note that T blasts examined on day 6  following activation exhibited 
cytotoxicity which was not necessarily attributable to CD95L expression since 
CD95-specific blocking reagents failed to universally inhibit apoptosis induction. 
The expression of CD95-independent cytotoxicity was not a donor-specific 
phenomenon but rather seemed to reflect the existence of alternative cytotoxic 
mechanisms in activated human T cells. Clearly alternative pathways of apoptosis 
induction could be triggered in these cells during SEB stimulation and, whilst 
their nature is undefined in these studies, it is possible that other death-inducing 
ligands such as TRAIL or the as yet undefined DR3-ligand (Wiley et al., 1995; 
Kitson et al., 1996; Chinnaiyan et al., 1996) as well as TN Fa or the classical 
secretory pathway of perforin and granzymes may be involved. W hatever the 
mechanisms underlying the ability of these T cells to induce the apoptosis of 
Jurkats, the persistence of some form of cytotoxicity at least during the first 6  days 
of activation (figure 5.3, A) implied that T cells must maintain an "apoptosis 
resistant" phenotype in order to survive this time period.
Having examined the acquisition of cytotoxicity following the transition of T cells 
from a resting to an activated state, the effect of TCR restimulation on CD95L
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upregulation and the triggering of AICD in previously activated T cells was 
investigated. The rationale for such an approach was that resting T cells are 
thought to be relatively insensitive to AICD (Wesselborg et al., 1993) since they 
have not yet upregulated CD95 expression (figure 4.11, A). Previously activated 
T cells in contrast express high levels of CD95 and thus can potentially receive 
signals via this route following the TCR-driven upregulation of CD95L expression 
(Wesselborg et al., 1993).
To investigate the process of AICD, SEB or anti-CD3 antibody was used for the 
provision of TCR signalling in previously activated T blasts. Since the induction 
of AICD has also been documented in Jurkat T cells, and the use of anti-CD3 
antibody bypasses the need for TCRap engagement, this approach was also taken 
in J16 cells. The key finding from this set of experiments is that both cell types 
were largely resistant to AICD. Consistent with the CD95 resistance documented 
in chapter 4, despite clear evidence that TCR engagement triggered the induction 
of functional CD95L expression in T blasts, there was nevertheless only a small (< 
10%) increase in T cell apoptosis under these conditions. Thus, treatment with 
SEB or anti-CD3 allowed upregulation of CD95L which was presumably 
available for ligation of the CD95 receptor, and yet did not initiate an apoptotic 
pathway in the majority of T blasts as measured by JAM assay or TUNEL. It is 
interesting to note that even the most compelling data for a TCR-driven apoptotic 
response (SEB treatment of donor 1, figure 5.6) was characterised by apoptosis in 
only approximately 30% of the population, again arguing that the majority of 
these T cells were resistant to CD95-mediated death. In fact, the stimulation of 
cell cycle progression in T blasts following anti-CD3 treatment provides evidence 
that this event generated a predom inantly positive signal under these 
circum stances, rather than promoting an apoptotic outcome despite the 
upregulation of CD95L expression.
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The Jurkat T cells (J16) examined in this study also exhibited resistance to AICD 
in contrast with the findings of others (Takahashi et al., 1989; Dhein et al., 1995) 
possibly reflecting variation between Jurkat cell lines. In this regard, it is notable 
that Jurkat cell lines which do not exhibit anti-CD3 induced apoptosis have 
previously been reported (Zhu and Anasetti, 1995). Unlike the situation in T 
blasts, the lack of AICD in J16 cells appeared to be based on the failure to 
upregulate CD95L in response to TCR stimulation, rather than a lack of CD95 
sensitivity in this cell line. The analysis of cell cycle changes highlighted the 
differential response to anti-CD3 treatment exhibited by J16 cells compared to T 
blasts: whilst J16 cells underwent cell cycle arrest under these conditions, 
accumulating in G0/G1 region of the DNA histogram, T blasts in contrast 
exhibited increased S-phase entry following TCR signalling. This finding is in 
line with other studies which have documented anti-CD3 induced growth arrest 
rather than apoptosis induction in Jurkat cell lines (Zhu and Anasetti, 1995).
Data from murine studies have indicated that, in contrast with these observations 
in T blasts, anti-CD3 treatment resulted in apoptosis of the majority of activated T 
cells (74% apoptosis) (Ettinger et al., 1995) and similarly murine T cell 
hybridomas were largely sensitive to apoptosis via this route (Brunner et al., 1995; 
Ju et al., 1995; Yang et al., 1995). Published support for the process of AICD in 
human T cells is more limited and whilst approximately 50% sensitivity to anti- 
CD3 induced apoptosis has been documented (Groux et al., 1993), work by 
Krammer and colleagues (Dhein et al., 1995) demonstrated apoptosis in only a 
minority of T cells (less than 30% in most experiments) following anti-CD3 
treatment, despite the authors' interpretation of these data as evidence for 
apoptosis sensitivity. AICD has also been documented in human T cell clones 
(Alderson et al., 1995; Hargreaves et al., 1997) although again there is variation in 
the degree of cell death monitored with the apoptotic response being confined to 
approxim ately 45% in the former study. M oreover, since it has been 
demonstrated here that T cell clones do not necessarily reflect the responses of
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peripheral blood T cells with regard to CD95 sensitivity (figures 4.20, 4.21) it is 
likely that the propensity to undergo AICD is also altered in these cells. Similarly, 
results from murine T cell hybridomas cannot necessarily be extrapolated to 
normal human T cells since the cell death may not be identically regulated in these 
cells. For example the substantial CD95L surface staining of TCR-stimulated 
A 1.1 murine cells using the CD95-Fc protein is notable in the report by Brunner 
and colleagues (Brunner et al., 1995), but equally unexpected in this study is the 
extremely low CD95 receptor expression even following cellular activation, 
possibly indicating that control of receptor expression may be more important 
than regulation of ligand availability for the control of the CD95 pathway in this 
particular T cell hybridoma.
In vivo work on AICD has utilised SEB injection allowing the responding cells to 
be tracked by virtue of their distinct TCR-V6  chains. In this system, SEB-reactive 
T cells first proliferate then are deleted by apoptosis, such that they have been 
removed from the mouse by 2 weeks following immunisation (MacDonald et al., 
1991). The mechanism of T cell elimination is not defined in these studies and 
whilst in vitro work using CD4+ T cells from MRL +/+, M RL-/pr and M KL-gld  
mice has indicated that SEB-induced apoptosis is CD95-dependent (Ettinger et al., 
1995), the availability of costimulatory ligands in the SEB activation step is not 
clear in these experiments and may not precisely reflect in vivo events. In 
addition, it is difficult to address whether the in vivo approach of high dose 
(lOmg) SEB injection accurately models the immune response to invading 
pathogens, since there may be key differences in the location and nature of antigen 
presentation events, the induction of costimulatory ligands and the persistence of 
antigen. T cell recognition of peptide antigen is known to involve APC-mediated 
processing such that discontinuous epitopes are presented in the context of the 
HLA antigen-binding groove. In contrast, superantigens bypass conventional 
recognition requirements by interacting outside of the specificity-determining 
regions on both TCR and HLA (Herman et al., 1991; Dohlsten et al., 1993;
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Kappler et al., 1989), and can even bind directly to the T cell antigen receptor in 
the absence of HLA (Lando et al., 1993). Thus, the mechanisms which normally 
restrict which T cells respond to a particular challenge are clearly not applicable to 
superantigen-driven activation, and the nature of the cells acting as APCs in such 
in vivo responses has not been defined. Moreover, the kinetics of antigen 
clearance may differ in this system since it is unclear how long superantigens 
remain associated with the TCR and it is possible that persistent signalling via this 
route may contribute to apoptosis induction. In support, it has been observed that 
T cell elimination may be preferentially associated with superantigen- rather than 
peptide- induced responses (Weber et al., 1995). Thus in vivo SEB studies offer a 
powerful tool for examining T cell activation in the context of a multi-cell type 
immune response, however, whilst the observed SEB-induced deletion is likely to 
be CD95-mediated (AICD), this remains to be formally demonstrated.
The fact that human T cells appeared less sensitive to AICD via CD95 than their 
murine counterparts raises the possibility that the CD95 system may be 
differentially regulated in these two species. In support of this concept, there are a 
number of species-specific differences pertaining to the molecules which mediate 
this process. Accordingly it has been demonstrated that the murine form of 
soluble CD95L is largely inactive whilst the human form of this protein exhibits 
potent cytotoxicity (Tanaka et al., 1995) rendering it potentially dangerous to cells 
which are constitutively sensitive to CD95 ligation. The absence of functional 
soluble CD95L in the murine system may explain why naive T cells express 
higher levels of surface CD95 in mice compared to humans (Ettinger et al., 1995) 
and are constitutively sensitive to apoptosis via CD95L (Suda et al., 1996). A 
more fundamental difference may relate to the activation-induced regulation of 
CD95 expression in the two systems: whilst human T cells exhibit stable CD95 
expression following activation (Owen-Schaub et al., 1992), in murine T cells 
surface expression of this receptor is subject to greater modulation with initial 
activation-dependent upregulation being followed by subsequent downregulation
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(Ettinger et al., 1995; Tucek-Szabo et al., 1996). It is thus conceivable that the 
CD95 system may be preferentially regulated by control of CD95 receptor 
expression in mice whilst the control of sensitivity to CD95 ligation might achieve 
the same aim in humans.
In summary, whilst the induction of apoptosis was clearly not a major response 
following TCR ligation in T blasts, the data provided evidence that the first part of 
the AICD process, namely the induction of CD95L expression, was intact in these 
cells. This supported the notion that the stimuli used to mimic antigen 
engagement of the TCR (SEB or anti-CD3) were competent to deliver the 
requisite signals for this process, and further evidence for reagent efficacy was 
provided by the calcium mobilisation data (figure 5.9) in addition to the effective 
induction of proliferation (figure 3.2). The lack of apoptosis in these cultures, 
therefore, could not be attributed to a lack of CD95L upregulation, but rather 
appeared to reflect the insensitivity of activated T cells to the induction of death 
via the CD95 pathway.
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CHAPTER 6 
Protection from CD95-Mediated Apoptosis
164
6.1 INTRODUCTION
The experiments presented in Chapters 4 and 5 indicated that protective 
mechanisms were clearly operating in normal activated T cells to prevent the 
induction of apoptosis following CD95 ligation. This view is not widely accepted, 
even though resistance to apoptosis is evident in part of the population (often the 
majority) in nearly all the apoptosis studies published (Miyawaki et al., 1992; Klas 
et al., 1993; Alderson et al., 1995; Brunner et al., 1995; Dhein et al., 1995; Peter et 
al., 1997). In choosing to ignore those cells which are resistant to CD95-mediated 
killing, it is possible that the most interesting biological question is being 
overlooked in such studies, namely the control of the CD95 pathway under normal 
circumstances. Understanding the regulation of the sensitivity of T cells to 
apoptosis is of potential therapeutic relevance since the ability to manipulate this 
phenotype would confer enormous clinical potential for example in the context of 
autoimmunity where the elimination of a subset of autoreactive immune cells may 
be desirable. Therefore, this chapter presents experiments carried out to 
investigate the nature of the CD95 resistance evident in T blast cultures and 
examines the circumstances under which this resistance might be conferred under 
physiological conditions.
To probe the protective potential of various experimental treatments, the 
constitutively CD95 sensitive Jurkat T cells were utilised as a model for 
investigating the control of CD95 resistance. Accordingly, Jurkats were subjected 
to experimental treatments with a view to inhibiting the process of CD95- 
mediated apoptosis and providing information about how this process might be 
controlled to generate CD95 resistance in T blasts.
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6.2 RESULTS
6.2.1 Role of Antigen-like Signals
It has been established that during T cell activation, the surface expression of both 
CD95 and CD95L is upregulated, therefore it is likely that antigen-derived signals 
via the TCR may accompany CD95 engagement under these circumstances. To 
investigate whether the provision of TCR-like signals could modulate the response 
to CD95 ligation in Jurkat T cells, the phorbol ester PMA was used as an activator 
of PKC. J16 cells were subjected to a 1 hour pre-incubation with PMA prior to a 
4 hour treatment with the apoptotic anti-CD95 antibody CH11, following which 
apoptosis was assessed by annexin-FITC binding (figure 6.1). This analysis 
revealed that the extent of apoptosis induced by CH11 treatment was markedly 
reduced in the presence of PMA, since the percent annexin-stained cells decreased 
from 55.8% to 39.7%. Inclusion of PMA therefore lead to a 32.6% inhibition of 
CHI 1-induced apoptosis in this experiment, as measured by PS exposure and 
analysis of results from 5 independent experiments indicated that the inhibition of 
CD95-mediated apoptosis by PMA was statistically significant (p < 0.05).
In order to further investigate the ability of PMA treatment to inhibit CD95- 
mediated apoptosis, the effect of titrating the concentration of PMA on apoptosis 
induction through the CD95 pathway was examined in the JAM assay (figure 6.2). 
In addition, the effect of the non-PKC -activating phorbol ester 4a-phorbol was 
also investigated as a control for PMA treatment. 3H-thymidine labelled J16 cells 
were therefore pre-incubated with the indicated concentration of PMA or 4 a - 
phorbol for 1 hour prior to a 4 hour treatment with CHI 1. These data revealed 
that the inhibition of apoptosis by PMA was dose dependent and reproducible, 
although this treatment did not necessarily prevent apoptosis in the whole 
population. In contrast 4a-phorbol did not detectably inhibit CD95-mediated 
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Figure 6.1: Effect of PMA on C H ll-induced  apoptosis of T cells. J16 cells 
were pre-incubated for lh with PMA (0.04pg/ml) then treated for 4h with the anti- 
CD95 antibody CH11 (O.lpg/ml). Apoptosis was measured by annexin-FITC 
binding and is visualised as an increase in fluorescence in the gated region. 
Presented histograms are representative of 5 separate experiments and pooled data 
indicate that inhibition of CHI 1-mediated apoptosis by PMA was significant at 
the level of p < 0.05. Mean values (+/- SEM) for pooled data were as follows: 
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Figure 6.2: Effect of PMA and 4a-phorbol on CD95-induced apoptosis. 3H-
thymidine-labelled J16 cells were pre-treated for lh  with PMA (A) or 4a-phorbol 
(B) and exposed to the anti-CD95 antibody CH11 for 4h. Apoptosis was measured 
by JAM assay and the mean (+/-SEM) of triplicate wells is shown. Apoptosis was 
calculated as the % decrease in CPM relative to control-treated cells. Data are 













Figure 6.3: Effect of varying the timing of PMA addition on CD95-induced 
apoptosis. 3H-thymidine labelled J16 cells were pre-incubated for the indicated 
time period relative to the addition of the anti-CD95 antibody CH 11 (thus -2h 
indicates PMA addition 2h after the commencement of CH11 treatment). 
Following a 4h incubation with CH11 (O.lpg/ml) cells were harvested and 
apoptosis was assessed by JAM assay. The mean (+/-SEM) of triplicate wells is 
shown and % apoptosis is calculated relative to control-treated cells. Data are 
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Figure 6.4: Effect of the PKC inhibitor RO-31/8220 on CD95-mediated 
apoptosis. 3H-thymidine labelled J16 cells were pre-incubated for lh  with the 
PKC inhibitor RO-31/8220 then exposed to the anti-CD95 antibody CH11 for 4h. 
Apoptosis was measured by JAM assay and was calculated relative to control- 
treated cells. The mean (+/-SEM) of triplicate wells is shown and presented data 
are representative of 5 independent experiments from which pooled data indicate 
that the potentiation of C H ll-induced apoptosis (0.05pg/ml) by RO-31/8220 
(0.5|xM) was significant at the level p < 0.05. Mean values (+/- SEM) for pooled 
data were as follows: control = 2.7 (+/- 1.5), CH11 = 30.0 (+/- 5.1), CH11 + RO- 
31/8220 = 47.3 (+/-5.5).
170
requirement for the observed protection. Toxicity controls using PI exclusion 
assay indicated that the viability of J16 cells was not compromised by PMA or 
4a-phorbol treatment, even at the highest dose (0.1|ig/ml) during these 5 hour 
assays. Kinetic analyses indicated a requirement for pre-incubation with PMA to 
allow detectable protection from CD95-mediated apoptosis, with the effect 
plateauing at the 2 hour pre-incubation time point (figure 6.3). Addition of PMA 
at the same time as (or after) CHI 1 treatment did not observably reduce the extent 
of apoptosis.
Since PKC activation appeared to inhibit CD95-mediated apoptosis, it was also of 
interest to investigate the effect of the PKC inhibitor RO-31/8220 (Davis et al., 
1989) on this pathway (figure 6.4). At the concentrations of RO-31/8220 utilised, 
this compound alone did not induce apoptosis, but when used in combination with 
CHI 1 resulted in marked potentiation of the apoptotic response. For example the 
percentage apoptosis when O.lfig/ml CH11 was used increased from 28.9% to 
52% if cells were first pre-incubated with 0.5pM  R 0 3 1/8220 (figure 6.4). 
Analysis of data from 5 independent experiments revealed that the potentiation of 
CD95-mediated apoptosis by R 0 3 1/8220 was statistically significant (p < 0.05) 
when 0.05jxg/ml CHI 1 and 0.5|iM R 0 3 1/8220 were used.
Since PMA appeared to protect J16 cells from CD95-mediated apoptosis, the 
effect of this treatment on apoptosis in SEB blasts was also examined in order to 
assess whether this mechanism of protection may be of relevance to normal T 
cells. The experiment presented in figure 6.5 illustrates one of the larger apoptotic 
responses observed in T blasts (32%) although, consistent with earlier results, this 
response was still limited to a minority of the population. Inclusion of PMA with 
the CHI 1 treatment, however, markedly reduced the degree of apoptosis induction 
as measured by annexin-FITC binding, implying that receptors which activate 
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Figure 6.5: Effect of PMA on C H ll-induced apoptosis in T blasts. Day 6 SEB
blasts were incubated for 15h with the anti-CD95 antibody CH11 (0.5pg/ml) in 
the presence of PMA (0.04pg/ml) where indicated. Apoptosis was measured by 
annexin-FITC binding. A CD95-dependent increase in fluorescence of 31.82% 
was observed in the absence of PMA compared to 10.22% in the presence of 
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Figure 6 .6 : Effect of anti-CD3 treatm ent on C H ll-induced  apoptosis in T 
cells. J16 cells or day 6 SEB blasts were treated for 15h with the anti-CD95 
antibody CHI 1 (0.5pg/ml) in the presence of immobilised anti-CD3 (plate-coated 
at 10|ig/ml) where indicated. Apoptosis was measured by annexin-FITC binding. 
CHll-induced increases in fluorescence of 68.76% (in the absence of anti-CD3) 
and 69.33% (in the presence of anti-CD3) were observed for J16 cells and 18.83% 
(in the absence of anti-CD3) and 4.88% (in the presence of anti-CD3) were 
measured for SEB blasts. Data are representative of 3 independent experiments.
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Given that a major signal which drives PKC activation in T cells is ligation of the 
TCR (Genot et al., 1995), the effect of anti-CD3 signalling on CD95-induced 
apoptosis was also assessed. Accordingly both J16 cells and SEB blasts were 
exposed to immobilised anti-CD3 prior to exposure to the anti-CD95 antibody 
CH11. Interestingly, whilst in J16 cells this did not result in protection, SEB 
blasts in contrast exhibited a marked reduction in the apoptotic response (virtually 
to baseline levels) in the presence of anti-CD3 with the percent annexin-stained 
cells decreasing from 41.85 to 27.9% under these conditions (background 
apoptosis was 23.02%) (figure 6 .6 ). These data suggested that signalling through 
the TCR offered one potential mechanism for the prevention of CD95-mediated 
apoptosis in T cells. Such a mechanism would explain how activated T cells 
could survive despite upregulated expression of both CD95 and its ligand.
6.2.2 Role of Costimulatory Signals
As indicated previously (chapter 3), during the course of T cell activation CD28 is 
both downregulated by CD80 as well as subsequently upregulated in a manner 
which is dependent on the provision of TCR-like signals. Early activated T cell 
cultures are therefore heterogeneous for CD28 expression whilst expression of 
CD95 is nevertheless homogeneous (this point has been previously illustrated in 
figure 3.4, panel B). This heterogeneity therefore provides a useful system in 
which to assess the significance of CD28 expression on T cell responses. 
Accordingly, early activated T cell populations were treated with the apoptotic 
anti-CD95 antibody CH11 and dual stained for TUNEL positivity and CD28 
expression with a view to discerning differential responses between the CD28 
high and CD28 low populations (figure 6.7). Interestingly, this analysis revealed 
that cells expressing high levels of CD28 were resistant to CD95-mediated 
apoptosis since there was no decrease in the CD28 high annexin dull (upper left) 
population following CHI 1 treatment. In contrast, the cells which have
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F igure 6.7: Sim ultaneous analysis of CD28 expression and apoptosis 
following CH11 treatm ent of T blasts. Day 3 SEB blasts were incubated for 15h 
with the anti-CD95 antibody CH11 (0.5pg/ml) then stained for CD28 expression 
(FL2-fluorescence) and assayed for apoptosis induction by TUNEL analysis (FL1- 
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Figure 6 .8 : Effect of CD80 transfectants on C H ll-induced  apoptosis in T 
cells. J16 cells or day 6 SEB blasts were incubated for 15h with the anti-CD95 
antibody (CH11) in the presence of CD80 transfectants or untransfected CHO 
cells. Apoptosis was measured by annexin-FITC binding. J16 cells exhibited a 
CHI 1-induced increase in fluorescence of 71.52% (in the presence of CHO cells) 
and 70.18% (in the presence of CD80 cells). SEB blasts exhibited a C H l l -  
induced increase in fluorescence of 30.77% (+ CHO cells) and 3.96% (+ CD80 
cells). Data are representative of 4 similar experiments.
176
undergone apoptosis in this experiment can be seen to have derived from the 
CD28 low population of starting cells. These data indicated that low CD28 
expression pre-disposed to CD95 sensitivity in these cultures and that conversely, 
T cells which expressed high levels of CD28 were protected from CD95-mediated 
apoptosis. Moreover, the demonstration that CD28 high cells were protected from 
apoptosis gave the first indication that expression of high levels of CD28 might 
potentially offer a mechanism for the delivery of anti-apoptotic signals.
To test this hypothesis directly, J16 cells and SEB blasts were exposed to CHI 1 in 
the presence or absence of CHO cells transfected with CD80 (figure 6 .8 ). These 
results demonstrated that whilst J16 cells could not be protected via this route 
(under these experimental conditions), SEB blasts underwent substantially less 
apoptosis if exposed to the ligand for CD28 simultaneously with the anti-CD95 
antibody CH11. Accordingly the percentage of annexin-stained cells decreased 
from 54.18% to 27.37% (background apoptosis was 23.41%) upon inclusion of 
CD80 transfectants in this experiment. This indicated that signalling via the 
CD28 receptor stimulated anti-apoptotic activities. Whilst a role for CD28 in T 
cell survival has been inferred from a number of studies (Boise et al., 1995; Noel 
et al., 1996a; Sperling et al., 1996; Vella et al., 1997), direct evidence of this 
nature has been lacking and this appears to be the first demonstration of a direct 
role for CD28 ligation in the prevention of CD95-mediated apoptosis in normal 
human T cells.
Since CD28 ligation could protect from apoptosis, this prompted an analysis of 
the expression of the CD28 ligands CD80 and CD86  in T blasts cultures, since 
inducible T cell expression of these molecules has been documented (Sansom and 
Hall, 1993; Pichler and Wyss-Coray, 1994). Resting human T cells failed to 
express detectable levels of CD80 and CD8 6 , and the first stimulation with SEB 
only triggered m arginal CD 86  upregulation (figure 6.9). Subsequent 
restimulations, however, resulted in a sequential increase in the expression of
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Figure 6.9: Expression of CD80 and CD86  on T cells. Resting human T cells, or 
SEB blasts restimulated with SEB as indicated, were stained for surface 
expression of CD80 and CD86 (open histograms). Filled histograms indicate 
control staining with secondary antibody only. Data are representative of 2 similar 
experiments.
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F igure  6.10: Reciprocal effect of CD80 transfectan ts  and  CTLA4-Ig 
trea tm en t on C H ll-induced  apoptosis in T blasts. Day 6 SEB blasts were 
incubated for 15h with the anti-CD95 antibody CHI 1 (0.5pg/ml) in the presence 
of CD80 transfectants, untransfected CHO cells, control Ig (human Ig, 2pg/ml), 
CTLA4-Ig (2pg/ml) or IL-2 (10 IU/ml) as indicated. Apoptosis was measured by 
annexin-FITC binding and the % increase in fluorescence relative to control- 
treated cells is shown. This experiment was repeated 4 times and similar trends 
were observed.
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these molecules as illustrated in figure 6.9. In particular, CD86  was expressed at 
substantial levels in repeatedly activated T cells. Thus one interaction which 
might confer a CD95-resistant phenotype on activated T cells is the ligation of 
CD28 by CD80/86 expressed on T cells. To investigate the contribution of such 
an interaction to the CD95 resistance observed in T blasts, signalling via the CD28 
receptor (by T cell CD80/86) was blocked by the inclusion of CTLA4-Ig during 
the incubation with CH11 and the effect on apoptosis induction was assessed by 
annexin-FITC binding (figure 6.10). This analysis revealed that inclusion of 
CTLA4-Ig during CH11 incubations resulted in potentiation of CD95-mediated 
apoptosis, indicative of a protective role for T cell CD80 family members. The 
extent of CTLA-Ig-induced potentiation of CD95-mediated apoptosis was variable 
between cultures with up to 30% potentiation being observed under these 
experimental conditions. It is likely that pre-incubating cultures with CTLA4-Ig 
prior to the anti-CD95 challenge might result in more substantial potentiation of 
apoptosis and this therefore represents a target for further investigation. The 
variability in the degree of potentiation observed may reflect the variable 
expression levels of CD80/86 on different T blast lines. Overall these data 
suggested that CD28 ligation offered one route for the protection of T cells from 
CD95-m ediated apoptosis, and that T cell expression o f CD80/86 could 
potentially play a role in regulating this process.
The nature of the anti-apoptotic signal transduced by CD28 is not yet clear. Since 
a feature of CD28 signalling is enhanced cytokine production (Gimmi et al., 1991; 
Jenkins et al., 1991; Linsley et al., 1991a; Razi-Wolf et al., 1992; Sansom et al., 
1993), one possibility is that protection could be mediated by IL-2 production, 
therefore the effect of the addition of exogenous IL-2 on apoptosis induction of 
was assessed. As indicated in figure 6.10, IL-2 failed to inhibit CD95-mediated 
apoptosis implying that the protection conferred by CD28 engagement could not 









Figure 6.11: CD95 expression and apoptosis sensitivity in T cells activated by 
su p ern a tan t transfer. Supernatants from day 3 T blasts (activated using anti- 
CD3 and CD80 transfectants) were transferred to resting purified T cells (day 0). 
CD95 expression of supernatant-treated T cells was measured on days 3 and 6 and 
compared with that of cells incubated in medium (upper panel). Sensitivity to 
CD95-mediated apoptosis (0.05pg/ml CH11, 15h) was assessed on day 6 by 
annexin-FITC binding and compared with cells treated with medium or SEB 
(pulsed onto CHO-DR/CD80) (lower panel). Apoptosis is shown as the % annexin 
bright cells in each sample. Data are representative of 3 independent experiments.
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is in line with reports indicating a lack of effect of IL-2 on CD95-induced 
apoptosis (Zipp et al., 1997).
Since signalling via the TCR CD3 complex (figure 6 .6 ) and via the CD28 receptor 
(figures 6 .8  and 6.10) appeared to provide protection from CD95-mediated 
apoptosis in T blasts, this suggested that "correct" activation signals (i.e. antigen 
plus costimulation) might play a role in promoting T cell survival. In order to 
address the role of TCR and CD28 signalling in the protection of T cells from 
CD95-mediated apoptosis, experiments were undertaken in which the provision of 
these signals were deliberately bypassed. Accordingly, resting purified T cells 
were "activated" by culture in the supernatants from T blasts which had been 
stimulated for 3 days with immobilised anti-CD3 in the presence of CD80 
transfectants. Surface staining of T cells treated with supernatants from activated 
T cells revealed upregulated expression of the CD95 receptor (figure 6.11, upper 
panel) therefore sensitivity to CD95 ligation was examined and compared both 
with unstimulated T cells and with HLA-DR/SEB/CD80 activated cells. This 
analysis revealed that despite equivalent CD95 expression, T cells activated by 
supernatant transfer showed increased sensitivity to CD95-mediated apoptosis 
compared to T cells stimulated with HLA-DR/SEB/CD80. These data support the 
contention that TCR and CD28 signalling offer protection from CD95-induced 
apoptosis and suggest that ineffective activation predisposes to apoptosis.
6.3 DISCUSSION
Based on the observation that normal activated T cells were largely resistant to the 
induction of apoptosis via the CD95 pathway, an investigation of the nature of the 
stimuli which may be involved in maintaining this resistance was initiated. The 
data presented indicate that one contributory factor to the control of CD95-
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mediated apoptosis was the activation status of cellular PKC, such that stimulation 
with the phorbol ester PMA inhibited the apoptotic response, whilst the PKC 
inhibitor RO-31/8220 in contrast potentiated this pathway. These findings are 
supported by previous studies which have demonstrated a role for PKC-activating 
phorbol esters in the promotion of T cell survival (Tomei et al., 1988; Rodriguez- 
Tarduchy and Lopez-Rivas, 1989; Lucas et al., 1994). A key pathway for the 
triggering of PKC activation in T cells is ligation of the TCR (Genot et al., 1995) 
implying that this may represent one route by which sensitivity to CD95-mediated 
apoptosis may be modulated. Interestingly, whilst this hypothesis was not 
supported by the studies in Jurkat cells, it did prove to be the case in superantigen 
activated peripheral blood T cells, with anti-CD3 treatm ent resulting in 
reproducible inhibition of CH ll-induced cell death. One factor highlighted by 
these studies, therefore, was that although certain biological responses are 
conserved between Jurkats and normal T cells (e.g. protection from apoptosis by 
PMA), these homologies are not universally applicable and the limitations of 
Jurkat cell lines as a model of normal human T cells should be understood.
For SEB blasts, therefore, a signal through the CD3 component of the T cell 
receptor was sufficient to markedly inhibit the apoptotic response to CD95 
engagement. These data contrast with the reports documenting AICD following 
anti-CD3 treatment of human T cells (Groux et al., 1993; Alderson et al., 1995; 
Dhein et al., 1995), and suggest that under these conditions TCR signalling was 
promoting T cell survival rather than triggering an apoptotic programme. Since 
the percentage of cells induced to undergo apoptosis in the above reports was 
relatively low (less than 50%), one possibility is that CD3 signalling can trigger 
both apoptosis and survival depending on the context in which signalling is 
delivered. T cell populations clearly exhibit a degree of heterogeneity and the 
choice between life and death within an individual T cell following TCR 
signalling may be influenced by factors such as the activation or differentiation 
state. Thus the observed outcome of anti-CD3 treatment at the population level
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may represent the net result of both apoptosis induction and survival signalling. 
Given that the data presented in this chapter indicate a role for "correct" activation 
signals in the promotion of cell survival, the variation in the extent of AICD 
observed between reports (Groux et al., 1993; Alderson et al., 1995; Dhein et al., 
1995; Boshell et al., 1996) could potentially reflect the nature or effectiveness of 
the initial activation stimulus.
The inhibition of apoptosis by TCR signalling is in line with recent studies on B 
lymphocytes which demonstrated the promotion of cell survival following 
antigen-receptor engagement (Rothstein et al., 1995; Foote et al., 1996) and is 
further supported by the recent association of TCR signalling with T cell survival 
in murine systems (Suda et al., 1996; Kirberg et al., 1997). The duration of TCR- 
mediated protective signals following T cell antigen engagement may thus define 
a window of time for T cell immune functions to proceed prior to the acquisition 
of sensitivity to apoptosis. The persistence of antigen, for example due to 
incomplete elimination of pathogens or immune complex retention on germinal 
centre follicular dendritic cells, is believed to contribute to immune memory 
(Ahmed and Gray, 1996; Sprent et al., 1997) and is in line with the finding that 
anti-CD3 treatment can promote T cell survival.
Consistent with a role for activation signals in protection from T cell death, further 
experiments indicated that signals delivered by CD80 could also protect SEB 
blasts from CD95-mediated apoptosis. Again, parallel studies in Jurkat cells 
failed to mimic this phenomenon, highlighting the possible dysregulation of 
certain signalling pathways in transformed cell lines. The degree of protection 
conferred by CD28 ligation in T blasts varied between donors (as did the degree 
of apoptosis in response to CD95 ligation, and the degree of potentiation afforded 
by CTLA4-Ig treatment) indicating that additional factors such as the CD80/86 
expression and activation/differentiation status of these cells may influence such 
responses.
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CD80-mediated protection from apoptosis was not mimicked by exogenous 
addition of IL-2, indicating that the anti-apoptotic signal(s) induced was not 
mediated by this cytokine. Protection from AICD by CD80 is not likely to occur 
by inhibiting the induction of CD95L since a) experiments described in the 
previous chapter illustrated equivalent CD95L induction regardless of CD80 
provision (figure 5.10) and b) protection was demonstrated to be downstream of 
CD95 engagement in experiments using CH11 for direct CD95 ligation (figures 
6.8  and 6 .10). Upregulation of B C L X l represents one candidate for mediating 
the CD80-induced protective effect, although transfection studies have indicated 
that this protein can inhibit CD95-mediated apoptosis in Jurkats (Boise et al., 
1995) but not normal T blasts (Moreno et al., 1996). Previous work in our 
laboratory has established that ligation of CD28 alone in activated T cells is 
sufficient to trigger induction of the transcription factor Nuclear Factor kB 
(NFkB) (Edmead et al., 1996) which has recently been implicated in protection 
from TNFR-induced apoptosis (Liu et al., 1996; Baichwal and Baeuerle, 1997). 
Given the homologies between CD95- and TNFR-induced signalling (Boldin et 
al., 1996; Cleveland and Ihle, 1995), it is possible that NFkB could represent one 
potential target for CD28-mediated survival effects. Alternatively, CD28 
stimulation is known to lead to the recruitment and activation of the lipid kinase 
PI3K (Ward et al., 1993; Cai et al., 1995) which has been linked to the activation 
of the serine/threonine kinase PKB (Burgering and Coffer, 1995). Recent studies 
have indicated a role for PKB activity in the prevention of apoptosis in a number 
of systems, including the protection from c-myc-induced apoptosis in fibroblasts 
(Kauffman-Zeh et al., 1997), thus PKB activation may offer an additional 
mechanism for CD28-mediated protection from apoptosis.
The function of T cell CD80 expression remains largely unknown. The 
upregulation of both antigen presenting molecules (HLA-DR) and costimulatory 
molecules (CD80 and CD8 6 ) suggests a potential role in the presentation of
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antigen, although this may negatively rather than positively regulate T cell 
responses (Houssaint and Flajnik, 1990; Sidhu et al., 1992; Pichler and Wyss- 
Coray, 1994; Hargreaves et al., 1997). Clearly the presented findings suggest that 
one potential function of T cell CD80 may be in the maintenance of T cell 
survival and the nature and physiological role of CD28-mediated anti-apoptotic 
signals warrants further investigation. A role for costimulatory signals in T cell 
survival has been indicated by a number of reports (Groux et al., 1992; Boise et 
al., 1995; Mueller et al., 1996; Radvanyi et al., 1996; Sperling et al., 1996; Vella 
et al., 1997) including the demonstration that T cells from CD28 knockout mice 
effectively initiate proliferation but fail to sustain responses (Lucas et al., 1995) 
and the recent investigations into the relative provision of costimulatory versus 
apoptosis ligands during antigen presentation (Lu et al., 1997a; Lu et al., 1997b). 
However, the data presented here appear to be the first demonstration that the 
provision of CD80 can directly inhibit CD95-mediated apoptosis.
CD80 transfectants and CD86  transfectants were found to be equally effective at 
inhibiting CD95-mediated apoptosis under these conditions, indicating that either 
ligand was potentially capable of providing this protective signal. Nevertheless, it 
would be of interest to determine the relative contribution of CD86  versus CD80 
in the triggering of CD28-mediated survival signalling under physiological 
circumstances since these molecules appear to be expressed on APCs with 
different kinetics (Azuma et al., 1993; Stack et al., 1994; Fleischer et al., 1996). 
In addition, establishing the duration of the protective signal conferred by CD28 
ligation represents a target for future investigation and interestingly work in our 
laboratory has demonstrated that the provision of CD80 alone (i.e. in the absence 
of TCR signalling) is sufficient to trigger proliferation in previously activated T 
cells, but that this response is only intact until approximately 12 days following 
the initial activation stimulus (Edmead et al., 1996). Thus these data demonstrate 
the potential for independent signal transduction via CD28, but suggest that this
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ability is restricted to a certain time window following the initiation of T cell 
activation.
Since T cells themselves can clearly express costimulatory ligands in an 
activation-dependent manner (figure 6.9), it would also be interesting to 
investigate the potential role of T cell:T cell interactions in the promotion of cell 
survival in vivo. In this regard a recent study has indicated that T cell CD86  
molecules may represent preferential ligands for CTLA4 rather than CD28 
(Greenfield et al., 1997) and understanding how T cell:T cell interactions may 
regulate immune responses via apoptosis induction (Hargreaves et al., 1997), 
anergy induction (Sidhu et al., 1992), CTLA4 signalling (Greenfield et al., 1997) 
or potentially via CD80/86-mediated survival signalling represents an attractive 
area of research. These issues are of particular relevance to human T cells given 
their expression of HLA class II molecules which is not paralleled in mouse T 
cells (Pichler and Wyss-Coray, 1994). Expression of costimulatory ligands 
represents a further intriguing difference between mice and humans since CD86  is 
detectable on resting murine T cells and is subject to downregulation during the 
activation process whilst conversely CD80 is upregulated (Prabhu Das et al., 
1995). This contrasts with the expression patterns observed in human T cells 
(figure 6.9) and may have a bearing on T cell susceptibility to apoptosis if these 
ligands were to deliver a similar protective signal in mice.
The finding that the two signals which were required for productive T cell 
activation were also implicated in conferring resistance to CD95-mediated 
apoptosis was supported by the supernatant transfer experiments, and highlighted 
the significance of the in vitro activation protocols used for such studies. Clearly 
suboptimal T cell activation, which may support a degree of short term  
proliferation but which fails to provide a truly costimulated TCR-derived 
stimulus, is likely to be defective in the induction of anti-apoptotic signals 
associated with these pathways. Accordingly, stimulation of purified T cells with
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PHA in the absence of ligand for CD28 may be sufficient to trigger suboptimal 
proliferation, but may not prove effective at protecting cells from apoptosis. 
Interestingly, one of the studies which is most contentious in the light of my data 
utilised PHA treatment of purified T cells (i.e. in the absence of CD80 positive 
APCs) as the initial activation stimulus (Klas et al., 1993), so perhaps the lack of 
CD95 resistance in these experiments is not surprising since the signals which 
have been demonstrated in this thesis to confer resistance to apoptosis have not 
been delivered to these T cells. Similarly in the study by Owen-Schaub and 
colleagues (Owen-Schaub et al., 1992), purified human T cells were activated 
simply by the addition of IL-2, a protocol which I view as a form of "bystander" T 
cell activation since antigen- and costimulation- derived stimuli are lacking, and 
the sensitivity of these cultures to apoptosis is in line with my data pertaining to T 
cells stimulated with activated supernatants. The previously presented finding 
(chapter 3) that "correct" activation of T cells is associated with the upregulation 
of surface CD28 expression to high levels suggests that CD28 upregulation may 
represent one potential mechanism for the promotion of survival in cells which 
have received these activation signals.
One interpretation of these data is that CD80-costimulated SEB, anti-CD3, PHA 
or ConA responses offer a more physiologically relevant model for T cell 
activation than does uncostimulated PHA-driven proliferation given our current 
understanding of the in vivo requirements for this process. Rather than 
representing an isolated finding, the CD95 resistance documented here may 
therefore accurately reflect the normal in vivo situation under conditions when the 
T cell activation stimulus fulfils a two signal requirement. In addition, these 
findings are supported by studies on T cells which have been activated using anti- 
CD3 and anti-CD28 in which resistance to irradiation-induced apoptosis has been 
observed (Mueller et al., 1996). Moreover, a recent report by Krammer and 
colleagues documents CD95 resistance in human T cells stimulated with myelin 
basic protein or tetanus toxoid. Since the CD95-sensitive controls for these
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experiments were Jurkat T cell lines (rather than normal activated T cells) it is 
possible that the CD95 resistance is not specific to these particular antigens, but 
rather is a feature of "correct" T cell activation involving antigen and 
costimulatory signals in line with the findings of this thesis.
Since the survival of at least a subset of antigen-specific T cells is presumably a 
requirement for the maintenance of immune memory, mechanisms must exist to 
ensure resistance of these T cells to apoptosis, for example following encounter 
with soluble CD95L. One such mechanism which has been shown to prevent 
apoptosis in cytokine-deprived T cells involves the secretion of a protective 
30kDa soluble factor from stromal cells which is associated with the upregulation 
of B C L X l (Gombert et al., 1996). In addition, cytokines which signal through 
the IL-2 receptor common y  chain can enhance T cell survival via BCL-2 
upregulation (Akbar et al., 1993b; Akbar et al., 1996) although paradoxically such 
interactions may also increase T cell sensitivity to AICD (Wang et al., 1996b). 
Increased intracellular glutathione levels have also been implicated in the 
promotion of T cell survival (Hyde et al., 1997). The data presented in this thesis 
suggest that "correct activation" via signalling through the TCR and CD28 may 
offer a further mechanism to confer resistance to apoptosis in T cells, in this case 
in response to CD95 ligation. Clearly T cells must be efficiently eliminated in the 
wake of an immune response to ensure immune cell homeostasis, however these 
data indicate that T cells activated by antigen and costimulation are not 
constitutively sensitive to apoptosis via CD95 ligation and imply that additional 
interactions, or the termination of protective signalling, may be required for 
susceptibility to ensue. Alternatively, downregulation of T cell responses may be 
largely achieved by mechanisms other than CD95 and the growing family o f T 
cell death receptors may be relevant in this regard (Chinnaiyan et al., 1996; Pan et 
al., 1997).
189
In summary, the resistance to CD95-mediated apoptosis documented in both 
chapter 4 and chapter 5 could potentially be conferred by the ligation of receptors 
such as the TCR and CD28 during the process of productive T cell activation. By 
linking the nature of the activation process to the delivery of survival signals, this 
offers a mechanism for allowing cells which may be inappropriately activated, for 
example bystander T cells, to apoptose following transient activation, whilst cells 
receiving the requisite signals during priming may be protected from apoptosis via 
this route. Since the molecules which allow CD95-mediated apoptosis (CD95 and 
CD95L) are both upregulated during T cell activation, the potential for cell death 
is already in place at this time and it is therefore likely that T cell survival is 
manipulated by controlling the signals which confer resistance to apoptosis. The 
duration of TCR or CD28-mediated resistance to apoptosis has not yet been 






One interesting observation arising from studies on the process of CD95-mediated 
apoptosis in Jurkat T cells was that CD95 ligation appeared to affect T cell CD28 
expression. CD28 is known to provide a potent stimulatory signal to T cells 
favouring proliferation and cytokine production, and signalling via this receptor 
has also been implicated in the promotion of cell survival as discussed in the 
previous chapter. It follows that stimuli which alter the expression levels of this 
molecule may have important consequences for T cell responses. Therefore 
experiments were performed to investigate CD95-mediated CD28 downregulation 
in Jurkat T cells and to document the kinetics and specificity of this response. In 
addition, the mechanism underlying CD95-mediated CD28 downregulation was 
investigated.
7.2 RESULTS
During studies on CD95-mediated apoptosis in J16 cells, it became apparent that 
CD95 ligation could modulate T cell surface receptor expression. Accordingly, 
treatment with the anti-CD95 antibody CH11 induced a rapid and time dependent 
decrease in the surface expression of CD28 as measured by surface staining and 
FACS analysis (figure 7.1). Kinetic analysis demonstrated that loss of CD28 was 
evident by as little as 3 hours following CH11 treatment, and that by 6  hours the 
majority of cells exhibited downregulated expression of this receptor (figure 7.1). 
Downregulation appeared to be specific to CD28 since the levels o f other 
receptors examined, including CD2, CD3, CD5, CD48 and CD58 were not 
detectably affected by CH11 incubation and data for CD58/LFA3 expression are 
shown in figure 7.1. In addition a control IgM antibody, OBI, had no detectable 









Figure 7.1: Effect of antibody-mediated CD95 engagement on T cell surface 
m arker expression. J16 cells were incubated with anti-CD95 antibody (CH11, 
0.05jig/ml) or a control IgM antibody (OBI, supernatant) for the indicated time 
periods then stained for expression of CD58 or CD28 (filled histograms). Open 
histograms show staining with secondary antibody only. Data are representative of 
>8 individual experiments.
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Figure 7.2: Effect of ligand-mediated CD95 engagement on T cell surface 
m arker expression. J16 cells were incubated with control supernatant (NEG) or 
CD95L (COS-7 cell supernatant) for 4h and stained for surface expression of 
CD58 or CD28 (filled histograms). Open histograms show staining with 
secondary antibody only. Data are representative of 3 separate experiments.
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% increase in the CD28 low population relative to control
Control CH11 CH11 +ZB 4 ZB4
J16 0 21.75 0.51 -0.36
JLW 0 0.65 ND ND
SEB blasts 0 11.68 0.1 -1.53
ND = not determined
Table 7.1: Effect of the blocking anti-CD95 antibody ZB4 on CHll-mediated 
CD28 downregulation. J16 cells JLW cells or SEB blasts (day 6 ) were incubated 
for 6h (15h for SEB blasts) with the anti-CD95 antibodies indicated and CD28 
expression was measured by FACS. CH11 was used at 0.05|ig/ml and ZB4 was 
used at O.ljig/ml. The values indicate the % increase in a CD28 low region 
(arbitory gate) relative to control-treated cells. Data are representative of 3 
experiments.
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Since antibodies do not necessarily reflect the biological effects of natural ligand, 
these studies were also extended to the use of soluble CD95L for the provision of 
CD95 engagement (figure 7.2). In accordance with the CH11 experiments, 
incubation of J16 cells with soluble CD95L lead to rapid and specific CD28 
downregulation without observable differences in the expression of other T cell 
surface receptors (CD58 expression shown figure 7.2). Thus CD28 
downregulation was shown to be a rapid and specific response which occurred 
following CD95 engagement by both antibody and natural ligand.
In order to elucidate the relationship between CD95-mediated apoptosis induction 
and CD95-mediated CD28 downregulation, experiments were performed to 
address whether non apoptotic anti-CD95 antibodies were competent to induce 
CD28 downregulation. The anti-CD95 antibody ZB4, which binds to CD95 but 
fails to induce apoptosis did not downregulate CD28 expression (table 7.1) 
indicating that signal transduction, as opposed to simple antibody-receptor 
interactions, was a requirement for this effect. Furthermore, CHI 1-induced CD28 
downregulation was inhibited in the presence of ZB4 confirming that this 
phenomenon is mediated by the CD95 receptor (table 1). This was a useful 
control since CD28 is known to downregulate following the interaction with its 
ligand CD80 (chapter 3) thus it was of relevance to preclude the possibility that 
CH11 was interacting non-specifically with CD28. The tabulated data also 
indicate that the Jurkat cell line selected for CD95 resistance (JLW) did not 
appreciably downregulate CD28 expression following CD95 engagem ent 
supporting the concept that signal transduction, ra ther than sim ple 
antibody:receptor interactions, was a requirement for this effect (table 1). In 
addition CD95-mediated CD28 downregulation was observed in SEB activated 
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Figure 7.3: Comparison of CD95 ligation and etoposide treatm ent on T Cell 
CD28 surface expression. J16 cells were incubated for 6h with the anti-CD95 
antibody CH11 (0.05pg/ml) or etoposide (1 jag/ml) then stained for surface 
expression of CD28 and assayed for annexin-FITC binding. Data are 
representative of 3 similar experiments.
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Given that non-apoptotic antibodies did not cause CD28 downregulation, it was 
therefore of interest to determine whether the cells which had downregulated 
CD28 following CH11 treatment were committed to apoptosis. Since the 
annexin-FITC assay detects very early events in the apoptotic pathway and 
effectively measures commitment to apoptosis (Martin et al., 1995b) this assay 
was therefore utilised. Dual staining for surface CD28 receptor expression and 
annexin-FITC binding revealed that those cells which had downregulated CD28 
expression following CHI 1 treatment were in the early apoptotic (annexin bright) 
population (figure 7.3). It appeared, therefore, that decreased surface expression 
of CD28 was linked to the induction of apoptotic signalling via the CD95 
receptor. Therefore to assess whether downregulation of CD28 was a common 
feature of apoptosis-inducing signals in T cells, the topoisomerase II inhibitor 
etoposide was utilised to provide an alternative model of apoptosis induction. 
Treatment with this compound lead to the appearance of an distinct annexin bright 
population (44% were induced to express PS under these conditions), however the 
levels of CD28 expression nevertheless remained high in these cells. These data 
indicated that CD28 downregulation was not simply a feature of the induction of 
apoptosis in T cells, but rather was a specific response following CD95 signal 
transduction.
In an attempt to distinguish the signals required for CD28 downregulation from 
those necessary for apoptosis induction, a number of experiments were performed. 
CD95 signal transduction is reported to involve acidic sphingomyelinase activity 
(Cifone et al., 1993; Gulbins et al., 1995), and one published approach for the 
inhibition of this enzyme is the use of chloroquine (2mM), a lysosomotrophic 
agent which neutralises the acidic environm ent necessary for acidic 
sphingomyelinase activity (Boucher et al., 1995). In order to assess the role of 
CD95-induced acidic sphingomyelinase signalling in CD28 downregulation, 
experiments were undertaken to elucidate the effect of chloroquine on this 
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Figure 7.4. Effect of chloroquine on CD95-mediated apoptosis. (A) 3H-
thymidine labelled J16 cells were pre-treated for lh  with the indicated 
concentration of chloroquine prior to addition of the anti-CD95 antibody CH11 
(O.lpg/ml) for a further 4h incubation. Apoptosis was measured by JAM assay 
and is calculated as the % decrease in CPM relative to control-treated J16 cells. 
Columns represent the mean (+/-SEM) of triplicate wells. (B) Parallel analysis of 
membrane integrity by PI exclusion was carried out on cells treated with the 
indicated concentrations of chloroquine as described above. 105 cells were 
removed for FACS analysis immediately prior to harvesting for JAM analysis. 
Loss of membrane integrity is visualised as an increase in FL-2 fluorescence due 





























CD95-mediated apoptosis the JAM assay was used, and in order to control for any 
toxicity resulting from chloroquine treatment, PI exclusion was simultaneously 
monitored by FACS. Examining the results of the JAM assay in isolation (figure 
7.4, panel A), it appeared that chloroquine treatment effectively inhibited CD95- 
induced apoptosis, since the percent apoptosis following CHI 1 treatment fell from 
73.9% to 26.3% in the presence of this compound (500|iM). In addition, the 
control data indicated that incubation of Jurkats with these chloroquine doses in 
the absence of CH11 induced only a minor increase in DNA fragmentation as 
measured by JAM assay. However, when the PI exclusion assay was analysed 
(figure 7.4, panel B), it became clear that at these doses chloroquine was having a 
toxic effect resulting in the loss of membrane integrity and consequent PI uptake. 
Ironically, since the JAM assay is relatively specific to apoptosis detection, as 
opposed to necrosis measurement, the toxicity of chloroquine was not visualised 
as cell death in this assay. Similarly, the use of any assay which relies upon 
characteristics such as DNA fragmentation to measure apoptosis would not detect 
the necrotic effect of a compound such as chloroquine, and may explain why 
certain apoptosis inhibition studies yield contradicting results (Eischen et al., 
1994; Schraven and Peter, 1995; Janssen et al., 1996). These data emphasise the 
need for caution in the interpretation of apoptosis inhibition studies since cells 
which have already undergone necrosis will no longer be able to activate an 
apoptotic pathway leading to DNA fragmentation: thus treatments resulting in 
necrotic cell death may be misinterpreted as inhibiting apoptosis induction. 
Hence, apart from providing the valuable lesson that "dead cells don't apoptose", 
chloroquine did not appear to be a useful tool for the inhibition of CD95 signal 
transduction in Jurkat T cells and alternative options were therefore explored.
In addition to acidic sphingomyelinase, CD95 ligation also triggers the activation 
of a cascade of cysteine proteases (caspases) which are believed to be essential for 
the successful induction of apoptotic cell death in T cells. Despite the 










Figure 7.5: Effect of the caspase inhibitor Z-VAD-FMK on CD95-mediated 
apoptosis and CD28 downregulation. (A) 3H-thymidine labelled J16 cells were 
pre-incubated for lh with Z-VAD-FMK (IO jliM ) then treated for 4h with the 
indicated concentration of the anti-CD95 antibody CH11. Apoptosis was 
measured by JAM assay and is presented as the % apoptosis relative to control- 
treated samples The mean (+/-SEM) of triplicate wells is shown. (B) J16 cells 
were pre-incubated for lh with lOpM Z-VAD-FMK then treated for 4h with 
CHI 1 (0.05pg/ml) prior to staining for CD28 expression (filled histograms). Open 
histograms indicate staining with secondary antibody alone. Data are 
representative of 3 experiments.
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actin, ot-fodrin and lamin B1 (Lazebnik et al., 1994; Martin et al., 1995a; Martin 
and Green, 1995), it is not yet clear which caspase target is responsible for 
committing cells to apoptosis. However, a requirement for caspase activity for 
apoptosis induction can be demonstrated with the use of cell permeant peptide 
fluorom ethyl ketones such as Z-VAD-FM K (Cbz-V al-A la-A sp(O M e)- 
fluoromethyl ketone) which inhibits a broad range of caspases (Sarin et al., 1996). 
Treatment of J16 cells with this caspase inhibitor potently inhibited CD95- 
mediated apoptosis induction in the JAM assay, as illustrated in figure 7.5 (A). 
To assess whether caspase inhibition was a useful tool for the segregation of the 
signals required for apoptosis induction from those required for CD28 modulation, 
the effect of Z-VAD-FMK on CD95-induced CD28 downregulation was also 
examined. The data presented in figure 7.5 (B) illustrate that Z-VAD-FMK was 
in fact an effective inhibitor of CD95-induced CD28 dow nregulation, 
demonstrating that the signals which mediate the change in CD28 expression are 
downstream of a caspase-driven step. It was therefore not possible with the 
available reagents to separate CD28 downregulation from apoptosis induction.
In order to further characterise CD95-mediated CD28 downregulation, studies 
were undertaken to determine the mechanism by which this process operated. 
Surface receptor expression can be modulated in a variety of ways, including 
receptor internalisation, receptor shedding or even changes in the production or 
stability of the mRNA which encodes that receptor. To address the latter 
possibility, experiments were performed to determine whether CH11 treatment 
resulted in a difference in the detectable levels of CD28 mRNA. Total cellular 
RNA was therefore extracted from control- and CHI 1-treated J16 cells and 
northern blot analysis performed. Methylene blue staining of the RNA following 
transfer to a nylon membrane allowed the ribosomal bands to be visualised (figure 
7.6, panel C) and indicated loading equivalence: RNA from CHO cells was 
included as a negative control for CD28 and LFA3 expression. Hybridisation 
studies with a CD28-specific probe revealed a striking reduction in CD28 mRNA
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Figure 7.6: Effect of CD95 engagement on CD28 mRNA levels. J16 cells were 
treated for 4h in the presence of absence of the anti-CD95 antibody CH11 
(0.05|ig/ml). RNA was isolated and probed for CD28 (panel A) or CD58 (panel 
B). Binding of 32P-labelled probes was visualised by autoradiography. CHO cells 
were used as a negative control since they do not express the T cell molecules 
CD28 or CD58. Total RNA was visualised by methylene blue staining (panel C). 
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Figure 7.7: Comparison of CH11- and CD80-induced CD28 downregulation.
J16 cells were treated with the anti-CD95 antibody CH11 (0.05|ig/ml) or CD80 
transfectants (at a ratio of 1:3, transfectant:T cell) for 7h then stained for surface 
expression of CD28. Transfectants were gated out on autofluorescence during 
FACS analysis. The filled histogram shows CD28 expression on untreated cells 
and the solid line represents treated cells. The dotted line shows control staining 
with secondary antibody alone. Data are representative of 3 experiments.
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levels as early as 4 hours following CH11 treatment (figure 7.6, panel A). The 
efficiency of recovery of RNA from both control and CHI 1-treated cells was 
equivalent at this time point as determined by spectrophotometric analysis 
suggesting that there was no generalised degradation of RNA at this time. 
Furthermore, probing for CD58 revealed no obvious decrease in the mRNA for 
this protein following CHI 1 treatment (figure 7.6, panel B). These data therefore 
indicated that the effect of CD95 ligation on CD28 surface expression was 
operating, at least in part, at the level of transcription.
The downregulation of CD28 in peripheral blood T cells following engagement 
with its own ligand (CD80/86) has already been presented (chapter 3) and further 
studies were therefore carried out to investigate whether this response also 
occurred in Jurkat cells and to compare it with CD95-m ediated CD28 
downregulation. These data revealed that CD80-mediated CD28 downregulation 
was conserved in Jurkat T cells indicating similarity in the regulation of CD28 
expression between Jurkats and normal peripheral blood T cells (figure 7.7). In 
addition, this experiment showed that the processes of CD95-mediated and CD80- 
mediated CD28 downregulation occurred with broadly similar kinetics since 
downregulation was largely complete by 7 hours with either treatment (figure 
7.7).
7.3 DISCUSSION
The initial observation that CD95 derived signals could mediate T cell surface 
receptor modulation proved to be a phenomenon which was specific to the CD28 
receptor and which was triggered following both antibody and natural ligand 
(CD95L) treatment. The rapidity and specificity of this response was suggestive 
of potential biological relevance, as opposed to representing merely a side effect
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of apoptosis induction, and this finding was therefore subject to further 
exploration.
In an attempt to dissect which CD95-induced signals were required for CD28 
downregulation and which were required for apoptosis induction, a number of 
experiments were performed. Initial studies with chloroquine to inhibit acidic 
sphingomyelinase revealed that toxicity was associated with this compound when 
used at the concentrations deemed to inhibit apoptosis, and demonstrated the 
caution required for the use of pharmacological inhibitors in apoptosis assays 
since such experiments must also control for necrotic cell death. The caspase 
inhibitor Z-VAD-FMK was therefore utilised as an inhibitor of CD95 signalling 
since this reagent did not induce toxicity as measured by PI incorporation (in fact 
it was previously demonstrated to inhibit the loss of plasma membrane integrity 
associated with long term CH11 incubation in figure 3.1, panel A). At the time 
when these experiments were performed, the activation of caspases was thought to 
be a late event in CD95-mediated signal transduction, occurring immediately prior 
to cell death and thus representing commitment to an apoptotic fate. Therefore, 
by using this reagent it was envisaged that the CD95 pathway would be inhibited 
at a distal point such that the ultimate induction of death would be prevented, but 
the upstream (membrane proximal) components of CD95 signalling would be 
allowed to proceed. Thus whilst cell death would be prevented under these 
conditions, the CD95-derived signals which controlled CD28 downregulation 
might remain intact. The consequent demonstration that CD28 downregulation 
could occur in the absence of apoptosis induction would negate the possibility that 
CD28 downregulation was a result of cell death. However, as indicated in figure 
7.5 (B) Z-VAD-FMK did in fact inhibit CD95-mediated CD28 downregulation 
and therefore could not be used to segregate the signalling requirements for CD28 
downregulation and apoptosis in this manner.
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Subsequent studies on the role of caspase signalling have indicated that the 
positioning of caspase activity just prior to cell death is an oversimplification. The 
temporal hierarchy of caspases in the apoptotic pathway is now beginning to be 
unravelled and current data suggest that whilst caspase 1 activation is a relatively 
early event, occurring prior to mitochondrial permeability transition, caspase 3 
activation lies further downstream in this pathway, and appears to occur after 
these mitochondrial changes (Susin et al., 1997). Accordingly, the activation of 
caspase 1 does not appear to represent commitment to apoptosis since the 
induction of cell death can be prevented downstream of this event, for example by 
B C L X l (Boise and Thompson, 1997). Therefore, if the signals required for 
CD28 downregulation were mediated by caspase 1, then Z-VAD-FMK could 
inhibit both CD28 downregulation and apoptosis, yet under physiological 
conditions CD28 downregulation could potentially occur without apoptosis 
induction in the presence of BCLX l.
Furthermore, during the course of these studies a caspase which associates directly 
with the cytoplasmic tail of the CD95 receptor was identified (caspase 8 ) (Muzio 
et al., 1996; Medema et al., 1997) implicating caspase activation as an even earlier 
event in CD95-mediated signal transduction than previously considered. The 
additional finding that caspase inhibitors can block CD95-induced ceramide 
generation in Jurkat cells (Gamen et al., 1996) places caspase activity upstream of 
sphingomyelinase activation in this system. Thus as a result of the limited number 
of tools available as inhibitors of CD95 signal transduction, it was not possible to 
segregate the signals required for CD28 downregulation from those necessary for 
apoptosis induction since caspase activation is clearly an early signal which 
precedes both events. However, the fact that CD28 downregulation is not a 
feature of etoposide-induced apoptosis provides compelling evidence that this 
phenomenon is not a result of apoptosis induction, but rather is a specific result of 
CD95 signal transduction.
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Perhaps the most interesting finding pertaining to these studies on CD95-mediated 
CD28 downregulation, was the mechanistic data which suggested that CD95 
signalling induced a dramatic decrease in mRNA for CD28. The levels of mRNA 
for other proteins (CD58 shown in figure 7.6) did not appear to be affected under 
these conditions whilst in contrast CD28 mRNA was almost undetectable only 4 
hours following CH11 treatment. The fact that the observed downregulation 
appeared to be transcriptionally controlled suggested that the CD28 molecule 
could be specifically targeted in this way, allowing CD28 functions to be rapidly 
silenced under certain circumstances. Furthermore, the fact that a transcriptional 
event is so rapidly perceived at the protein level indicates that the duration of 
CD28 molecules at the cell surface is relatively short, again implying that surface 
expression of this receptor is carefully controlled. Consistent with this 
supposition, data have already been presented illustrating the tight control of 
CD28 expression during the T cell activation process, as surface expression of this 
receptor is both downmodulated by CD80 engagement and subsequently 
upregulated to high levels (chapter 3).
Intriguingly, the downregulation of CD28 following engagement with its own 
ligand (CD80/86) has also been reported to be under transcriptional control 
(Linsley et al., 1993), and the decrease in receptor expression occurs with similar 
kinetics to that seen following CD95 engagement (figure 7.7). Whilst CD95 and 
CD28 are historically believed to have widely different biological functions, that 
of apoptosis induction versus that of costimulation, they nevertheless appear to 
posses certain functional similarities. For example, CD95 ligation has been 
reported to costimulate T cell proliferation under certain circumstances (Alderson 
et al., 1993) suggesting that CD95 signalling can potentially provide components 
of a CD28-like pathway. In this regard, CD95 shares a number of signalling 
features with CD28 including the activation of sphingomyelinase (Boucher et al., 
1995; Tsuruta et al., 1995; Edmead et al., 1996) and JNK (Su et al., 1994; Wilson 
et al., 1996). Since both CD80 and CD95L induce CD28 downregulation, and
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that in both cases the process appears to be transcriptionally controlled, it is 
possible that CD28 downregulation is a consequence of a common signalling 
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Figure 7.8: Schematic diagram illustrating both shared and distinct 
components within CD95 and CD28 signalling pathways. Since the 
sphingomyelinase pathway is common to both receptors, this represents a 
candidate pathway in the CD95- and CD28-mediated downregulation of CD28 
mRNA. S-Mase = sphingomyelinase, JNK = c-Jun N-terminal kinase, AP-1 = 
Adaptor Protein 1.
Given the involvement of acidic sphingomyelinase in both CD28 and CD95 
signalling, one candidate signalling intermediate involved in CD28 surface 
modulation is ceramide. Ceramide is implicated in diverse biological processes
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including proliferation, growth arrest and apoptosis (Boucher et al., 1995; Jayadev 
et al., 1995; Tepper et al., 1995) all of which are consistent with the activation of 
this pathway by both CD28 and CD95. In addition, ceramide generation has been 
linked to the triggering of both NFkB and JNK, and work by colleagues in this 
laboratory has recently established that whilst CD28 can activate both pathways in 
normal T cells (Edmead et al., 1996), CD95 triggers only JNK activation. Thus 
ceramide-induced JNK is common to both CD28 and CD95 pathways and 
represents a potential candidate for negatively regulating the transcription of the 
CD28 gene as illustrated in figure 7.8, presumably via the transcription factor AP- 
1 of which it phosphorylates the c-Jun component (Su et al., 1994).
The phenomenon of CD95-mediated CD28 downregulation may be of interest in 
the context of HIV infection where T cells have been shown to express 
diminishing levels of CD28 with disease progression (Choremipapadopoulou et 
al., 1994) and intriguingly exhibit increased sensitivity to CD95-mediated 
apoptosis (Estaquier et al., 1995). One implication of these findings is that CD28 
downregulation may promote CD95 killing, possibly contributing to the CD4+ T 
cell depletion associated with AIDS. Thus T cell CD28 expression may be 
providing a protective mechanism which is gradually lost during HIV infection. 
Further support for this concept comes from the demonstration that CD28 
expression is downregulated in late passage T cell clones and that this phenotype 
is associated with increased susceptibility to apoptosis (Pawelec et al., 1996).
In summary, therefore, these data link the two key T cell receptors CD28 and 
CD95 by illustrating that CD95 ligation leads to rapid and specific 
downregulation of CD28 expression. This phenomenon appears to be under 
transcriptional control and is associated with the induction of early apoptotic 
membrane changes (PS exposure). The fact that both CD80 and CD95L can 
trigger the downregulation of CD28 at a transcriptional and protein level is 
indicative of functional similarities between the signalling pathways initiated by
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CD28 and CD95, and further work is required to identify which component(s) of 
these pathways is responsible for mediating CD28 downregulation. Both CD80- 
mediated and CD95L-mediated CD28 downregulation also occur in normal 





The T cell response to antigen engagement is subject to considerable regulation 
depending on the context in which TCR signalling is initiated. For example, 
CD28 costimulation extensively modifies the outcome of antigen presentation in 
terms of 3H-thymidine incorporation (Gimmi et al., 1991; Linsley et al., 1991a; 
Razi-W olf et al., 1992; Sansom et al., 1993), cytokine production (Lindsten et al., 
1989; Fraser et al., 1991; Jenkins et al., 1991; Fraser and Weiss, 1992; Thompson 
et al., 1993) and the promotion of T cell survival (Groux et al., 1992; Radvanyi et 
al., 1996). W hilst CD28 positively regulates T cell activation, conversely, 
engagement of its homologue, CTLA4, provides a negative regulatory signal 
(Walunas et al., 1994; Krummel and Allison, 1995; Krummel and Allison, 1996; 
Walunas et al., 1996). In addition, the availability of ligands for death receptors 
such as CD95 may influence the nature or magnitude of the subsequent T cell 
response (Lu et al., 1997a; Lu et al., 1997b). Thus the net result of T cell antigen 
recognition is determined by multiple receptor: ligand interactions which 
collectively allow T cell responses to be regulated in the periphery. Consequently 
such mechanisms form the basis for discrimination between the generation of 
tolerance and immunity following the encounter of peripheral T cells with antigen. 
Data from knockout mice imply that peripheral tolerance mechanisms operated by 
receptors such as CTLA4 and CD95 may be equally important in the prevention 
of autoimmunity as central tolerance by thymic deletion (Bluestone, 1997). The 
lymphoproliferation and autoimmune features that characterise mice deficient in 
CD95 (MKL-lpr) or CD95L (MRL-gld) reveal a key role for the CD95 system in 
the maintenance of peripheral tolerance, presumably via the induction of apoptosis 
to preclude and/or terminate immune responses. However, the specific 
contribution o f T cells to this phenotype remains unclear and the relative 
importance of CD95-mediated elimination of B cells, and APCs in the prevention 
of autoimmunity is poorly understood. Evidence from in vivo (Ettinger et al., 
1995) and in vitro (Dhein et al., 1995; Boshell et al., 1996) work has demonstrated 
the involvement of CD95-induced T cell apoptosis in the downregulation of T cell 
responses to superantigen, supporting a role for CD95 in the maintenance of
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immune cell homeostasis. Nevertheless, an appreciation of the mechanistic and 
kinetic regulation of the CD95 system, particularly in humans, is lacking and 
formed the basis for this investigation.
This study therefore examined the expression and function of CD95 and CD95L 
in the context of defined in vitro activation conditions in order to elucidate the role 
of the CD95 system in the control of human T cell responses. Results indicate 
that, contrary to current perceptions, activated human T cells are largely resistant 
to CD95-mediated apoptosis despite upregulation of CD95, and activation- 
induced expression of CD95L. Thus these data provide a new perspective on the 
role of the CD95 pathway both in the killing of T cells by interaction with CD95L 
on a neighbouring cell, and the triggering of T cell suicide by AICD following 
TCR restimulation. Since the findings appear controversial in the light of work by 
Klas and colleagues (Klas et al., 1993), a large proportion of the study has 
rigorously analysed the systems used in order to verify that the observed 
resistance to apoptosis was not artefactual. Carefully controlled experiments have 
consistently documented CD95 resistance and have suggested that the discrepancy 
with the above study is more likely to arise from the unusual T cell activation 
conditions employed in which the provision of costimulation was lacking. Since 
the data in this thesis indicate that protection from CD95-mediated apoptosis is 
associated with the provision of TCR and CD28 signalling, apoptosis sensitivity in 
T cells stimulated with PHA in the absence of costimulatory ligand is not entirely 
unexpected. Indeed, we have been able to demonstrate that the provision of 
costimulation during PHA activation of purified T cells can convert CD95 
sensitivity to CD95 resistance (McLeod et al., 1997).
It is pertinent to question how the dogma that activated human T cells were CD95 
sensitive came to be so widely accepted on the basis of so few reports. As 
previously highlighted (chapter 4), the percentage CD95-induced apoptosis in 
these studies is not always dramatically higher than that documented here, yet the
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conclusions drawn are substantially different. Thus there may have been a 
tendency to interpret data from human T cells such that it was consistent with the 
prevailing hypothesis that CD95-expressing cells were CD95 sensitive. Whilst 
clearly this is the case for a proportion of activated human T cells, the data 
presented here suggest that in fact resistance to apoptosis may predominate in 
these cultures, implying the existence of protective mechanisms in most, but 
intriguingly not all, of these cells.
Current thinking regarding CD95-mediated apoptosis has largely been influenced 
by studies on murine T cells (Brunner et al., 1995; Ju et al., 1995; Ettinger et al., 
1995) with little concession to the potential differences which may exist in the 
human system. Since there are clearly cell type-specific differences in the 
mechanism by which CD95 induces apoptosis, illustrated for example by the 
requirement for elevated intracellular calcium for CD95 signalling in human B 
cells (Oshimi and Miyazaki, 1995) but not T cells (Gulbins et al., 1995; Vignaux 
et al., 1995), it seems likely that species-specific differences may also exist. 
Differential control of peripheral tolerance mechanisms in mice and humans is not 
altogether a surprising finding given the evolutionary divergence and thus the 
differing immune requirements of these two species. Accordingly, whilst a lack 
of primary health care makes the successful induction of immunity a necessity in 
the murine system, the short life span associated with this species renders the 
prevention of autoimmunity potentially less of a priority, since tolerance must 
only be maintained for a relatively short time period. In contrast, the markedly 
increased longevity typical of humans demands the existence of long term 
tolerance mechanisms and conversely the maintenance of immune memory is 
likely to be altered in humans for similar reasons. Clearly there are many parallels 
between mice and humans in terms of the molecules involved in peripheral 
tolerance and much can be leamt from in vivo studies in this area, however subtle 
inter-species differences in immune features serve as a timely reminder that the 
functional biology of mice and humans cannot be assumed to be identical. Most
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notably the lack of MHC class II expression (the murine equivalent of HLA 
molecules) on activated murine T cells presumably precludes the possibility of T 
cell:T cell antigen presentation in this species. Conversely, the induction of HLA 
class II molecules on human T cells permits such interactions and may offer an 
additional mechanism to negatively regulate T cell responses (Houssaint and 
Flajnik, 1990; Sidhu et al., 1992; Pichler and Wyss-Coray, 1994; Hargreaves et 
al., 1997).
Hypothesis: A Personal Perspective on the CD95 System
In seeking to understand the role of the CD95 system in the human T cell 
response, it is relevant to consider why and when we need activated T cells in 
order to mount a successful defence response. For what purposes do we require 
clonal T cell expansion? When does this response need to be shut down? What is 
the role of CD95 in respectively limiting or mediating these processes? Specific 
antigen-reactive T cells are clonally expanded in order to a) facilitate antibody 
production from B lymphocytes which share the same antigen specificity 
(although may recognise a different epitope of that antigen) b) perform cytotoxic 
functions and c) co-ordinate the recruitment and activation of additional immune 
cells including accessory cells (neutrophils, basophils, eosinophils) and 
macrophages. The requirements of an effective immune system are to ensure that 
defence responses are mounted against foreign antigens but not self tissue, and 
that subsequently the contributory immune cells are eliminated or silenced such 
that the status quo is restored yet immune memory is maintained. Consequently 
the control of T cell activation and the ultimate demise of T cells by apoptosis 
must reflect these aims.
In contemplating the involvement of CD95 in the above processes, it is tempting 
to presume that CD95-mediated apoptosis functions in the latter stages of an
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immune response to facilitate the removal of activated T cells. Such a prediction 
is consistent with the activation induced upregulation of both CD95 and CD95L 
and a situation in which T cells could be eliminated by cell suicide (AICD) or by 
interaction with CD95L-expressing APCs. Since the pathogen responsible for 
initiating the immune response should have been effectively removed by this 
stage, the expression of costimulatory ligands on APCs may now decrease given 
that pathogen-associated products (such as LPS) are implicated in the upregulation 
o f these molecules (Razi-Wolf et al., 1992). Thus there may be preferential 
expression of death ligands such as CD95L as opposed to costimulatory ligands 
(CD80/86) on APCs at this time, a situation which could potentially favour T cell 
apoptosis rather than T cell activation in line with published studies (Lu et al., 
1997a; Lu et al., 1997b) and consistent with the potentiation of CD95-mediated 
apoptosis by inclusion of CTLA4-Ig (figure 6.10).
Whilst the downregulation of T cell responses is clearly important and apoptosis is 
a likely mechanism for achieving this, the timing of this process must nevertheless 
be consistent with the fulfilment of T cell immune function. For example, the 
CD95-induced elimination of T cells only four or six days following stimulation 
consistent with the 2 reports previously cited (Owen-Schaub et al., 1992; Klas et 
al., 1993), is difficult to reconcile with a role for such cells in the provision of 
effective B cell help or cytotoxic function. Given the observed kinetics of serum 
antibody detection and isotype switching (also believed to be T cell dependent), 
and the timing of peak T cell responses (MacDonald et al., 1991; MacLennan et 
al., 1997), acquisition of cytotoxic function (Ortiz et al., 1997) and expression of 
VLA antigens (Ortiz et al., 1997), it is clear that survival of at least some T cells 
beyond day six may be necessary for an effective immune response to be 
mounted. In addition, it is envisaged that at least a subset of antigen-specific T 
cells must persist to provide immune memory such that secondary immune 
responses can be rapidly initiated upon re-infection. Thus in postulating a role for 
CD95-mediated apoptosis in the termination of an immune response, the timing of
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the T cell contribution to immunity should be considered: if the only limit on 
CD95 sensitivity was a four to six day maturation period, it is difficult to see how 
this is consistent with the effective provision of immune function. Whilst the 
CD95 system may contribute to the termination of immune responses, there is also 
likely to be an important role for growth factor deprivation in the induction of 
apoptosis under these circumstances. In particular, since the initiating pathogen 
may have been effectively eliminated by this stage, there is likely to be reduced 
antigen availability for the triggering of AICD, consistent with the possibility that 
cytokine deprivation induced apoptosis may be a key mechanism for removal of T 
cells at these times (Akbar et al., 1993a; Akbar et al., 1996).
The data presented in this thesis support an alternative (although not mutually 
exclusive) role for the CD95 system in the differential apoptosis of bystander 
versus “correctly activated” T cells. Results demonstrate that T cells which have 
been activated in the presence of ligand for TCR and CD28 are largely protected 
from CD95-mediated apoptosis, and that the triggering of TCR or CD28 signals in 
T blasts can promote resistance to CD95. The proportion of the population 
exhibiting CD95 sensitivity in these studies (up to approximately 35%) may 
represent T cells which did not receive appropriate activation signals but instead 
may have become activated in a “bystander” manner due to the cytokine-rich 
environment. Since CD95 expression is relatively homogeneous in these cultures 
and the transfer of supernatant from activated blasts to resting T cells upregulates 
CD95 expression, this suggests that bystander activated T cells can express 
equivalent CD95 to those which were correctly activated by antigen and 
costimulation. Consistent with the hypothesis that CD95 sensitive cells may have 
lacked one of these two signals, this subset is characterised by low CD28 
expression (figure 6.7) whereas the co-ordinated provision of both TCR and CD28 
signalling is associated with the upregulation of CD28 expression to high levels 
(figures 3.8-3.9).
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Thus a key role for the CD95 system may be in limiting the expansion of 
bystander activated T cells rather than solely in the termination of immune 
responses. Accordingly T cells activated non-specifically by the cytokine 
environment may initiate a proliferative response, but the subsequent rapid 
acquisition of CD95 sensitivity in such cells, consistent with the findings of Klas 
and colleagues (Klas et al., 1993) may limit their ability to drive an effective 
immune response. The expression of functional CD95L on correctly activated T 
cells, as documented in this thesis, would provide a mechanism for the removal of 
CD95 sensitive bystander T cells, in addition to the deletion of autoreactive B 
cells as previously reported (Rathmell et al., 1995). Furthermore, the release of 
soluble CD95L would preclude the requirement for cellrcell contact in the 
elimination of these potentially dangerous immune cell subsets. A role for CD95 
early on in the prevention of immune response initiation (rather than solely in 
immune response termination) is more commensurate with the kinetics by which 
CD95 sensitivity is acquired in the studies by Klas and colleagues and Owen- 
Schaub and colleagues (Owen-Schaub et al., 1992; Klas et al., 1993), and is 
supported by the detectable effect of CD95 stimulation during the initial 
stimulation of resting T cells in three day proliferation assays (figure 3.4). Such a 
model is consistent with the requirement for functional CD95 and CD95L in the 
maintenance of peripheral tolerance, as indicated by the autoimmune phenotype of 
MRL-/pr and -gld mice, since bystander T cells by definition have bypassed the 
two-signal activation requirements designed to preclude responsiveness against 
self tissue. Thus any defect in the CD95 system is likely to compromise the 
deletion of potentially autoreactive T cells and consequently may allow the onset 
of autoimmunity.
The CD95 resistance documented in this study has prompted a re-assessment of 
the role of the CD95-mediated apoptosis in the human T cell immune system. In 
the light of this data, I propose that the CD95 system may exist to regulate the 
nature rather than the magnitude of immune responses by controlling which T
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cells are permitted to survive long enough to provide effector functions, based on 
the differential apoptosis sensitivity of correctly activated versus bystander T 
cells. This model is consistent with a role for CD95 in the maintenance of 
peripheral tolerance by the prevention of bystander-driven autoimmune responses. 
Thus given the questions raised by this thesis, it is clear that much remains to be 
learnt about the role of CD95 in T cell homeostasis. A better understanding of 
how the CD95 system influences the generation of T cell tolerance versus 
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(B) Suppliers Contact Numbers
The following list states the location and telephone numbers of the specialist 
suppliers of reagents.
Amersham International pic (Aylesbury, UK)
Appligene (Britley, UK)
Becton Dickinson (UK) Ltd (Oxford, UK)
Boehringer Mannheim (Lewes, UK)
British Biotechnology (Oxford, UK)
Calbiochem (UK) Ltd (Nottingham, UK)
CP Pharmaceuticals Ltd (Wrexham, UK) 
(Distributed via Fisons, Leicester, UK)
Dynal (UK) Ltd (Bromborough, UK)
Enzyme Systems Products (California, USA) 
(Contact via internet web page)
Fahrenheit Laboratory Supplies (Bristol, UK)
Hybaid Ltd (Teddington, UK)
Life Technologies (Paisley, UK)
National Blood Service (Bristol, UK)
NBL Gene Sciences Ltd (Cramlington, UK)















Oxoid Ltd (Basingstoke, UK)
(Distributed via Farenheit Laboratory Supplies, Bristol, UK)
Pharmacia Biotech Ltd (St Albans, UK) 01727 814000
Promega Ltd (Southampton, UK) 01703 760225
R&D Systems Europe Ltd (Abingdon, UK) 01235 529449
Serotec Ltd (Oxford, UK) 01865 373899
Sigma Aldrich Ltd (Poole, UK)
Skatron Ltd (Newmarket, UK)
01202 733114 
01638 660600
TCS Biologicals Ltd (Buckingham, UK) 01296 714071
Wallac Ltd (Milton Keynes, UK)
(Distributed through Fisons and Pharmacia Biotech)
Whatman Scientific (Maidstone, UK) 01622 692022
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Appendix 2: Media
(A) Dulbecco’s Minimal Essential Medium (DMEM) (pH 7.4)
The following were added to 400ml of autoclaved ddH20:-
DMEM(IOX) 55ml
FCS 50ml
Penicillin /  Streptomycin 5ml
(lOOOO^tg/ml/ lOOOOIU/ml)
Sodium bicarbonate 28ml (0.4% final)



















Appendix 3: Buffers and Solutions
(A) Phosphate Buffered Saline (pH 7.3)
5 tablets were added to 500ml ddH20 and autoclaved.
(B) Solutions for Agarose Gel Analysis of Fragmented DNA
The molarity indicated represents the final concentrations of reagents in the 
completed solution.
Tris-EDTA (TE) fpH 8.0)
Tris-HCL lOmM (pH 8.0)
EDTA ImM (pH 8.0)
IPX Tris Acetate EDTA (TAE) (pH 8.0)
Tris-base 24.22g (0.4M)
Sodium acetate 2.05g (0.05M)
Na2EDTA 1.86g(0.01M)
ddH 20 to 500ml
(C) HEPES Buffer for Annexin-FITC Binding Assay




(D) Solutions for Ca^+ measurement
HBSS (pH 7.4} HEPES-buffered saline (pH 7.4}
CaCl2 .2 H2 0 1.3mM NaCl 137mM
M gS04.7H 20 0.8mM KC1 5mM
NaCl 140mM Na2HP0 4 ImM
NaHC03 4.2mM Glucose 5mM
Na2HP0 4 .12H2 0 1.3mM CaCl2 ImM
Glucose 5.6mM MgCl2 0.5mM
BSA lg /1
HEPES lOmM
(E) Solutions for Northern Blot Analysis








H 3PO4  (conc.) 
ddH20
89g
3-4mls, to pH 
to 1 litre
20X SSC (pH 7.0")
Sodium chloride 175.3g
Sodium citrate 8 8 .2g











Diethyl Pvrocarbonate fDEPCVtreated H^O
500p,l of DEPC was added to 500ml ddH20, mixed and left at room temperature 
overnight, followed by autoclaving.
Methylene Blue
Methylene blue was made up in 0.3M sodium acetate, pH 4.2.
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